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ABSTRACT 
Much circumstantial evidence has pointed to peripheral blood 
leukocytes as one site of persistence of Human Cytomegalovirus (HCMV) in 
healthy carriers. However, the exact population of peripheral blood cells 
that carry HCMV and to what extent they express HCMV gene products in 
not known. I have examined the sites of HCMV persistence in the 
peripheral blood of healthy carriers. Analysis of pure cell populations by the 
use of the polymerase chain reaction (PCR), sensitive to between 1 and 10 
copies of the HCMV genome, showed that the predominant site of 
persistence was the monocyte. In addition, analysis of healthy seronegative 
subjects revealed that a significant number (30%) also harbored HCMV. 
Finally, study of granulocytes demonstrated no evidence of persistent 
HCMV. 
Expression of HCMV during persistence was also analyzed, by using 
reverse transcription PCR (RT-PCR) with a sensitivity of between 1 and 100 
infected fibroblasts. RNA from monocytes showed no evidence of 
polyadenylated immediate early (IE) or late transcripts. In contrast, in vitro 
differentiated monocyte-derived macrophages (MDM) did show evidence of 
HCMV gene expression with the class of HCMV genes expressed dependent 
on the method of differentiation. MDM treated with hydrocortisone (HC) 
and phorbol 12-myristate 13-acetate, expressed only lEI, but not IE2, 
glycoprotein B (gB) or phosphoprotein 28 (pp28) transcripts. Whereas, MDM 
treated with granulocyte-macrophage colony stimulating factor and HC 
expressed lEI, IE2 and gB, but not pp28 transcripts. In both cases, 
cocultivation experiments did not show plaques. Therefore, in the healthy 
carrier, persistence of HCMV in monocytes is independent of HCMV lytic 
gene expression, but in vitro differentiation of monocytes to MDM induced 
endogenous HCMV transcription consistent with the known permissivity of 
in vivo differentiated macrophages to HCMV infection. 
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1.1 INTRODUCTION 
CHAPfERI 
INTRODUCTION 
Some of the earliest reports, of what was later determined to be 
human cytomegalovirus disease, examined a fatal congenital 
disseminated form of unknown infection (Jesionek & Kiolemenoglou, 1904; 
Ribbert, 1904). In the histologic examination of tissues from these cases, 
cellular enlargement with intranuclear inclusions were noted and the 
disease was named cytomegalic inclusion disease (CID). Historically, 
these fatal infections were thought to be due to a syphilitic agent or a 
protozoan and, in accordance with the latter etiology, one group, in 1910, 
proposed the name Entamoeba mortinatalium for the causative agent. 
Eventually, however, Goodpasture and Talbot, (1921) postulated that the 
swollen cells were actually host cells that were injured by a virus. Two 
pieces of evidence, in particular, supported this. First, the observation that 
cellular inclusions in CID tissues were similar to those seen in varicella 
skin lesions (Tyzzer, 1906; Lipschutz, 1921) was noted. Second, guinea pig 
disease transmitted from filtered guinea pig salivary gland extracts was 
reported (Cole & Kuttner, 1926). Eventually, human cytomegalovirus 
(HCMV) was able to be replicated in vitro (Rowe et al., 1956 Smith, 1956; 
Weller et al., 1957), allowing the true nature of the unknown agent to 
become clear and permitting studies of HCMV clinical infections. The 
name cytomegalovirus (Weller et al., 1957) originated from the effects 
produced in tissue culture and, thus, the virus gets its name from this 
cytopathic effect. 
1 9 
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1.2 lIERPESYmUS 
1.2.1 Classification. Viral Structure and Qr~anization of the Genome 
In general, Herpesviruses have a distinct virion architecture with a 
central core containing double-stranded DNA. This is surrounded by an 
icosahedral capsid, which is coated with an asymmetric, amorphous 
tegument and an envelope, containing viral glycoproteins. The family 
Herpesyiridae is classified into the subfamilies Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae (Roizman et al., 1981) on 
the basis of biologic properties. Cytomegaloviruses are grouped as 
betaherpesviruses due to their long replication cycle, their species 
specificity and their cytopathic effects. The subfamily contains the genera 
Cytomegalovirus (HCMV) and Muromegalovirus (murine 
cytomegalovirus). In addition, the newly discovered human herpes virus 6 
(Salahuddin et al., 1986) has been classified as a betaherpesvirus and 
shows a close phylogenetic relationship to the genome of HCMV 
(Lawrence et al., 1990; Thomson et al., 1991). 
HCMV is the largest known human herpesvirus and contains a 50% 
more complex genome than the alphaherpesvirus, herpes simplex. This 
is thought to be due to various gene acquisitions and duplications as well 
as sequence divergence. The large double stranded DNA genome of 
HCMV is present in the form of a torus in the core of the mature virion. It 
is organized into long and short unique sequences flanked by terminal 
repeats that are present internally in an inverted orientation and 
juxtaposed (Figure 1.1). The small direct terminal repeats are thought to 
be involved in cleavage and packaging and appear to be conserved among 
herpesviruses (Mocarski & Roizman, 1982; LaFemina & Hayward, 1983; 
Spaete & Mocarski, 1985; Marks & Spector, 1988). The internal repeats 
divide the genome, such that the unique portions are known to invert 
relative to each other leading to isomerization. Equimolar portions of these 
20 
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isomers are present in virions extracted from infected cells. HCMV is the 
only betaherpesvirus with an isomerizing genome. 
1.3 GENE EXPRESSION AND REPLICATION 
HCMV gene expression during productive infection is coordinately 
regulated and sequentially ordered (DeMarchi, 1981; Wathen & Stinski, 
1982; McDonough & Spector, 1983). Viral gene expression can be divided 
into three different kinetic classes (Figure 1.2). The first proteins to be 
synthesized, (l or immediate-early, regulate transcription of the second 
group of HCMV proteins, the ~ or early proteins (Chang et al., 1989; 
Spector et al., 1990) as well as transactivate cellular genes (Dudding et al., 
1989; Santomenna & Colberg-Poley, 1990; Hagemeier et al., 1992a) and 
heterologous viral genes (Davis et al., 1987; Tevethia et al., 1987; Walker et 
al., 1992). During the early phase, a number of regulatory proteins and 
viral enzymes are synthesized. These early proteins allow virion DNA 
replication to proceed. The origin of DNA replication during lytic infection 
has recently been defined (Hamzeh et al., 1990) and is located in the center 
of the UL between 0.35 to 0.40 map units. After DNA replication, the late or 
y phase of replication proceeds. The late proteins consist primarily of viral 
structural components. The expression of these genes leading to 
production of virions occurs over a period of 72 hours in fully permissive 
cells in vitro. 
1.3.1 Immediate Early Genes 
The immediate early (IE) period follows virus entry into the cell and 
is independent of de novo viral protein synthesis such that they are still 
expressed in the presence of cyclohexamide. The IE RNA of HCMV arises 
from at least 3 regions of the HCMV genome (DeMarchi, 1981; Wathen et 
21 
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HCMV SEQUENCE ARRANGEMENT 
b' ala' c' 
INVERTED 
INTERNAL 
REPEATS 
c a 
TERMINAL 
REPEATS 
Figure 1.1. Genome Arrangement of Human Cytomegalovirus. The 
sequence arrangement shown here is that of the group E herpesviruses 
(Roizman, 1990) and is seen in both HCMV and herpes simplex viruses. 
One terminus has several copies of sequence a (designated by an open 
rectangle with vertical lines) next to a longer sequence b (shown by an open 
rectangle filled with diagonal lines) and the other terminus has a single 
copy of a (designated by the closed rectangle) and a more internal sequence 
c (shown by an open rectangle filled with cross-hatched lines). Sequences 
from both termini are repeated in an inverted orientation (inverted 
sequences shown as primes) and juxtaposed internally. The terminal and 
internal repeats divide the genome into a unique long (UL) and a unique 
short region (Us). Both unique components can invert relative to each 
other and, therefore, form 4 isomers which are found in equimolar 
populations in DNA extracted from virions. 
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Figure 1.2. Gene Expression After In Vitro HCMV Infection of Permissive 
Cells. The diagram represents the 3 components of the viral cascade after 
entry of virus into a permissive cell. Immediate early genes are expressed 
first, followed by early and then late genes. The final event in productive 
infection is lysis of the cell and release of intact virions. 
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at., 1982). These are the major immediate early or MIE (Stinski et al., 
1983; Jahn et al., 1984; Stenberg et at., 1984; Akrigg et al., 1985), the UL36-
38 (Wilkinson et at., 1984; Tenney & Colberg-Poley, 1990; Tenney & Colberg-
Poley, 1991; Kouzarides et at., 1988), and the Us3 (Weston, 1988) 
loci. There is also some poorly characterized, low-abundance IE 
transcription from the Us EcoRI B fragment and the UL EcoRI A and D 
fragments (DeMarchi 1981; Wathen & Stinski, 1982; McDonough & 
Spector, 1983). 
The MIE region is the area of highest transcriptional activity, and is 
localized between map units 0.66 and 0.77 in the unique long component of 
the viral genome. This is the same for all HCMV strains that have been 
investigated and corresponds to the HindIII-E fragment of the HCMV 
strain AD169 and the XbaI-E and -N fragments of strain Towne. This MIE 
region encodes the major lEI and IE2 proteins (Figure 1.3) and is 
comprised of a group of differentially spliced RNA regulated from the 
same promoter. They produce different proteins at different times during 
lytic infection (Stenberg et at., 1984; Akrigg et at., 1985; Stenberg et at., 
1985; Stenberg et al., 1989) and have been shown to exert their 
transactivational effects via different mechanisms (Hagemeier et al., 
1992). 
IE 1 is the most abundant polypeptide at IE times and first appears 
In the cytoplasm, within 1 hour following infection, where it is 
phosphorylated and transported to the nucleus. As mentioned above, lEI 
is known to upregulate other cellular promoters and also has been 
reported to upregulate its own promoter in primary fibroblasts 
(Cherrington & Mocarski, 1989: Stenberg et al., 1990). The latter activation 
occurs primarily via the 18 bp repeat elements present in the MIE 
enhancer/promoter (Cherrington & Mocarski, 1989) which are known 
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Figure 1.3. MIE Transcription Unit. IE 1 and IE2 are transcribed in a 
right to left direction in the prototype genome arrangement (top) where 
terminal and internal repeats are labeled TR and IR and long and short 
components of the genome are labeled Land S, respectively (Figure 1.1). 
Predicted transcripts are shown as exons (thick lines) linked by spliced 
introns (thin lines). Transcriptional polyadenylation endonuclease 
cleavage sites (AATAAA), translational starts (ATG) or stops (TAA, TGA) 
are also noted. The lEI and IE2 transcripts have the same 5' leader 
sequence generated from exons 1,2, and 3 alternately spliced to exon 4 or 5 
to produce either lEI or IE2, respectively. The single asterisk defines the 
IE2 transcript which is the functionally active trans activating and 
auto regulating IE2 protein (Pizzorno et al., 1991), whilst the double 
asterisk defines the transcript which may be a cyclohexamide artifact 
(Pizzorno et al., 1991). At late times of infection, a 1.5 kb transcript has 
been identified initiating from a cryptic promoter near the 5' end of exon 5. 
The IE2b transcript (Stenberg et al., 1985) has been predicted from 
northern blots of infected permissive cells in the presence of 
cyclohexamide. The IE2b transcript has a functional T ATA motif and 
CCAAT box just 3' to the lEI gene and is a low abundance spliced 
transcript but is otherwise poorly characterized. 
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to contain a consensus sequence for the transcription factor NF-kB (see 
below). Subsequently, Sambucetti et al. (1989) reported that a transcription 
factor, with all the characteristics of NF-kB, played a central role in MIE 
enhancer/promoter activation in infected fibroblasts and was mediated 
through the lEI protein. On the other hand, IE2 has also been shown to 
upregulate expression from heterologous HCMV early genes (Malone et 
al., 1990) as well as heterologous non-HCMV promoters (Hermiston et al., 
1987) but is reported to down-regulate its own MIE enhancer/promoter 
(Pizzorno et al., 1988). However, whilst no DNA-binding of lEI to the MIE 
enhancer/promoter has been shown (Stenberg and Stinski, 1985), IE2 has 
recently been shown to directly bind to the cis repression signal (CRS) 
located between the TATA box and the cap site of the MIE 
enhancer/promoter (Lang & Stamminger, 1993). 
The MIE RNA are controlled by a complex upstream enhancer-
containing promoter (Stinski, 1990) that contains 4 functional units, a 
modulator region which is most 5' to the transcriptional start site, an NFl 
cluster, an enhancer and a promoter (Figure 1.4). Each component of the 
MIE upstream regulatory region will be discussed individually, but I will 
use the term MIE enhancer/promoter to refer specifically to the intact MIE 
upstream regulatory region including the modulator, the NFl cluster, the 
enhancer and the promoter. 
By definition, initial expression from the MIE transcription unit 
occurs without de novo protein synthesis and must depend on viral and 
cellular factors. Expression may be mediated through a tegument protein 
component of the virion particle, possibly the phosphorylated 71 kd protein 
transcribed from the UL 82 gene, (Liu & Stinski, 1992) similar to activation 
of the HSV IE promoter by the viral tegument protein VP16 (O'Hare & 
Goding, 1988). Or, this expression may be mediated through attachment 
of virion components to the cell plasma membrane and activation of the 
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Figure 1.4. Upstream Enhancer-Containing Promoter of the MIE 
Transcription Unit. The repeats are highly conserved among human, 
simian, and murine CMV s and are separated by irregular stretches of 
nonrepetitive DNA. The promoter (-65 to +3) is sufficient for a low level of 
transcription and contains a CAAT box and a TATA element. The 
enhancer or regulatory region II (-520 to -65) stimulates downstream gene 
expression from cognate and foreign promoters and is one of the strongest 
known enhancer/promoters. The 17 bp, 18 bp, 19 hp, and 21 bp sequences 
present in regulatory region II are as follows, respectively: 
5' ACTTGGCAGTACATCAA 3', 5' CTAAACGGGACTTTCCAA 3', 
5' CCCCATTGACGTCAATGGG 3', and 5' ACGGTAAATGGCCCG 
CCTGGC 3'. The modulator region (Lubon et at., 1989; Shelhoum et at., 
1989b; Stamminger and Fleckenstein, 1990) which is -1145 to -750 has been 
found to act on promoter expression in a differentiation-dependent 
fashion. The imperfect dyad symmetry detailed in Shelhourn et al. 
(1989b), is shown in the modulator region upstream of regulatory region I. 
The sequence 5' TGGC\AN5GCCAA 3' constitutes the NFl sites present 
in regulatory region I. One NFl site, not depicted here, is also present in 
the first intron of the IE1 gene. 
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proto-oncogenes c-fos and c-jun (Boldogh et al., 1990). The modulator region 
(Nelson et al., 1990) seen in Figure 1.4 has been shown to contain inducible DNase I 
sites (Nelson & Groudine, 1986). In addition, this region has been shown to 
negatively regulate expression of the MIE enhancer/promoter in T cell lines and 
epithelial cell lines (Lubon et al., 1989). And this region has been implicated in 
negative regulation in undifferentiated teratocarcinoma T2 cells, mediated at least 
in part, thrQugh binding of negative regulatory factors to an imperfect dyad 
symmetry located between -985 and -935 (Shelbourn et al., 1989b). The functional 
significance of the NFl sites is unknown. But, they do not appear to be involved in 
mediating negative regulation of the MIE enhancer/promoter in undifferentiated 
teratocarcinoma cells (Shelbourn et al., 1989b). The enhancer contains multiple 
partially conserved repeats of 17, 18, 19, and 21 bp, as well as SP1 sites (Figure 1.4). 
These regions of the enhancer were shown to coincide with constitutive DNaseI 
hypersensitive sites (Nelson and Groudine, 1986) suggesting an open chromatin 
structure and that these areas may be active or potentially activatable. Some of the 
upstream regulatory regions and some of the enhancer repeats contain consensus 
sequences for known eukaryotic DNA binding proteins, e.g. the NFl sites are 
putative site~ for CAAT binding protein (CBP) super family, while the 19 and 18 bp 
elements have consensus sequences for cyclic AMP response element binding 
factor (CREB/ATF) and NF-kB, respectively. The 17 bp elements can be deleted 
without negative effect on the strength of the promoter while the 19 and 18 bp 
repeats are functionally important elements for basal promoter activity 
(Fickenscher et al., 1989). The 19 bp repeats have been shown to be necessary for 
cAMP responsiveness (Stamminger et al., 1990). In addition, the 19 bp repeats 
have been noted to have some homology with the consensus sequence recognized by 
the transcription factor AP-l. AP-1 can be induced by the phorbol ester 
tetradecanoylphorbolacetate (TPA) which is thought to act through the protein 
kinase C pathway. Although phorbol esters have been implicated to mediate 
activation of the HCMV MIE 
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enhancer/promoter through induction of AP-l in monocytic cell lines 
(Lebkowksi et al., 1987), upregulation could also have been due to removal 
of negative regulatory cellular factors upon phorbol ester differentiation. 
It is not clear that the putative AP-l binding elements present in the 19 bp 
repeats play any role in direct AP-l-mediated activation of the MIE 
enhancer/promoter. The 18 bp repeat has been shown to be necessary for 
lEI mediated transactivation of the MIE enhancer/promoter (Cherrington 
& Mocarski, 1989) and the factor which binds to this element has been 
shown to be indistinguishable from NF-kB (Sambucetti et al., 1989). As lEI 
has not been shown to bind directly to DNA, it is possible that it acts 
through induction of NF-kB (Sambucetti et al., 1989) but exactly how this 
induction occurs is unclear. The 21 bp elements (Figure 1.4) have been 
shown to bind negative regulators of gene expression in undifferentiated 
teratocarcinoma cells (Kothari et al., 1991) and also act in association with 
the imperfect dyad (Figure 1.4) to negatively regulate HCMV gene 
expression in an undifferentiated monocytic cell line, THP-l (Sinclair et 
al., 1992). Finally, the promoter (Figure 1.4) contains a TATA motif, 
located within 65 bp upstream of the transcription start site, which directs 
transcription using the cellular RNA polymerase II and other basal 
transcription factors. 
Another region of the genome transcribed during IE time is located 
in the US, and has been designated the open reading frame HQLF-l or 
HindIII fragment Q left reading frame (Weston & Barrell, 1986; Weston, 
1988). Specifically, it is located in the EcoRI fragment L of strain AD169 
and codes for 4 differentially splice RNA with common 5' and 3' ends. 
Although not as strong as the MIE enhancer/promoter, this gene also has 
an upstream enhancer with 11 bp and 18 bp repeats. The latter are 
homologous to those in the major IE enhancer/promoter but their 
significance is not well defined. 
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A potential glycoprotein has been described that is transcribed 
during IE times (Kouzarides et al., 1988). It lies in the UL between 0.21 
and 0.24 map units and is located at the HindIII Z and J fragment 
junction. The 3.4 kb RNA codes for a predicted protein of 56 kd with 
characteristics of a membrane bound glycoprotein. It is unusual in the 
fact that no other known herpesviruses code for IE glycoproteins and there 
is no homology to known HSV glycoprotein genes. The protein product has 
not as yet, been identified. 
1.3.2 Early and Late Genes 
Early genes are defined as those genes which are able to be 
transcribed in the presence of inhibitors of viral DNA synthesis (Figure 
1.2). In HCMV, early gene transcription can be detected throughout most 
of the genome, but most abundantly from the genomic repeat sequences 
and sequences adjacent to the repeats. The early phase of gene 
transcription extends for 24 hours or more and many early genes continue 
to be transcribed at late times. The most abundantly transcribed gene at 
early times is located in the large repeat sequences between 0.011 and 0.032 
map units (Greenaway & Wilkinson, 1987). It is therefore present in 2 
copies in every HCMV genome. This 2.7 kb unspliced RNA is transcribed 
8-24 hours after infection and continues to be transcribed throughout 
infection, however a viral protein product has not been identified. One 
other early gene of importance is the DNA polymerase gene which is 
located between 0.31 and 0.33 map units. This RNA transcript is an 
unspliced 4.7 kb mRNA that encodes the viral specific 140 kd polymerase 
(Kouzarides et al., 1987a). 
Late genes are classically defined as those transcribed after DNA 
replication (Figure 1.2). However, for HCMV there are few genes which 
are true late genes. In fact, most late genes do not require viral DNA 
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synthesis for transcription and thus are often termed delayed early genes. 
Delayed early and/or late genes code primarily for structural components 
of the virion and include genes coding for the matrix-tegument, the 
nucleocapsid, and the glycoprotein components of the envelope. One true 
late gene used in this study was the matrix-tegument gene located at 0.63 
to 0.65 map units in the UL coding for an unspliced 1.3 kb transcript. The 
product of this gene is a phosphorylated 28 kd protein which is extremely 
hydrophilic and highly immunogenic (Meyer et al., 1988) and was used in 
this study in the examination of reactivation of HCMV from differentiated 
monocyte-derived macrophages. 
1.4 CLINICAL ASPECTS OF ReMV INFECTION 
1.4.1 Epidemiolo~ 
HCMV has become a successful pathogen of man due to primarily 
three factors. First, most acute infections in healthy subjects are 
asymptomatic and associated with little or no morbidity, therefore, 
allowing these individuals to continue normal activity at a time when viral 
shedding would be maximum. Second, the virus can be transmitted 
vertically and horizontally during either primary infection, reinfection, or 
reactivation. Thirdly, in the healthy individual, it is never eradicated but 
persists in the host for the rest of the life of the individual (Ro, 1990). 
Therefore, the seropositive individual is a ready source of virus which can 
be transmitted to susceptible individuals through an, as yet ill-defined, 
ability to reactivate. Reactivated virus can be transmitted through close 
sexual and nonsexual contact (e.g. passage through an infected birth 
canal, breast feeding from a seropositive mother, or close family or play 
group contact) or through organ transplantation and blood transfusion. 
Classically, seroprevalence to HCMV ranges from 40-100% with a 
rough correlation between prevalence of antibody and the socioeconomic 
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conditions of the population (Table 1.1). A more recent epidemiological 
survey using the polymerase chain reaction technique suggested that the 
prevalence may be greater than previously reported (Bevan et aZ., 1991). In 
the latter report the overall prevalence was 20% higher than data 
generated by latex agglutination on the same healthy blood donor 
population. 
Age related seroprevalence studies suggest two primary periods 
associated with HCMV acquisition: the perinatal period and the age of 
sexual maturity. The latter is accounted for by both heterosexual and 
homosexual transmission (Drew et aZ., 1981; Mintz et aZ., 1983; Chandler 
et aZ., 1985; Handsfield et aZ., 1985; Collier et aZ., 1987). 
1.4.2 Patho~enesis 
The pathogenesis of HCMV infections appears to be multifactorial 
involving both direct cytopathic effects of the virus and perhaps 
immunopathologic effects contributed by the host cell-mediated immune 
response (Grundy, 1990; Pasternack et aZ., 1990). It is known that HCMV 
can produce tissue destruction in tissue culture and in vivo as manifested 
by cytomegalic cells. It is also known that decreasing viral load with the 
use of antiviral drugs correlates with improvement in some patients and 
can be used prophylactically to decrease the incidence of disease in other 
patients (Merigan et aZ., 1992). The virus replicates so slowly in vitro and 
most likely in vivo (Alford & Britt, 1990) that immunocompetent hosts are 
often able to contain viral spread, therefore limiting cytopathology, 
whereas subjects with impaired immune function or the immature fetus 
manifest various levels of disease severity. 
The immune response is generally considered to be protective. 
Antiviral antibodies are known to ameliorate disease in some cases 
through prophylaxis or therapy (Weimar et aZ., 1990; Skarp-Orberg, 1990; 
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Snydman et al., 1987; Winston et al., 1987) and in general, the seropositive 
transplant recipient is not at as great a risk of serious HCMV disease as 
the seronegative recipient of a seropositive organ (Rubin, 1990). In 
addition, there is evidence to support the fact that cell-mediated immunity 
is protective in animal models and in the clinical setting (Starr & Allison, 
1977; Quinnan et al., 1982; Rook et al., 1984; Ho, 1980; Reddehase et al., 
1985). Advances in defining the antigen targets recognized by CMV-
specific cytotoxic T lymphocytes (CTLs) have shown that not only late 
antigens but also non structural HCMV IE and early antigens are 
recognized by HCMV specific CTLs in both murine and human systems 
(Reddehase et al., 1984a; Reddehase et al., 1984b; Reddehase et al., 1986; 
Koszinowski et al., 1987; Borysiewicz et al., 1988a; Borysiewicz et al., 
1988b). One mechanism, therefore, by which CTLs contain viral infection 
may be lysis of cells at an early stage of infection preventing 
dissemination. Similarly, IE specific CTLs may be one mechanism by 
which the immune system controls persistent or reactivated latent virus in 
the normal immune carrier. 
However, there are other reports, that indicate viral reactivation can 
occur even in the presence of high titer neutralizing antibody (Chou, 
1990b). For example, prior immunity does not completely protect the 
seropositive allograft recipient. These patients are still at risk of 
reactivation of HCMV or of superinfection from HCMV strains carried in 
transplanted organs (Chou, 1990; Rubin, 1990; Smyth et al., 1991). 
Similarly, severe manifestations of congenital HCMV infection in 
neonates born to HCMV immune mothers have been reported (Stagno et 
at., 1973), although this is very rare. 
In addition, both animal models and clinical evidence suggest that 
immunopathologic mechanisms of disease mediated by CTLs may exist 
(Shanley et al., 1982: Grundy et al., 1987a; Grundy et al., 1990). There are 
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Table 1. Prevalence of Antibody to HCMV in Adult Populations 
Location 
Lyon, France 
Freiburg, Germany 
St. Gallen, Switzerland 
Albany 
Melbourne 
Houston 
Buenos Aires 
Hong Kong 
Sendai, Japan 
Manila 
Morocco, Morocco 
Entebbe, Uganda 
Percentage with CF* 
antibody to CMV 
40 
42 
45 
45 
54 
79 
81 
9i 
00 
100 
93 
100 
-----------------------------------------------------
Data from Ho, 1990. 
* CF = Complement Fixation 
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many factors to be considered in evaluating the relevance of these reports 
(Pasternack et aI., 1990) but in general the lack of correlation of virus titers 
with severity of histopathology or with mortality (Grundy et al., 1987a) 
make it necessary to consider immune mechanisms as another possible 
component of pathogenesis of disease. 
Finally, aspects of HCMV's ability to interact with the host immune 
response should be mentioned. It has been reported that HCMV impairs 
the ability of lymphocytes and monocytes to produce and respond to 
interleukin-1 and interleukin-2 (Kapasi & Rice, 1988). As well, HCMV has 
been reported to impair function of HCMV-specific CTLs (Schrier and 
Oldstone, 1986) and to change the ratio of helper/suppressor T cells by 
decreasing the helper subset and increasing the suppressor subset 
(Carney et al., 1981). In congenitally infected neonates, the same 
impairment of HCMV -specific CTLs has been demonstrated and a 
termination in viral shedding is correlated with a return of these cells to 
normal function. 
1.4.3 Cone-enital HCMV 
HCMV rarely causes disease in immunocompetent children 
infected in the perinatal period. Even infants infected in the immediate 
postnatal period either in the course of delivery or by postnatal breast 
feeding are rarely symptomatic. Unfortunately, this is not true in 
congenitally infected infants. 
HCMV is the most frequent cause of congenital viral infections in 
humans (Weller, 1971) and is endemic worldwide leading to an average 
incidence of congenital infection in 1% of all newborn infants (Alford et al., 
1990). There is, in contrast to other viral diseases, a direct relationship 
between positive serostatus of the mother and prevalence of congenital 
infection. Maternal immunity, therefore, is unable to prevent both HCMV 
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reactivation during pregnancy and HCMV transmission to the fetus 
(Stagno et al., 1977; Schopfer et al., 1978; Stagno et al., 1982). It has been 
shown that transmission of reactivated persistent virus is the most 
common source of congenital infection due to HCMV (Stagno et al., 1977; 
Stagno et al., 1982). 
Historically, congenital HCMV infection, as defined by excretion of 
virus within the first week of life, is a condition that has been associated 
with severe signs and symptoms (Weller & Hanshaw, 1964). The most 
devastating disease complex, cytomegalic inclusion disease or CID (Weller 
& Hanshaw, 1964), has been described since the early parts of this century 
and represents about 10% of congenital infection due to HCMV. This 
severe form of congenital infection is overwhelming associated with 
primary infection of the mother and tends to be associated with infection in 
the early trimesters of pregnancy. Yet, not all fetuses born to mothers 
with primary infection during pregnancy will be affected and it has been 
described that the risk of severe disease may be predicted by positive 
amniotic fluid cultures (Grose et al., 1992). It has recently been 
appreciated that a significant number of other neonates, who are 
asymptomatic at birth, are also at risk for serious sequelae. These infants, 
born to HCMV carriers, represent 90% of congenitally infected neonates 
and have no apparent manifestations at birth (Pass et al., 1980). 
Children born to HCMV carriers, who transmit infection from 
endogenous reactivated virus, have a high risk of developmental and other 
physical abnormalities (5-15%). These include: sensorineural hearing 
loss, microcephaly, motor defects (spastic diplegia or quadraplegia), 
mental retardation, chorioretinitis, and dental defects. These are usually 
recognized within the first 2 years of life, but progressive hearing loss can 
occur (Melish & Hanshaw, 1973; Saigal et al., 1982). In the USA, 
reactivated virus in healthy female carriers who are pregnant leads to the 
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infection of 30,000-40,000 children per year of whom 4500-6000 will have an 
associated serious outcome as a direct effect of this infection (Yow, 1989). 
1.4.4 Immunocompromised Adults and HCMV Infection 
Analogous to congenital infections, reactivation of persistent virus 
either from transplanted organs, transfused blood, or the subjects own 
endogenous virus, is the most frequent source of infection in 
immunocompromised adults (Rubin, 1990). Primary infection is rare. 
HCMV is the single most important infectious agent affecting recipients of 
organ transplants, where approximately 2/3 of recipients will have HCMV 
infection 1-4 months after transplant. The high incidence of HCMV 
infections in these patients is due to a large reservoir of persistent virus 
(table 1.1) in the population in general, and is specifically correlated with 
the use of immunosuppressive drugs and allograft rejection (Rubin, 1990). 
In particular, the use of antithymocyte globulin is associated with the 
highest morbidity due to HCMV infection following transplantation. 
1.5 HERPES VIRUS PERSISTENCE 
All human Herpesviruses have the ability to persist after 
symptomatic or asymptomatic primary infection (Whitley, 1990; Miller, 
1990a; Alford & Britt, 1990; Gelb, 1990; Pellett et at., 1992). In general, 
these viruses have developed different mechanisms of persistence after 
primary infection and mechanisms to avoid elimination by the host 
immune system. Since these forms of chronic infection or carrier states 
are generally asymptomatic and are often associated with limited viral 
production they have been loosely termed latent infections. However, on a 
molecular level the term latency will be used here to mean: the reversibly 
nonproductive infection of a cell with or without limited viral gene 
expression by a replication-competent virus (see Garcia-Blanco & Cullen, 
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1991 for review). In addition, the word persistence has been used to mean 
continuous low level production of progeny virus in asymptomatic carriers 
(see Garcia-Blanco & Cullen, 1991 for review) but more generally to mean 
any mechanistically-based continuance of virus (Sissons et al., 1991). 
Because it is convenient to have a general term which can be applied to 
viral maintenance in the normal human carrier when little is known 
about the actual mechanisms of maintenance, I will use the term 
persistence as an undefined mechanism of viral continuance. Virus 
persisting by production of progeny virus in the otherwise asymptomatic 
host will be termed low level lytic/replicative viral persistence. 
The latent forms of the neurotropic Alpha subfamily viruses, 
human herpes simplex virus 1 and 2 (HSV1, HSV2) and varicella-zoster 
virus (VZV), are present in sensory ganglia (Baichwal & Sugden, 1988; 
Whitley, 1990; Alford & Britt, 1990) and show restricted gene expression. 
They can be reactivated in yiyo to cause local lesions in the distribution of 
the sensory ganglia in which they reside (e.g. thoracic dermatomal 
distribution of zoster latent in thoracic dorsal root ganglion, or vermilion 
border lesions from HSV latent in the trigeminal ganglia). The 
mechanism of herpes simplex latency has been studied extensively. On a 
molecular level, HSV 1 appears to be present in an unintegrated episomal 
form with estimates of 20 copies per latently infected cell (see Stevens, 1989 
for review). Latent HSV 1 and HSV 2 express RNA which maps to the long 
terminal repeat and are transcribed from the strand opposite the 
immediate early gene ICPO. The unspliced and spliced products of the 
latent transcript, 2 of which predominate, are unusual in the fact that they 
are not polyadenylated (although some less abundant polyadenylated 
transcripts do exist in the latent state in ganglia), they are uncapped, 
restricted to the nucleus and have no identified protein product (Wagner et 
al., 1988; Stevens, 1989). It has therefore been theorized that these latency 
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associated transcripts or LATs (Stevens et ai., 1987) are nothing more than 
stable introns spliced from of an 8.3 kb pre-messenger RNA which has 
been found in lytic infection (see Garcia-Blanco & Cullen for review). 
However, the mature transcript from this 8.3 kb RNA is found only in lytic 
infection and not in latent infection and it would seem that the LATs 
represent more than just stable introns as they are found in both HSVl, 
HSV2 and in other neurotropic herpes viruses (Rock et ai., 1986; Cheung, 
1989). As the LATs are antisense to and overlap one-third of the 3' end of 
ICPO, it has been postulated that they could form stable RNA duplexes 
with ICPO transcripts as a mechanism of latency. However, LAT(-) 
mutants are not impaired in their ability to establish or maintain latency 
(Hill et ai., 1990; Block et al., 1990) and LAT appears to function primarily 
in the reactivation process (Hill et ai., 1990). HSV 1 can be reactivated from 
latently infected ganglia in vitro by explantation followed by in vitro 
culturing, and in yivo by a number of stimuli (Whitley, 1990). Explantation 
has been shown to up regulate host cell expression of AP-l and Oct 1, the 
latter of which is necessary for activation of immediate early gene 
expression by the tegument protein VP16 during lytic infection (O'Hare & 
Goding, 1988). The observation that only low levels of OCT 1 are found in 
ganglion cells have, therefore, been postulated as one mechanism of 
preventing HSV alpha gene expression during latency but other workers 
have postulated that an inhibitory protein (the neuronal form of OCT 2) can 
efficiently compete with VP16 for binding to viral DNA TAATGARAT 
motif in IE gene promoters and therefore repress expression (see Garcia-
Blanco & Cullen, 1991 for review). The principle mediator, however, of the 
switch from latency to reactivation is likely to be ICPO. This gene product 
is sufficient and probably necessary for reactivation (Zhu et al., 1990). It 
transactivates itself, as well as other immediate early genes, and early 
genes of the HSV cascade (see Garcia-Blanco & Cullen, 1991 for review). 
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For VZV, less is known. However, RNA expression has been 
documented in latently infected cells and explantation induces expression 
of IE RNA and some protein products, but without production of viral 
progeny as in HSV (see Stevens, 1989 for review). Unlike HSV LAT, these 
transcripts are found in at least 5 widely separated areas of the genome. It 
is not known in what physical state the genome exists in the ganglia. In 
addition, controversy exists as to which cell type harbors VZV genome 
during latency. Two groups have suggested that ganglionic neurons 
harbor VZV (Gilden et al., 1986; Hyman et al., 1983) while others (Croen et 
at., 1988) have suggested that the virus is present in satellite cells of the 
ganglia. The latter group postulates that this location may account for the 
in yiyo clinical differences between HSV reactivation (more frequent but 
less extensive) and VZV reactivation (much less frequent but more 
extensive lesions). It could be that satellite cells have to produce more 
virus to reach a threshold of infectious particles necessary to infect nearby 
neuronal cells. The larger production of viral particles leads to more 
extensive lesions upon reactivation, but the difficulty in reaching this 
threshold limits the number of clinical reactivations. Although these 
neurotropic viruses are related, the limited data on VZV latency suggest a 
different mechanism to HSV latency. 
Epstein-Barr virus (EBV), the prototype human 
lymphotropic virus is a member of the Gamma subfamily and, exhibits 
both latency and low level replicative persistence depending on the cell type 
infected. It is latent in yiyo in B cells with restricted gene expression, but 
there is some low level spontaneous reactivation (Miller, 1990a; Garcia-
Blanco & Cullen, 1991). In epithelial cells, however, it is persistent with 
low level chronic production of progeny virus in the more terminally 
differentiated epithelial layers (see Allday & Crawford, 1988 for review; 
Young et al., 1991). In B cells, the genome is maintained as an episome in 
40 
Introduction 
relatively high copy number, at approximately 60 copies per cell (see 
Stevens, 1989 for review). It is much less common to find it integrated (e.g. 
Namalwa cell line, 1B4 cell line). Most information concerning EBV 
latency is generated from studies of immortalized B lymphoblastoid cell 
lines (LCL), EBV-carrying Burkitt lymphoma (BL) cells, or 
nasopharyngeal carcinoma (NPC) cells. There are at least 6 nuclear 
antigens (EBNA 1-6) and 2 membrane antigens (LMP & TP) expressed in 
in vitro maintained LCL. In general, the transcriptional pattern is 
complex with long range splicing, spanning large areas of the genome 
(see Stevens, 1989 for review) and final mRNA products appear to be 
generated by alternative splice and polyadenylation site selections. The 
kinetics of EBNA protein expression suggest that EBNA2 and EBNA5 are 
expressed earlier than EBNA1 and EBNA3,4,6 (Allday et al., 1989). In all 
three phenotypes of EBV carrying cells mentioned above, EBNA 1 is 
expressed (Klein, 1989) but the three cell types differ in their expression of 
the other 5 nuclear antigens and LMP. LCLs express all of the EBNAs and 
LMP while NPC express LMP only in addition to EBNA 1 and BL express 
only EBNAl and none of the other latency associated genes. Three gene 
products, EBNA2, EBNA4 and LMP have been shown to contain epitopes 
for cytotoxic T cells and T-cell populations obtained from 
immunocompetent individuals readily kill autologous EBV-carrying LCLs 
in vitro (Moss et al., 1978). Therefore, it is difficult to explain how LCL-like 
cells might survive in vivo. It may be that a more restricted pattern of 
expression than seen in LCLs may exist in vivo (Qu & Rowe, 1992). 
Activation of EBV, like HSV, can be stimulated by a number of physiologic 
changes. In vitro, phorbol esters such as TPA, antibody to 
immunoglobulin, butyrate and calcium ionophores have all been shown to 
increase the efficiency of reactivation. The principle mediator of such 
induction of the lytic cycle is the ZEBRA protein, expressed by the BZLF-1 
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open reading frame (Miller, 1990b). ZEBRA acts through AP-1-like DNA 
elements and shares protein sequence similarity with the c-fos component 
of AP-1 (Farrell et at., 1989). In addition, TPA is thought to act through 
AP-1 sites which are present in the BZLF-1 promoter. Expression of 
ZEBRA is sufficient to trigger the viral lytic cascade (Flemington & Speck, 
1990). 
The Beta subfamily of human herpes viruses includes human 
herpes virus 6 (HHV6) and HCMV. HHV6, isolated by Salahuddin et at. 
(1986), has been shown to be the etiologic agent of roseola infantum 
(Yamanishi et at., 1988) but its significance as a more serious pathogen is 
unknown. Viral replication can be induced by in vitro cultivation of T cells 
from patients with lymphoproliferative disorders or HIV and monocytes 
have been reported to be a site of persistence in healthy carriers (Kondo et 
at., 1991). Beyond this little is known concerning the state of persistence. 
Despite the fact that HCMV was initially isolated in tissue culture 
more than 30 years before HHV -6, the amount of information with respect 
to the state of persistence of HCMV is still limited. There are limited data 
regarding the cell type which harbors virus in the healthy carrier, even 
less is known about transcriptional expression during persistence and 
there is no information on the physical state of the genome in persistence. 
One report (Schrier et at., 1985) suggested that lymphocytes harbored 
persistent HCMV in healthy carriers and expressed IE genes but 
productive infection was not detected by coculturing. However, the same 
group (Gnann et at., 1988) was not able to find evidence of persistent virus 
in pre-transplant kidney biopsies using the same in situ technique and the 
same probes, despite the fact that lymphocytes would have been present. 
This may reflect the fact that in situ hybridization is not sensitive enough 
to detect rare copy persistent virus. Toorkey & Carrigan, 1989, have 
reported that many different cells in different organs harbor persistent 
42 
Introduction 
HCMV and express lEI proteins but not late proteins. However, the 
tissues analyzed in this study were from autopsies and post mortem 
changes may influence viral IE expression and, therefore, not truly reflect 
the state of the virus in the healthy individual. Consequently, the sites 
persistence of HCMV are still poorly defined and there is no definitive 
evidence concerning transcriptional expression during persistence. 
Finally, there are no reports of successful reactivation of persistent HCMV 
from tissues of healthy carriers despite the fact that at least one group 
(Ibanez et al., 1991) have attempted to reactivate HCMV from WBC of 
healthy carriers as the latter cells have been implicated to harbor 
transmissible virus (Yeager et al., 1981; Adler, 1983; Tolpin et al., 1985; 
Gilbertet al., 1989, DeWitte, 1990). 
1.6 OBJECTIVES OF DIE S'JUDY 
With the dearth of information about the state of persistence of 
HCMV in the healthy carrier, I chose to pursue this area of study with the 
following objectives in mind. 
(i). Define specific cell types which harbor HCMV in the healthy 
carrier. As there is no animal model susceptible to human CMV and no 
in vitro latency system, it would be important to study a readily available 
tissue in the normal human host such that further molecular studies of 
persistence could be carried out more easily. As there is circumstantial 
evidence that HCMV exists in the peripheral blood of healthy carriers, 
most likely in the white cell fraction, I chose to determine the cell type(s) in 
the peripheral blood of healthy carriers that harbor HCMV. As persistent 
HCMV is likely present in very low copy number and as healthy volunteers 
would be able to donate only a limited amount of blood, this study would 
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require a highly sensitive system for analysis. Therefore, I decided to use 
the polymerase chain reaction as my primary methodology for detection of 
DNA since even a 50% efficiency of this method has a theoretical 
amplification power of over 109 with a nested PCR (Saiki et al., 1985). 
(ii). Identification of a specific site of persistence in the peripheral 
blood, would then permit an analysis of transcriptional activity of 
persistent HCMV in healthy carriers. Limited data suggest that there is a 
restriction in HCMV gene expression in PBMC during asymptomatic 
infection. However, the techniques used to define HCMV expression in 
these situations have been relatively insensitive. Therefore, reverse 
transcription coupled with PCR (RT-PCR) was chosen as a detection 
system for HCMV gene expression as it is highly sensitive. However, the 
need to use RT-PCR to detect low copy number transcripts would not 
permit a broad screen for evidence of HCMV transcription. Similarly, no 
animal or in vitro model of HCMV persistence/latency exists, in which to 
define putative latent/persistent transcription. Consequently, I decided to 
target specific HCMV genes of all phases of lytic infection. 
(iii). Finally, once the spectrum of HCMV gene expression during 
persistence was defined, I would then analyze the mechanism of this 
regulation using peripheral blood cells and established myeloid cell lines. 
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CHAel'ER2 
MATERIAlS AND METHODS 
All subjects were healthy adult volunteers. 
2.2 SEROLOGy 
2.2.1 ELISA 
Serologic status was determined using a competitive ELISA 
system (CompEnz-CMV, Northumbria Biologicals), in which the 
ELISA plate was supplied, pre-coated, with HCMV antigen. Fifty JlI of 
serum and 50 JlI of horseradish peroxidase-conjugated murine Mab 
anti-HCMV were incubated overnight at 4 0C. After 4 washes with 
PBS-Tween, sample and control wells received a working strength of 
3,3',5,5', tetramethyl benzidine substrate in an acetate/citrate buffer 
containing 0.025% (v/v) hydrogen peroxide, pH 6.0. This was allowed to 
incubate for 20 minutes at room temperature and the reaction was 
stopped with 2N H2S04. Plates were read at 450 nm on an ELISA plate 
reader (Titertek Multiskan® MC, Flow) and average values were 
determined for each sample and for the control wells. All samples 
were prepared in duplicate along with 1 positive, 3 threshold, and 2 
negative controls (supplied with kit). For duplicate test samples, 
obviously discordant values were disregarded and samples were re-
tested. Results were interpreted as positive for any test serum when the 
A450 was less than the mean A450 of the threshold control serum (to be 
considered a valid control the mean of the threshold values had to be 35-
65% of the mean value for the negative control). A negative result 
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occurred when the A450 of any test serum was greater than the mean 
absorbence value obtained in the threshold control serum. 
2.2.2 Latex A~~lutination 
HCMV latex agglutination assay (CMVScan@, Becton Dickinson) 
was used to confirm all seronegative values derived from the HCMV 
ELISA as this assay will detect both IgM and IgG anti-HCMV antibodies. 
This commercially available assay was performed by placing 25 JlI of test 
serum or control sera (supplied by the kit) onto individual circumscribed 
sample areas on a test card. Samples and controls then received one drop 
of latex particles which had previously been sensitized with CMV viral 
antigens. The cards were rotated in a moist chamber for eight minutes to 
mix the serum and latex particles. Readings were performed under 
bright light by comparing to controls. Visible clumping of particles 
indicated a positive result whereas, smooth and evenly dispersed particles 
indicated negative agglutination. 
2.3 MAINTENANCE OF CEI,I, 1,INES 
2.3.1 THP-1 Cells 
THP-1 cells (Tsuchiya et al., 1980) were obtained from the ATCC. 
This immortalized human cell line consists of premonocytic human cells 
originating from a child with acute monocytic leukemia. Upon 
differentiation with a number of chemicals, these cells develop into 
macro phages (Tsuchiya et al., 1982) despite the fact that they retain some 
granulocyte surface markers (Skubitz et al., 1983). Cells were maintained 
as suspension cultures in RPMI medium with 10% FCS and were split 1 to 
4 every 5-7 days. 
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2.3.2 F2002 and MRC5 Cells 
F2002 and MRC5 (Jacobs et al., 1970) fibroblasts were obtained from 
Flow and the ATCC, respectively. These cells were maintained in MEM 
Eagle medium (MEM) with 10% FCS. Cells were split 1 to 2 every 5-7 days. 
These cells undergo 42-46 population doublings before onset of decline in 
proliferation. For all experiments, passages ranging from 26-40 were 
used. To passage adherent monolayers, cells were washed twice in MEM 
without serum then detached with trypsin-EDTA (0.5g trypsin, 0.2g EDTA, 
0.85 g NaClIL, Gibco) and incubated at 37 0C for 5-10 minutes. Trypsinized 
cells were divided into new flasks and fresh MEM 10% FCS medium was 
added. 
2.3.3 Media and Cryopreseryation 
RPMI 1640 is an enriched formulation with a more extensive 
application for mammalian cells and was originally formulated for 
suspension cultures while MEM Eagle medium (Earle's salts) was 
designed for use with primary mammalian cell cultures e.g. MRC-5 cells. 
Both media were supplemented with 2 mM L-glutamine, 100 IU/ml 
penicillin, 100 mglml streptomycin, and 1 gIL sodium bicarbonate. For 
freezing, THP-1 cells were pelleted and resuspended in FCS with 10% 
DMSO then frozen at -80 °C overnight then transferred to liquid nitrogen 
for long term storage. To freeze HELF cells, 1 confluent T150 flask was 
trypsinized resuspended in 10 ml of MEM 10% FCS and centrifuged 200 xg 
for 5 minutes. Pelleted cells were resuspended in 4 ml of FCS with 10% 
DMSO and divided into 4 cryogenic vials (Corning). Vials were placed at 
-80 °C overnight then transferred to liquid nitrogen for long term storage. 
47 
Materials and Methods 
2.4 VIRUSES 
2.4.1 HCMV AD169 Strain 
HCMV strain AD169 was obtained originally from the ATCC (cat. 
no. VR-538), and was plaque purified twice. The virus was then 
propagated in F2002. Using a MOl of 0.01, the medium from HCMV 
infected fibroblasts was harvested on a daily basis until the cell monolayer 
was destroyed by CPE. Supernatants were clarified, aliquoted and frozen 
at -80 oCr Aliquots were plaque-titered using 10-fold dilutions of viral 
supernatant on HELF with a 1% agarose (SeaPlaque@, FMC Bioproducts) 
overlay. 
2.4.2 HCMV Clinical Isolates 
Clinical HCMV isolates, specifically the strain designated M, was a 
gift of Dr. Roz Smyth and Dr. Jane Minton and was cultured from a 
bronchoalveolar lavage sample from a heart-lung transplant patient. 
2.5 ISOLATION OF PBMC & PMNL BY DENSITY·GRADIENT 
CENTRIFUGATION 
Peripheral blood was obtained by percutaneous venepuncture and 
anticoagulated with either heparin (10 units per ml of blood) or with 0.5M 
EDTA pH 8.0 (final concentration 4 mM). Ten ml of anticoagulated blood 
was layered onto 10 ml of LymphoprepTM (9.6% (w/v) Sodium metrizoate 
and 5.6% (w/v) polysaccharide, Nycomed Pharma AS) in a 25 ml universal 
tube (Sterilin, England) and centrifuged at 800 xg for 15 minutes with no 
brake upon deceleration. The density gradient (B~yum, 1968) yielded an 
upper plasma layer, a cloudy white PBMC band at the plasma 
LymphoprepTM interface and a PMNL-enriched fraction lying at the top of 
the aggregated RBC pellet as shown in Figure 2.1. 
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The PBMC and the PMNL-enriched fraction were both washed twice 
as follows: 10-15 ml of sterile PBS were added to the cells and the tube was 
vigorously mixed to break-up cell clumps. After centrifugation at 450 xg 
for 10 minutes; the cell pellet was washed for a final time by discarding the 
supernatant and resuspending in 5 ml of sterile PBS followed by 
centrifugation at 200 xg for 5 minutes. All steps were performed in a 
sterile manner with sterile disposable plastic pipettes in a PCR-safe 
laminar flow hood in which neither virus or infected tissues had been 
processed. 
2.6 SEPARATION OF SPECIFIC CEI.I. POPULATIONS 
2.6.1 Isolation with Mab and FACS 
PBMC were labeled with mouse monoclonal anti-human CD3 IgG 
(derived from the mouse hybridoma cell line OKT 3 CRL 8001, purchased 
from the European Collection of Animal Cell Cultures) and a fluorescein 
isothiocyanate-conjugated F(ab')2 fragment of rabbit anti-mouse IgG 
(Dakopatts), or with fluorescein-conjugated mouse anti-human CD14 
antibody (Becton Dickinson). All antibody incubations were carried out at 
room temperature for 1 hour, were washed twice in 10 ml of PBS after each 
incubation and fluorescein-conjugated antibody incubations were 
performed in the dark. 
F ACS was performed on a EPICS C flow cytometer where droplets 
were electrostatically separated into positive and negative populations 
(gated using forward and 90 degree light scatter) with single fluorescence. 
2,6.2 Isolation of Monocytes by Adherence 
Adherent cells were isolated from PBMC or depleted from PMNL by 
plating the respective cell populations on 14 em plastic petri dishes in PBS 
and incubating for 1 hour at 37 oC in 5 % C02 (Treves et. aI., 1980). PBMC 
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... Top of Plosmo Leuel 
... PBMC Bond > Lymphpr.p~ 
... PMNL -Enriched Froction 
4----Red Blood Cell Pellet 
Figure 2.1. Density-Gradient Separation of Whole Blood. The figure 
shows a diagram of the separation achieved after density-gradient 
centrifugation with whole blood and LymphoprepTM and abbreviated 
labels are detailed as follows: PBMC = peripheral blood mononuclear 
cells and PMNL = polymorphonuclear leukocytes . 
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adherent cells, representing primarily monocytes, and PMNL-enriched 
non-adherent cells (neutrophils, eosinophils, and basophils) were 
collected. 
2.6.3 Isolation with Immunomametic Beads 
PBMC were harvested as described (Section 2.5) and adhered to 
plastic for 1 hour at 37 0C in 5% C02 (Section 2.6.2). Adherent cells were 
scraped and collected, whilst nonadherent cells were collected and divided 
in half for positive selection with anti-human CD4 or anti-human CD8 
using antibody specific immunomagnetic beads (Dynal®). Cells were 
incubated in the presence of the beads for 1 hour at 4 0C (bead to cell ratio: 
10-1). Beads with attached cells were washed 6 times in 10 ml of PBS per 
wash to remove any unbound cells. Finally, beads with attached cells, 
were resuspended in 2 ml of PBS. 200 J.11 were further processed with 
DetachaBead (Dynal®) according to manufacturer's directions and 
released cells were then cytospun (Cytospin 2, Shandon) onto glass slides 
for purity analysis. The remaining 1.8 ml of cells attached to beads were 
magnetically separated and the cell pellet was processed for DNA (section 
2.7). 
2.6.4 Purity Analysis 
To analyze purity after FACS, a small sample of cells was either 
resorted with the EPICS C flow cytometer or was fixed with 
paraformaldehyde and analyzed on the Coulter EPICS Profile machine. 
In addition, adherent and non-adherent cells were stained with a 
fluorescein-isothiocyanate conjugated mouse anti-human CD14 or CD3 
antibody to determine the percentage of mature monocytes or CD3 positive 
T lymphocytes present in cells adhering to plastic. 
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In order to detect the presence of contaminating monocytes in non-
adherent PMNL fractions, a staining technique to detect esterase using a-
naphthyl butyrate was employed. Slides of non-adherent PMNL were air 
dried and fixed for 30 seconds with cold buffered formalin acetone (pH 6.6). 
After rinsing with tap water, slides were allowed to incubate for 45 
minutes at room temperature with a substrate of a-naphthyl butyrate 
(Sigma) in phosphate buffer (pH 7.4) and a coupler of hexazotised new 
fuchsin (Sigma). Slides were then rinsed in tap water and counterstained 
with Mayers hematoxylin (Sigma) for 45 seconds. Resultant enzyme 
activity is seen as red-brown granules in monocytes. 
Purity of CD8+ and CD4+ cells was analyzed after using 
DetachaBead and cytospining cells onto slides. Cells were fixed on slides 
in acetone/methanol (1: 1) for 3 minutes at -20 °C and air dried. Then, 
slides with CD8 or CD4 cells were stained with either CD8 or CD4 antibody, 
respectively, or CD4 or CDS antibody, respectively, (CD4 and CD8 
antibodies were obtained from the Royal Free Hospital School of Medicine, 
Academic Department of Immunology), for 1 hour at room temperature. 
Following 2 washes in PBS/O.l% (v/v) Tween 20, a 1/30 dilution of rabbit 
anti-mouse fluorescein isothiocyanate-conjugated F(ab')2 fragment 
(Dakopatts) was applied to the cells for a further 60 minutes at room 
temperature. Following 2 more washes, slides were air dried and 
Citifluor was applied prior to UV microscopy. Positive controls were 
unselected non-adherent cells processed in the same way. In addition, 
cells were analyzed for the presence of monocytes by butyrate esterase 
staining as described above. All spots were performed in duplicate for 
each staining technique. 
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2.7 DNA EXTRACTION 
2.7.1 RNaselProteinase K Method 
Cells were washed, pelleted, and resuspended in 250 J.lI ofTE (10 mM 
Tris-HCI pH 8.0, and 1 mM EDTA). An equal volume of 2x PK buffer (300 
mM NaCI, 200 mM Tris-HCI pH 7.5, 25 mM EDTA pH 8.0) was added. 
One-tenth volume of 10% SDS (sodium dodecyl sulfate) was added and 
mixed well. RNase was added to a final concentration of 2 mg/ml and the 
solution was incubated at 37 °C for 1 hour. Following this, Proteinase K 
was added to a final concentration of 6 mg/ml and incubated at 37 0C for 2 
hours. Samples were extracted with an equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1), centrifuged at 10,000 xg for 5 
minutes. The aqueous phase was recovered and extracted with an equal 
volume of chloroform/isoamyl alcohol (24:1), and centrifuged at 10, 000 xg 
for 5 minutes. DNA was precipitated from the aqueous phase with 2.5 
volumes of ethanol at -20 0C overnight. The precipitated DNA was pelleted 
at 10,000 xg for 15 minutes, washed once with 70% ethanol, dried and 
resuspended in TE. DNA concentrations were estimated by comparison to 
known concentration standards of DNA on an ethidium bromide-stained 
0.6% agarose gel. 
Some DNA samples were extracted using the RNaselProteinase K 
method. These were the samples used for the CD3, CD14, and initial 
adherent cell studies (see Results Section 3.4.2). However, as this DNA 
preparation often led to a high percentage of non-amplifiable DNA 
samples (approximately 25%), an alternative method using sodium 
perchlorate was employed (section 2.7.2). 
2.7.2 Sodium Perchlorate Method 
DNA was extracted using a modified sodium perchlorate method 
(Weetman et al., 1990). Pellets of 105 to 106 cells were thoroughly mixed 
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with 600 III of solution 1 (100 mM NaCl, 50 mM EDTA, pH 8), followed by 50 
III of solution 2 ( 25% SDS), and finally 150 III of solution 3 (5M Na 
perchlorate). The cell pellet solution was extracted with 
phenol:chloroform:isoamyl alcohol (25:24:1, Sigma), centrifuged at 10,000 
xg for 15 minutes at room temperature. The aqueous phase was extracted 
with chloroform:isoamyl alcohol (24:1), and precipitated with an equal 
volume of isopropanol for a minimum of 15 minutes on ice. The DNA was 
pelleted by centrifugation at 10,000 xg for 15 minutes at room temperature, 
and washed twice with 70% ethanol. Ethanol was removed and the damp 
pellet was resuspended in TE 00 mM Tris-HCI pH 8.0, and 1 mM EDTA, 
Sigma). DNAs were dialyzed overnight at 4 0C against 1000-fold volume of 
TE. After dialysis, DNA concentration was analyzed by measuring the 
A260nm in a 1 cm path length of a diluted sample on a SP6-450 UV NIS 
Spectrophotometer (PYE UNICAM). Final concentration of DNA was 
calculated as follows: A260nm x 50 0 A260 unit = 50 Ilg/ml) x dilution 
factor = f..lg/ml. In some cases where the DNA samples were extremely 
small, 1 III of DNA was run on an 0.6% agarose gel and the concentration 
was visually estimated against known standards. DNA was frozen at -20 
0C for storage. 
All DNA extractions were performed in a PCR-safe manner (section 
2.10). 
2.8 RNA EXTRACTION 
2.8.1 Total RNA Extraction 
A total RNA extraction kit (Promega) based on the method of 
Chomczynski et al. (987), was used. All manipulations were carried out 
on ice and in a PCR-safe manner (see section 2.10). 
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Medium was removed from primary monocytes or MDM cells and 
any floating cells were pelleted at 300 xg for 5 minutes in PCR-safe sterile 
disposable 50 ml falcon tubes. Medium was decanted and pellets were held 
on ice until processed. Denaturing solution (DN solution), containing 
guanidinium thiocyanate in a citrate/sarcosine/(3-Mercaptoethanol buffer, 
was added directly to adherent monolayers and cells were scraped (using 
PCR-safe sterile disposable plastic cell scrapers, Greiner) into the DN 
solution. Adherent cell extracts were pooled from all flasks using PCR-
safe sterile disposable pipettes and added to the cell pellets collected 
initially from cells floating in the medium. Extracts were acidified with 
1/10 volume of 2M Na acetate, pH 4.0. An equal volume of acid 
phenol:chloroform:isoamyl alcohol was added, mixed well and allowed to 
settle for 15 minutes on ice then centrifuged at 10,000 xg for 30 minutes at 4 
0C. The aqueous phase was recovered and precipitated with 100% 
isopropanol on dry ice for at least 30 minutes or overnight at -80 0C. RNA 
was pelleted by centrifuging at 10,000 xg for 30 minutes at 4 0C. Pellets 
were resuspended with 100 III of DN solution, pooled and reprecipitated 
with and equal volume of 100% isopropanol on dry ice for at least 30 
minutes or overnight at -80 oC. RNA was pelleted at 10,000 xg for 30 
minutes at 4 0C. The pellet was washed with 75% ethanol and centrifuged 
at 10,000 xg for 5 minutes at 4 °C. After removing all ethanol by 
aspiration, pellets were further processed as detailed below with RNase-
free DNase (section 2.8.2). 
2.8.2 DNA-free RNA 
The acid/phenol-based RNA isolation did not yield DNA free RNA 
preparations (as determined by ethidium bromide stained agarose gel 
electrophoresis of RNA and by intron-spanning RT-PCR) and it was 
therefore necessary to remove contaminating DNA from all RNA isolated 
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from healthy subjects. Using RQFM, an RNase-free DNase (Promega), 
RNA samples were processed as follows: After the 75% ethanol wash 
RNA pellets were resuspended in 500 JlI ofRQ1 Buffer (40 mM Tris-HCI pH 
8.3, 10 mM NaCI, 6 mM MgCI2, and 10 mM CaCI2) with 2 U of rRNasin 
(Promega) and 15 U of RQFM. The mixture was incubated at 37 0C for 15 
minutes, then 1/2 volume of stop solution (50 mM EDTA, 1.5 M Na acetate, 
and 1% SDS) was added. RNA was extracted with acid 
phenol:chlorofom:isoamyl alcohol (25:24:1), precipitated with 1 volume of 
isopropanol, pelleted at 10,000 xg for 30 minutes at 4 oC, and washed once 
with 75% ethanol. The ethanol was removed by aspiration and the RNA 
pellet was resuspended in RNase-free water (Promega). For long term 
storage, RNA was reprecipitated with Na acetate pH 4.0 (final 0.25 M), and 
2.5 volumes of 100% ETOH and frozen at -70 0C. 
There were no solutions provided with the RQ1™ enzyme, therefore, 
all chemicals were prepared in a PCR-safe manner, see section 2.10. 
2.8.3 RNA Intemty Analysis and Concentration 
RNA integrity was examined by analysis on denaturing agarose 
gels and RNA concentration was determined by measuring optical density 
at 260 nm after removing all background DNA. 
Formaldehyde-denaturing agarose gel was prepared by melting 1.2 
g of agarose (ultraPURETM Agarose, Electrophoresis Grade, BRL) in 102 
mlofH20. The agarose solution was cooled to 50 0C and then the following 
were added in a fume cupboard: 24 ml of 5x MOPS buffer (Ix MOPS = 20 
mM MOPS, 8 mM Na acetate, 1 mM EDTA; prepared in 0.1% DEPC 
treated water and brought to pH 7.0 with 2N NaOH) and 6.5 ml of 37% 
formaldehyde. The gel was cast immediately. 
Five JlI of the RNA sample was evaporated to dryness by spinning 
under vacuum for 10 minutes in a Savant Speed Vac SC 100 model. 
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Samples were resuspended in 20 ~l of loading buffer (50% (v/v) deionized 
formamide, 6.5% (v/v) formaldehyde, Ix MOPS, 50 mg/ml ethidium 
bromide and 0.02% bromophenol blue). Resuspended samples were 
denatured at 80 °C for 20-30 minutes, placed on ice for 5 minutes, and 
electrophoresed in a formaldehyde-denaturing gel submerged in Ix MOPS 
and run at 3-5V/cm for 1-1.5 hours. The electrophoresed RNA samples 
were examined on a transilluminator (UVP, Inc.) at 312 nm for the 
integrity of ribosomal RNA as well as for the presence of any DNA. 
To determine RNA concentrations, 1 ~l of sample was diluted in 500 
~l of H20 and the absorbence at 260 nm (A260nm) was measured through 
a 1 em path length. If gel electrophoresis showed no evidence of DNA, this 
absorbence was deemed to represent RNA and RNA concentration (~g/ml) 
was determined as follows: A260 x 40 (lA260 = 40 ~g/ml of RNA) x 
dilution factor. 
2,9 REVERSE TRANSCRIPTION 
2.9.1 First Strand Synthesis 
First strand reverse transcription was carried out using 10 ~g of 
total RNA (approximately equivalent to 105 cells) and is detailed in section 
4.2.1. 
2.9.2 RT Sensitivity Analysis 
Total RNA was extracted from AD 169 strain HCMV infected MRC5 
cells, which had been infected for 1 week and showed 100% CPE. For every 
assay, 10 ng and 0.1 ng of RNA from HCMV infected cells, equivalent to 
102 and 1 HCMV infected cell respectively, were reverse transcribed in 
order to assess sensitivity of the RT. 
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2.10 PREVENflON OF PCR CONfAMINATION 
2.10.1 Sources of Contamination 
Contamination is a well recognized problem with PCR (Kwok & 
Higuchi, 1989; lvinson and Taylor, 1991; Jackson et al., 1991; Clackson et 
al., 1991) and particularly when using high cycle number or nested-peR, 
which are necessary to detect the extremely low copy genes and gene 
transcripts often found with persistent viral genomes. Amplification 
products from either the primary or the secondary phase of a nested PCR 
can easily be passed into other solutions from contamination of 
micropipettes or through handling with contaminated gloved hands. This 
has been termed PCR product carryover contamination (Kwok & Higuchi, 
1989; Williams, 1989; Gibbs et al., 1989; Sarkar & Sommer, 1990). DNA and 
RNA preparations from HCMV-infected tissue culture represent another 
source of micropipette or handling contamination that may be "carried 
over" to peR solutions. 
Moreover, when PCR target DNA is also in use as plasmid clones in 
the same laboratory, other problems occur. For example, plasmid 
handling contaminates gloved hands which may then contaminate PCR 
reactions (Kwok & Higuchi, 1989). Similarly, plasmid DNA may become 
aerosolized (one possible mechanism is through autoclaving) and become 
an airborne source of contamination. 
Rigorous procedures to minimize peR contamination, as detailed in 
sections 2.10.2 and 2.10.3, were used in the preparation of all solutions for 
peR and RT as well as for all solutions used in preparing DNA and RNA 
samples. When preparing positive controls from infected tissues, all work 
was done on a separate bench in a completely separate laboratory with 
different equipment and solutions. 
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2.10.2 Prevention of Carryover Contamination 
Prevention of carryover contamination required that all pre-
amplification peR (pre-PeR) work be carried out in an area that was 
completely separate from any post-amplification PCR (post-PCR) work. 
This was accomplished by the use of a laminar flow hood that was 
dedicated to the preparation of PCR-safe solutions and DNA and RNA 
from uninfected tissues. In addition, all equipment used for pre-PCR 
work was dedicated to that purpose. Finally, to prevent micropipette 
contamination, all pipette tips used for pre-PCR work were sterile ARTTM 
(aerosol resistant tips, Continental Laboratory Products). 
For the secondary phase of the nested PCR, all reaction mixes were 
initially prepared in the PCR-safe hood. Then, target DNA from the first 
phase amplification was added outside the hood on an otherwise PCR-safe 
bench using ARTTM tips with a special set of pipettes used only for 
secondary phase of peR. 
To prevent handling contamination, gloves were changed whenever 
entering the PCR-safe hood. All chemicals for PCR were dedicated to that 
purpose and kept in the PCR-safe lab. All equipment, including racks, 
tubes, microcentrifuge, etc. were also dedicated solely to pre-PCR work 
and kept in the PCR-safe lab. In addition, all PCR racks were rinsed in 
0.25 M HCI prior to use in the PCR-safe hood (Kwok & Higuchi, 1989). 
Disposable sterile gowns, were routinely used while working in the PCR-
safe hood (Bloch, 1992). 
2.10.3 Prevention of Airborne Contamination 
The laminar flow hood, dedicated to pre-PCR work, efficiently 
reduced airborne contamination of PCR reactions. Where possible, all 
chemicals were purchased as solutions. If this was not possible, 
chemicals were purchased solely for PCR and solutions prepared only 
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under PCR-safe conditions in the laminar flow hood. Chemicals were 
purchased in small quantities and made to solution by adding double-
processed sterile water (Sigma) directly to the bottle contents. 
Because the use of the laboratory autoclave gave rise to autoclaved 
solutions which were routinely positive for HCMV IE PCRs (probably due 
to contamination from autoclaved plasmid waste), the use of any 
autoclaved materials was avoided. All plastics were purchased sterile (if 
possible) and disposable. PCR tubes and 2 ml eppendorf tubes were used 
directly from the sealed bags and kept in the PCR-safe hood until used. 
2.11 POLYMERASE CHAIN REACTIONS 
2.11.1 PCR Oli~onucleotide Primer and Probe Synthesis 
PCR oligonucleotides were synthesized on the Applied Biosystems 
381A synthesizer using B-cyanoethyl phosphoramidite chemistry. After 
synthesis, oligonucleotides were extracted from the column with 1 ml of 
ammonia by incubating for 1-2 hours at room temperature, and 
deprotected for 8-18 hours by further incubation at 550 C. Oligonucleotides 
were precipitated on dry ice for 10 minutes in an equal volume of KAW 
buffer (3M potassium and 5M acetate) and 3 volumes of 100% ETOH. The 
oligonucleotide precipitate was pelleted at 10,000 xg for 10 minutes. The 
pellet was washed in 80% ETOH and all ETOH was removed by aspiration, 
as opposed to dessication, prior to resuspending in 100 III of TE. One III of 
the stock primer was diluted in 1 ml of H20 and an A260nm was 
measured through a 1 cm path length. Oligonucleotide concentration was 
determined by the following equation: A260nm x 20 (1 A260 unit = 20 
Ilg/ml of an oligonucleotide) x dilution factor = Jlg/ml. The stock solution 
was routinely stored at -70 oC until use. 
The general strategy for choosing primer sequences (Taylor, 1991; 
Saiki, 1989) was: 
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1. Primers should be about 20 bp in length. 
2. Primers should flank a product of small enough size to be easily 
visualized on agarose gel electrophoresis and subsequently easily 
transferable by Southern blotting. This size was approximately 250-500 bp. 
3. Primers should have about 50% G-C and 50% A-T composition so that 
annealing temperatures will be 55 0C (T annealing = T mel ting - 5 OC). 
4. Primer sequences should not have palindromes (to avoid stable loop 
formation) or any complementarity especially 3' complementarity (to avoid 
primer-dimer amplification). 
5. If possible primers should flank introns so that DNA and cDNA 
amplification products may be differentiated. This is helpful in 
distinguishing cDNA plasmid contamination of amplified DNA samples. 
2.11.2 HCMV Immediate Early Gene PCRs 
The HCMV Immediate Early Gene PCRs were used to amplify both 
DNA and cDNA products. The details of the specific PCRs, which include 
lEI, IE2 and US3 (HQLF-l) gene amplifications, are presented in the 
materials and methods sections of chapters 3 and 4 (see sections 3.2.2, 
4.2.2, 4.2.3 and 4.2.4). All PCRs were nested for maximum sensitivity 
(Mullis & Faloona, 1987; Bell, 1989; Jackson et ai., 1991). 
2.11.3 HCMV Early Gene PCR 
For experiments in sections 3.4.4 and 3.4.5 (HCMV DNA studies in 
Lymphocytes, and Polymorphonuclear Cells of Healthy Carriers) the early 
gene PCR was used. Details of the PCR are presented in the pertinent 
results section (section 3.2.3). 
61 
Materials and Methods 
2.11.4 HCMV Late Gene PCR 
For RT-PCR experiments, a late gene PCR was used to assess the 
degree of reactivation. The gene chosen for this analysis was a major 28 
kd structural phosphoprotein (pp28). Whilst, many late genes express 
RNA prior to true late times, this gene is an example of a late gene whose 
RNA is only expressed at late times of infection, after viral DNA 
replication (Meyer, et. al., 1988). Details of the PCR are presented in the 
pertinent results section 4.2.5. 
2.11.5 Histidyl-tRNA Synthetase PCR 
The histidyl-tRNA synthetase PCR was used as a control PCR for 
the ability to amplify DNA and cDNA after reverse transcription. As the 
amplification product spanned an intron, the cDNA product was 128 bp 
while the DNA product was approximately 370 bp (Tsui & Siminovitch, 
1987; Corrochano, 1991). Histidyl-tRNA synthetase is a multi copy 
housekeeping gene and required analysis of only 10 ng of DNA and 2 III of a 
50 III RT mix (the amount of total RNA from approximately 4 x 103 cells). 
The sequences of the primers and the intraexonic probe were: 
Sense Primer: 5'> TCATCAGGACCCAGCTGTGC <3', 
Anti-sense Primer: 5'> CTTCAGGGAGAGCGCGTGCG <3' and 
Probe: 5'> TGATCGAGGAGGAGGTGGCGA <3' 
For DNA, a 30 III reaction mix (50 mM KCI, 10 mM Tris-HCI pH 8.5 
at room temperature, 1.5 mM MgCI2, 0.01% gelatin, 0.5% Tween 20, 0.1% 
Triton X-100, 1 mM of each primer, 200 mM of each dNTP and 1.25 U of 
Promega Taq polymerase) was used. For cDNA, the same reaction mix 
with 1.0 mM MgCl2 was used. For both the DNA template and the cDNA 
template the cycling parameters were the same. All PCRs used a modified 
hot start (Erlich et al., 1991) then were heated to 94 oC for 5 minutes of 
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initial denaturation followed by 50 cycles of 94 0C for 30 seconds, 55 oC for 
30 seconds and 72 °C for 90 seconds. 
2.11.6 Optimization ofPCR 
Initially a standard recommended reaction mix (Gelfand, 1989; 
Saiki, 1989; Taylor, 1991) was used to amplify 103 copies oflinearized target 
plasmid (pGEM-2 vector containing a full-length cDNA of lEI). Then 
components of the PCR were varied to optimize the amplification. For 
each individual peR, more representative template was used for further 
optimization. These included both genomic DNA from HCMV infected 
cells and cDNA in RT mix after reverse transcription of RNA from HCMV 
infected cells. Finally, cycling parameters and the type of tube used for 
amplification were tested and optimized. 
Specific details of optimization are given in each pertinent results 
sections where PCRs are described. 
2.12 ANALYSIS OF PCR-AMPLIFIED DNA or eDNA 
2.12.1 A~arose Gel ElectrQphoresis 
Horizontal electrophoresis was performed in 0.6-2% (w/v) agarose 
gels at 5.0 V/cm. Agarose (ultraPURETM Agarose, Electrophoresis Grade, 
BRL) was melted in Ix TBE (O.09M Tris-borate, 0.002M EDTA, pH 8.0) and 
0.5 mg/ml of ethidium bromide was added. Samples containing Ix loading 
buffer (0.025% w/v bromophenol blue, 3.0% v/v glycerol) were loaded and 
electrophoresis was carried out in Ix TBE buffer. A commercially 
available 1 kb marker ladder (Gibco, BRL) was used as a molecular weight 
marker. The electrophoresed samples were examined on a 
transilluminator (312 nm) and photographed. 
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2.12.2 Slot Blottin~ 
Four ~l of PCR sample were denatured with 1 ~l of 5x denaturing 
buffer (4 M NaCI, 0.4 M NaOH, 0.04 M EDTA, pH 8.0) and heated to 100 0C 
for 5 minutes then placed on ice immediately before application to a 
Duralon-UV (Stratagene) nylon membrane. Samples were slot-blotted by 
suction and each well rinsed twice with 5 ~l of Ix denaturing buffer. The 
membrane was UV fixed (312 nm), DNA-side down, for 5 minutes prior to 
prehybridization. 
2.12.3 Southern Blottin~ 
Agarose gels were denatured (1.5 M NaCI, 0.5 M NaOH) for 45 
minutes and neutralized (1.5 M Tris-HCI pH 8.8, 1.5 M NaCl) for 45 
minutes prior to incubating in 20 x SSC for 10 minutes. Gels were placed 
on top of a 3M Whatman wick in a 20x SSC reservoir. A hybond nylon 
membrane (Hybond™ N, Amersham), cut to the size of the gel and wet in 
2-3x SSC, was placed on top of the gel and bubbles were gently removed by 
rolling a pipette across the membrane. One wet (2x SSC) and 2 dry 3M 
Whatman filters , in that order, were placed on top of the nylon 
membrane. Several layers of paper towels and a weight were placed on top 
of the 3M Whatman filters and the gel was left overnight to transfer. The 
next day, the nylon membrane was UV fixed as above (section 2.12.2). 
2.12.4 Radio-Iabelin~ of Probes 
For probing slot blots (section 3.5.1 and 3.5.2), a BamHIIBglII 
fragment of the HCMV lEI cDNA plasmid pJD083 (Akrigg et al., 1985) 
that spanned the entire HCMV peR exon 4 amplification product, was 
used. The probe was labeled using a random hexanucleotide priming kit 
(Prime-a-Gene TM, Promega). 
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For probing Southern blots, individual oligonucleotides specific for 
each PCR amplification product were end-labeled with [32p] as follows: 
300-400 ng of oligonucleotide probe was incubated with 5 f.ll of lOx blunt-end 
kinase buffer (0.1 M MgCI2, 0.5 M Tris-HCI pH 9.5, 50 mM DTT and 50% 
v/v glycerol), 4 f.ll of solution X (10 mM spermidine, 0.2 M Tris-HCI pH 9.5 
and 1 mM EDTA), 3 f.ll of gamma [32p]dATP (3000 Cilmmol) and 1 f.ll ofT4 
polynucleotide kinase (20U/ml) in a total volume of 50 Jll. The reaction was 
incubated for 1 hour at 37 oC, then brought to 100 f.ll volume with TE. To 
remove unincorporated dNTPs, 1-2 ml of 50% v/v DE-52 in 0.2 M NaCltrE 
was placed in a polyallomer wool plugged 2 ml syringe so that 0.5 to 1 ml of 
packed DE-52 remained after the NaCltrE had drained. After settling, the 
DE-52 was rinsed with 4 ml of TE and the 100 f.ll of probe was added to the 
column. Four ml of 0.2 M NaCIITE wash was used to remove the 
unincorporated label and the probe was eluted in two, 1 ml aliquots with 
0.5 M NaCltrE. The probe was stored at -70 oC until use. 
2.12.5 Prehybridization. Hybridization. Washine- & Autoradioe-raphy 
For slot blotting and for Southern blotting, prehybridization was 
carried out from 1-16 hours at 42 oC in prehybridization solution (Ix 
Denhardt's solution (2% w/v BSAIPentax Fraction V, 2% w/v Ficoll, 2% w/v 
polyvinylpyrrolidonelPVP 40,000 MW, made up in a solution of 3 M NaCI, 
and 0.3 M trisodium citrate), 5x SSC (0.75 M NaCI, 75 mM trisodium 
citrate), 2 mM Na2HP04, 2 mM NaH2P04, 50% (v/v) formamide, and 50 
mg/ml of herring sperm DNA). 
Slot blots were probed at 42 oC overnight with a [32p]dCTP-
radiolabeled 480 bp DNA probe (see above) in 10% (v/v) dextran 
8ulfate/prehybridization solution. Membranes were washed twice in 2x 
SSC and 0.1% SDS for 15 minutes at room temperature, twice in 1x SSC 
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and 0.1% SDS for 15 minutes at room temperature, and finally once in 
0.1% SSC for 1 hour at 65 0C. 
Southern blots were probed with [32P]-end-Iabeled specific 
oligonucleotide probes at 42 DC for 4 hours in 5x SSC, 0.5% (v/v) SDS and 5x 
Denhardt's solution. Membranes were washed twice in 6x sse for 10 
minutes at room temperature and once in 6x SSC for 5-10 minutes at 55 DC. 
All membranes were routinely autoradiographed at -70 DC for up to 
72 hours using 2 intensification screens. 
2.13 TIIP-I CEllI, I,INE 
2.13.1 THP-l Differentiation 
THP-1 cells were either treated with preservative-free 
hydrocortisone sodium succinate (Organon, U.K.) alone, phorbol 12-
myristate 13-acetate (Sigma) alone, or in combination. In addition, 1,25 
dihydroxy Vitamin D3 alone or in combination with phorbol 12-myristate 
l3-acetate, as well as granulocyte macrophage-colony stimulating factor in 
combination with hydrocortisone were used to differentiate THP-l cells. 
The use of these agents is detailed in section 5.2. 
2.13.2 Infection 
Differentiated or undifferentiated THP-1 cells were infected with 
HCMV strain AD169 (MOl of 10) or mock infected as detailed in section 
5.2.5. 
2.13.3 Indirect Immunofluorescence 
Immunofluorescent analysis using an HCMV anti-lEI murine Mab 
is described in detail in section 5.2.10. 
66 
Materials and Methods 
2M. MONOCYTE-DERIVED MACROPHAGE (MDM) PRODUCTION 
FROM ADBERENf MONQCYfES OF HEALlHY SUBJECTS 
2.14.1 MDM Differentiation 
Primary monocytes were differentiated to MDM with either phorbol 
12-myristate 13-acetate (Sigma) and hydrocortisone sodium succinate 
(Organon, U.K.), granulocyte macrophage-colony stimulating factor and 
hydrocortisone sodium succinate or 1,25 dihydroxy Vitamin D3 and 
phorbol 12-myristate 13-acetate. The use of these agents is detailed in 
section 5.2. 
2.14.2 Infection and Indirect Immunofluorescence 
Primary monocytes or MDM were infected with HCMV strain M 
(MOl of 10) or mock infected as described in detail in section 5.2.9. 
Immunofluorescent analysis using an HCMV anti-lEI murine Mab is 
described in detail in section 5.2.10. 
2.14.3 Cocultiyation with Fibroblasts 
Cocultivation of MDM (differentiated as described above and detailed 
in section 5.2) with permissive fibroblasts is detailed in section 5.2.11. 
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SUES OF HCMY' PERSISTENCE 
3.1 INTRODUCTION 
Many aspects of the biology and pathogenesis of HCMV are poorly 
understood. One area of uncertainty involves the site of virus persistence 
in the healthy seropositive individual. HCMV infection clearly can be 
transmitted by blood products from healthy donors to susceptible recipients 
(Adler, 1983; Tolpin et al., 1985). Moreover, the incidence of transfusion-
associated HCMV infection can be markedly reduced by using WBC 
depleted blood products (Yeager et at., 1981; Gilbert et at., 1989; De Grann-
Hentzen et at., 1989, DeWitte et at., 1990). These reports, therefore, 
suggested WBC as at least one possible site of HCMV persistence. 
However, other than one report (Diosi et al., 1969), HCMV has never 
been isolated from the buffy coat of healthy donors, even though a 
cumulative total of over 1500 buffy coats from blood donors was analyzed in 
4 different studies (Perham et at., 1971; Mirkovic et at., 1971; Kane et al., 
1975; Bayer & Tegtmeier, 1976; Jordan, 1983). In addition, it was not 
possible to detect HCMV sequences by dot blot analysis even using 10 Jlg of 
human DNA from healthy HCMV seropositive subjects (Saltzman et al., 
1988). Thus, although circumstantial evidence indicated that virus must 
be present in WBC of healthy carriers, it would seem to be present in 
extremely low copy number. 
Using more sensitive techniques, one group (Schrier et al., 1985), 
using in situ hybridization with an AD169 EcoRI J fragment probe, 
reported evidence of HCMV transcripts in PBMC (primarily T cells) of 
healthy seropositive and some seronegative subjects. In contrast, Gnann 
et al. (1988), using a similar in situ hybridization technique with the same 
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IE probe as well as a late probe (BamHI R fragment of strain ADI69), 
found no detectable HCMV signal in any healthy pre-transplant donor 
kidneys from seropositive subjects despite the fact that donor lymphocytes 
would have been present in the organs and even though transplanted 
kidneys from seropositive donors have the ability to transmit virus to 
seronegative and seropositive recipients (Chou, 1986; Grundy et al., 1988; 
Grundy et al., 1987). Consequently, it would appear that in situ 
hybridization is also not sensitive enough to detect such rare DNA or RNA 
copy numbers. 
Perhaps the most sensitive method of examination which has been 
applied to the detection of HCMV sites of persistence is the polymerase 
chain reaction. There have been 3 previous reports of detection of HCMV 
in PBMC of healthy carriers using the PCR technique (Stanier et al., 1989; 
Bevan et at., 1991; Stanier et al., 1992). However, there was no attempt in 
any of these publications to analyze specific cell populations harboring 
HCMV. 
Finally, although there have been a number of reports using the 
PCR technique to detect HCMV in clinically ill patients, these reports have 
failed to detect HCMV in healthy carriers (Shibata et al., 1988; Jiwa et al., 
1989, Rowley et al., 1991, Gerna et al., 1991) with one exception (Cassol et 
al., 1989). Cassol et al. (1989), found 1 of 10 healthy seropositive control 
subjects was PCR positive. These analyses indicated that although PCR in 
general was noted to be a sensitive technique, for the detection of low copy 
number template it would require a fully optimized PCR methodology and 
most likely nested amplification with blotting and probing of final products 
to detect low copy number sequences in healthy subjects. 
Thus, whilst HCMV must be present in peripheral blood leukocytes, 
the exact cell type harboring HCMV was unclear. I therefore decided to 
use highly purified populations of cells combined with a sensitive 
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amplification technique, PCR, (Saiki et al., 1985; Saiki et al., 1986; Mullis & 
Faloona, 1987; Saiki et al., 1988; Erlich et al., 1988) to attempt to define the 
specific site of persistence of HCMV in the peripheral blood of healthy 
asymptomatic carriers. I began by fractionating cells from the peripheral 
blood of healthy asymptomatic carriers into CD3 bearing PBMC (T cells), 
non-CD3 bearing PBMC (non-CD3 T cells, B cells, and monocytes), 
adherent PBMC (highly enriched monocyte population) and CD14+ PBMC 
(monocytes). Following this, CD4+ and CD8+ T cells were also examined. 
Ultimately, because detection of HCMV had been reported in the 
polymorphonuclear leukocyte fraction (PMNL) of peripheral blood from 
patients infected with HIV, other immunocompromised patients, and 
some immunocompetent patients acutely ill with HCMV (Fiala et al., 1975; 
Rinaldo et al., 1977; Saltzman et al., 1988; Dankner et al., 1990; Gerna et 
al., 1991; Revello et al., 1992), I also examined PMNLs of healthy carriers 
to determine whether the granulocyte might also represent a normal site 
of persistence which would be consistent with these clinical observations. 
8.2 MA'lERJA1S AND METHODS 
General materials and methods are detailed in Chapter 2. 
3.2.1 Preparation of DNA and Controls for Serone2'atiye Subjects 
DNA from specific cell types of healthy seropositive subjects was 
isolated as described in Materials and Methods section 2.7. However, 
specifically for the analysis of seronegative subjects, heparinized blood and 
similar volumes of control solutions (PBS containing the same batch and 
concentration of heparin) were processed side by side on LymphoprepTM 
gradients to yield PBMC and controls. This additional control was used as 
a further precaution to detect any possible false positive results due to 
amplification of contaminating DNA. PBMC and controls were divided 
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into 3 aliquots and frozen at -70oC to be processed into DNA on separate 
occasions, as described in Chapter 2 using the RNase and Proteinase K 
treatment followed by phenol extraction. 
3.2.2 HCMV Immediate Early Gene PCRs 
The HCMV Immediate Early Gene PCR was an asymmetric-nested 
amplification. The term asymmetric-nested is used here to describe the 
use of a single anti-sense primer paired with a sense primer for the initial 
30 cycle amplification and then the same anti-sense primer paired with a 
more internal sense primer for the secondary or nested 30 cycle 
amplification. The sequences of the primers and probe and a 
diagrammatic representation of their locations within lEI are shown in 
Figure 3.1. All were located in exon 4 (Akrigg et al., 1985). 
Alternatively, a fully nested PCR (Mullis & Faloona, 1987; Bell, 1989; 
Jackson et al., 1991) was used. The sequences and locations of the primers 
and the probe used for this PCR are shown in Figure 3.2. 
Optimized PCR parameters (detailed in section 3.3.1) for both PCRs 
were as follows: a 50 J.LI reaction mix contained 50 mM KCI, 10 mM Tris-
HCI pH 8.5 at room temperature, 2 mM MgCI2, 0.01% gelatin, 0.5% Tween 
20, 1 mM of each primer, 200 mM of each dNTP and 1.25 U of Taq 
polymerase (Perkin Elmer Cetus, Native Taq). The primary PCR routinely 
amplified 1 J.Lg of DNA. For the nested amplifications, 2 J.LI of the first 
reaction mix was used as a template. For both PCRs the cycling 
parameters were the same. Amplifications were performed on a Perkin 
Elmer Cetus Thermocycler and were 94 oC for 5 minutes of initial 
denaturation followed by 30 cycles of 94 oC for 30 seconds, 55 oC for 30 
seconds and 72 oC for 90 seconds. 
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Primary PCR Product 
Nested PCR Product 
Oligonucleotide Probe 
Sense primer: 
-. 
1 
5' > CTGCAGAACTTGCCTCAGTGCTCCCCTGAT < 3' 
Anti-sense primer: 
5' > GTTCTCAGCCACAATTACTGAGGACAGAGG < 3' 
Nested sense primer: 
564 bp 
405 bp 
-
5' > GGTCACTAGTGACGCTTGTATGATGACCATGTACGG < 3' 
Probe: 5' > GCCGCATTGAGGAGATCTGCATGAAGGTCT < 3' 
.-
2 
Figure 3.1. HCMV lEI Asymmetric-Nested peR. Panel A shows the 
organization of the HCMV lEt region at the top (thick lines representing 
exons and thin lines representing introns) and at the bottom, the HCMV 
lEt asymmetric-nested peR. This PCR initially amplified a 564 bp product 
(30 cycles) using a sense (arrow t) and anti-sense (arrow 2) primer from 
exon 4. This was followed by a second amplification (30 cycles) using a 
more internal sense primer (arrow 3) but the same anti-sense primer as in 
the first 30 cycles. The final product was 403 bp. 
(Panel B) Primer sequences are listed. For probing, an oligonucleotide 
internal to the secondary nested primers was used. 
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RT6 
Primary PCR Product 
515 bp 
Nested PCR Product 
295 bp 
Oligonucleotide Probe 
-
Sense primer: 
5' > GGTCACTAGTGACGCTTGTATGATGACCATGTACGG < 3' 
Anti-sense primer: 5' > GATAGTCGCGGGTACAGGGGACTCT < 3' 
Nested sense primer: 5' > AAGTGAGTTCTGTCGGGTGCT < 3' 
Nested anti-sense primer: 5' > GTGACACCAGAGAATCAGAGGA < 3' 
Probe: 5' > GCCGCATTGAGGAGATCTGCATGAAGGTCT < 3' 
Figure 3.2. HCMV lEI Nested PCR. (Panel A) The organization of the 
HCMV lEI region is shown at the top and the design of the HCMV lEI 
fully nested PCR is shown below. This nested PCR consisted of two 30 cycle 
sets of amplification and initially yielded a 373 bp product with a secondary 
293 bp product. All primers used for the HCMV amplification were located 
in exon 4 and were: primary sense primer (arrow 1), primary anti-sense 
primer (arrow 2), nested sense primer (arrow 3) and nested anti-sense 
primer (arrow 4). A probe internal to the secondary primer pair was 
prepared for blotting. 
(Panel B) Primer and probe sequences are shown. 
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3.2.3 HCMV Early Gene PCR 
For experiments in sections 3.4.4 and 3.4.5 an early gene PCR was 
used. This amplified a 315 bp portion of the major early gene (Greenaway 
& Wilkinson, 1987). The sense primer, anti-sense primer and internal 
oligonucleotide probe, respectively, were: 
5' > CGTTATCCGTTCCTCGTAGG < 3', 
5' > GTTTCGTTGTTGTCGGTAGT < 3' and 
5' > CCTACCACGAATCGCAGATGA < 3'. 
PCR parameters optimized (see section 3.3.1) for the early PCR were the 
same as for the IE 1 PCRs detailed above except, a 30 JlI reaction mix was 
used with 2.5 mM MgCI2, 0.1% Triton X-100 and 0.75 U ofTaq polymerase 
(Promega). In addition, a modified hot start was used (detailed in section 
3.3.1). The cycle parameters were the same as above except 50 cycles were 
used. 
3.2.4 Histidyl-tRNA Synthetase PCR 
The histidyl-tRNA synthetase PCR amplifies a multi-copy 
housekeeping gene and was used as a control PCR for the general ability to 
amplify DNA. A detailed description is given in section 2.11.5. 
3.3 RESULTS; PCB DETECTION 
3.3.1 Results of PCR Optimization 
General optimization parameters are discussed here, while specific 
results are detailed with the description of each individual PCR. Both low 
copy number HCMV infected cell DNA (which would be most like the in 
vivo situation) as well as plasmid targets and eDNA from RT preparations 
were tested. 
First, KCI concentration (0, 30, 50 & 60 mM) and 10 mM Tris-HCI pH 
(titration of pH 8.3,8.4,8.5,8.7 at 25 oC) were optimized. Greater than 75 
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mM KCI is reported to significantly decrease Taq activity, while enzyme 
activity varies with lesser concentrations depending on the specific PCR 
(Innis et ai., 1988; Gelfand, 1989; Yang et ai., 1989). Optimal activity ofTaq 
has a fairly broad pH range 8.2-9.0 at 25 0C in 10 mM Tris (Yang et ai., 
1989; Taylor, 1991). My analysis (Figure 3.3, top lanes 1-8) showed that 50 
mM KCI, 10 mM Tris-HCI pH 8.5 at room temperature was optimum and 
these values have been used to successfully amplify products in all PCRs 
used in this analysis. 
The presence or absence of gelatin was also tested. Gelatin has 
been recommended, although one report has suggested that it consistently 
decreased PCR yields when using a plasmid target (Yang et ai., 1989). For 
the IE PCRs, 0.01% gelatin increased detection of genomic template 
(Figure 3.3, top lanes 9 &10) but had no effect on detection of a plasmid 
template. 
The use of combinations of detergents (including NP-40, Tween 20, 
and Triton X-100) was also tested. It has been reported that detergents 
reverse inhibitory effects of SDS, which can inhibit up to 10% of baseline 
dNTP incorporation when present at a concentration of 0.01% (Gelfand, 
1989). In addition, other work suggests that some detergent is essential to 
obtain maximum processivity of Taq and to reduce the background caused 
by false terminations from the enzyme (Innis et ai., 1988; Taylor, 1991). In 
all peRs, it was found that NP-40 had no effect, whereas 0.5% Tween-20 in 
combination with 0.1% Triton X-100 was optimum (Figure 3.3, top lanes 11-
14). The 2 intra-exon 4 HCMV lEI PCRs used in this chapter employed 
only Tween 20. It was later in my study that I found Triton X-IOO to be 
optimal in combination with Tween 20. 
Primer concentrations and dNTP concentrations were used as 
recommended and were not optimized (Saiki, 1989; Taylor, 1991). The 
concentration of dNTPs used was held constant for all MgCl2 titrations. 
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Figure 3.3. Optimization of PCRs. (A) The ethidium bromide gel shows 
the results of optimization of 7 variables in representative PCRs. The top 
portion of the gel shows optimization of KCI (lanes 1-4 using a nested IE2 
RT-PCR detailed in 4.2.3; 266 bp cDNA product), of pH of Tris-HCI (lanes 5-
8 using a primary lEI RT-PCR detailed in 4.2.2; 353 bp cDNA product), of 
gelatin (lanes 9-10 using a primary lEI PCR detailed in 4.2.2; 1464 bp DNA 
product), and of detergents (lanes 11-14 using a primary lEI RT-PCR 
detailed in 4.2 .2; 353 bp cDNA product). Specifically, lanes 1-4 = 0, 30, 50 
and 60 mM KCI; lanes 5-8 = Tris-HCI pH 8.3, 8.4, 8.5 and 8.7; lanes 9-10 = 
1 % and no gelatin and lanes 11-14 = no detergents, 0.5% Tween 20, 0.1% 
Triton X-100 and 0.5% Tween 20 + 0.1% Triton X-100, respectively. The 
bottom of the gel shows the optimization of Taq products (lanes 1-3 using a 
primary lEI RT-PCR detailed in 4.2.2; 353 bp cDNA product), of MgCl2 
(lanes 4-9 using a primary lEI RT-PCR detailed in 4.2.2; 353 bp cDNA 
product) and of PCR tubes (lanes 10-12 using a histidyl-tRNA synthetase 
PCR; 370 bp DNA product detailed in 2.11.5). Specifically, lanes are: lanes 
1-3 = Beckman Taq , Perkin Elmer Cetus native Taq and Promega Taq; 
lanes 4-9 = 0.5, 1.0, 1.5, 2.0, 2.5 & 3.0 mM MgCl2 and lanes 10-12 = Sarstedt, 
Treft and Perkin Elmer Cetus GeneAmpTM tubes. (B) All lanes marked M 
are the 1 kb DNA marker (Gibco) with specific size bands as detailed. 
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This was important as dNTPs are known to quantitatively bind free Mg2+ 
(Saiki, 1989; Taylor, 1991). 
Taq concentration (0.5 U to 4 UI100 ~l reaction mix) as well as 
different Taq enzymes by various manufacturers were tested (Figure 3.3, 
bottom lanes 1-3). For low copy number target, 2.5 Units per 100 ~l of 
reaction mix of Promega native Taq was most successful. The 2 intra-exon 
4 lEI HCMV PCRs used in this chapter employed Perkin Elmer Cetus 
native Taq because it was only later that I determined Promega Taq to be 
optimal for low copy target. 
Optimum MgCl2 was evaluated by amplifying specific, low copy 
number template in varying dilutions ranging from 0.5-3.0 mM at 0.5 mM 
increments (Figure 3.3, bottom lanes 4-9). In general, excess Mg2+ is 
reported to result in increased mispriming events, whereas insufficient 
Mg2+ will reduce the yield of products (Saiki, 1989). It was particularly 
important to always use specific template in low copy number (so that a 
clear optimum was observed), while holding concentration of dNTPs 
constant (see above). Optimum MgCl2 concentration varied from PCR to 
PCR with a range of 1-2.5 mM MgCl2 used for the PCRs in this analysis. 
Cycle parameter optimization was tested. The temperature for 
denaturing, 94 oC, was used for genomic templates and cDNA. Taq half-
life at 94 0C is about 40 minutes (Gelfand, 1989). For a 50-cycle 
amplification with 30 seconds of denaturation per cycle, Taq undergoes 
less than 1 half life. The annealing temperature was determined by the 
base content of the primers (for 20 mer oligonucleotides): Tannealing = 
Tmelting (4x G+C) + (2x A+T) - 5 oC. Time for annealing was found to be 
30 seconds and, although longer times were just as efficient, 30 seconds 
was found to reproducibly amplify product. Shorter time intervals were 
not tested because it is reported to take a minimum of 20 seconds to 
equilibrate a 100 ~l reaction mix in the Perkin Elmer Cetus heating block 
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using 0.5 ml GeneAmpTM tubes. The extension temperature was 
determined by the optimum growth temperature for the Thermus 
aguaticus bacterium, 70-75 °C (Saiki, 1989). The optimum time for the 
extension phase was 90 seconds (times tested: 0.5 to 3 minutes in 30 second 
intervals). Any time less than 90 seconds was not efficient for all PCRs, 
even though Taq synthesizes DNA at a rate of 1 kb per minute (Saiki, 1989). 
Any time greater than 90 seconds showed no improvement. 
Although the temperature optimum of Taq polymerase is 70-75 0C it 
is able to function at lower temperatures and is as efficient as Klenow at 37 
0C. For this reason, nonspecific DNA synthesis from mis-priming 
(primers annealing to non-target sequences particularly at low 
temperatures) and primer-dimer annealing (primers annealing from 3' 
complementarity without any other DNA target necessary) can occur. 
These reactions compete for target-specific amplification and can 
markedly reduce PCR specificity and sensitivity. To eliminate this 
potential problem, all PCRs used a modified hot-start such that the 
complete PCR mix was placed on ice immediately after adding template, 
then transferred directly to a hot (94 OC) PCR machine block to begin 
denaturation (Haff & Atwood, 1989; Erlich, et at., 1991). 
U sing temperature optimums, determined above, the type of tube 
used in the Perkin Elmer Cetus machine was optimized. Three types of 
tubes were tested with DNA template and RT cDNA template (Figure 3.3, 
bottom lanes 10-12). It was found that the GeneAmpTM reaction tubes 
(Perkin Elmer Cetus) were optimal. The latter tube is designed specifically 
to fit the Perkin Elmer Cetus Thermocycler. Correct fitting of tubes in the 
sample block aids the efficiency of heat transfer to and from the sample 
and most likely influenced effectiveness of amplification. In addition, no 
volume larger than 50 I.Ll was used so that temperature equilibration was 
78 
Sites of Persistence 
rapid, particularly to maximize the hot starting procedure described 
above. 
3,3.2 PCR Sensitivity and Specificity 
Sensitivity of the asymmetric lEI PCR was 10 copies and the fully 
nested lEI PCR was 1 copy oflinearized pGEM-2 lEI plasmid (Figure 3.4). 
The early gene PCR was able to detect 10 femtograms of HCMV AD169 
infected cell DNA. As determined in Figure 4.5, comparing the 
amplification level of this same HCMV DNA stock to a known copy 
number plasmid control showed that 10 femtograms of DNA was 
approximately equal to 10 copies. Thus, the HCMV early gene PCR 
sensitivity had a level of detection equal to 10 copies. 
All primers amplified an area of the HCMV genome which has no 
complementarity to that of human DNA or other herpesviruses (Shaw et 
al., 1985, Chee et al., 1990). 
3.3.3 PCR Detection of Viral Variants 
These primers were used successfully to amplify HCMV DNA from six 
clinical HCMV isolates, from the AD169 strain, and from 20/20 healthy 
seropositive subjects. 
3.4 RESIJL'ISi srms OF PERSISTENCE 
3.4.1 Serology 
All subjects were unequivocally seropositive or seronegative. 
Seropositive values for the competitive ELISA ranged from 4%-20% 
(positive values <50%), and 82-104% (negative values >66%). For all 
seronegative subjects a confirmatory latex agglutination was done to rule 
out early primary infection. The latex agglutination assay detects IgM as 
well as IgG antibody. For all seronegative subjects, found to be PCR +, a 
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Figure 3.4. Sensitivity of HCMV lEI Nested PCR. Panel A is an ethidium 
bromide-stained agarose gel showing the amplification products from the 
primary 30 cycle HCMV PCR of 106, 104, 103 , 102, 101, and 1 copy of 
linearized pGEM-2 lEI plasmid and a non-DNA containing negative 
control, respectively (labeled 10: lanes 1 to 7). The secondary HCMV PCR 
(labeled 20: lanes 3 to 7) shows the nested amplification of 103, 102, 101, 
and 1 copy of linearized pGEM-2 lEI plasmid and a non-DNA-containing 
negative control from the primary PCR, respectively. The marker in lane 
M is a HindIII digest of lambda phage (Northumbria Biological); the 
marker in lane m is a 1 kb ladder (Gibco BRL). The arrow indicates the 
373 bp primary amplification products and the asterisk, the 293 bp 
secondary amplification products. Panel B is the Southern blot analysis of 
the gel in (A) probed with an HCMV-specific oligonucleotide. 
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Figure 3.5. Early Gene peR Sensitivity. The ethidium bromide gel in (A) 
and the Southern blot in (B ) show the results of an early gene PCR 
amplification of dilutions of a standard stock DNA control from HCMV 
AD169 infected cells. Lanes 1- 5 show the amplification of the following 
dilutions of the standard HCMV infected cell DNA control: 1 x 10-6 (100 
femtograms), 1 x 10-7 (10 femtograms), 5 x 10-8 (5 femtograms) , 1 x 10-8 (1 
femtogram) and no DNA H20 control, respectively. The limit of detection 
in this peR is 10 femtograms of DNA as shown by the 315 bp product seen 
in (A) lane 2 and the as shown by the probe specific Southern blot in (B) 
lane 2. The 1 kb DNA marker (lanes M) is detailed at the top left. 
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second serum was obtained 2-6 months after the initial one. All samples 
remained seronegative by latex agglutination and ELI8A. 
3.4.2 HCMV DNA is Present Primarily in CD3-. CDI4t. and Adherent 
PBMC of Asymptomatic Seropositive Individuals 
PBMC from 6 seropositive and 2 seronegative individuals were 
separated by FACS using a CD3 marker for T cells. Purity analyses of 
sorted populations of PBMC were performed on cells derived from these 
eight sorts. Purity ranged from 93.8 to 99.77% cells in the positively sorted 
populations and from 94 to 99.6% cells in the negatively sorted populations. 
For all 8 individuals, DNA was extracted from the sorted PBMC by 
RNaselProteinase K method and equal amounts (1 Jlg) of the CD3t and 
CD3- populations were amplified by asymmetric-nested PCR for HCMV 
IEl. For 5 of 6 seropositive subjects (Figure 3.6 panel A, SI, 82, S3, 85 & 
86), autoradiography of slot blot hybridization analyses reproducibly 
showed CD3- signal greater than CD3t signal The remaining 
seropositive subject (84) showed equal signal in the CD3t and CD3- cells . 
All DNAs, however, showed equal amplification in the histidyl-tRNA 
synthetase PCR (Figure 3.6, panel B). For the 2 seronegative subjects , one 
(Figure 3.6, 88) showed no HCMV signal in either the CD3- or CD3t cell 
DNAs while the other (Figure 3.6, 87) showed the same pattern as that of 5 
of 6 seropositive individuals, that is, the predominant HCMV positive 
signal was seen in the CD3- cells. 
To determine if the positive HCMV lEI signal in the CD3- cells was 
due to monocytes, DNA from adherent cells from 9 seropositive individuals 
was examined by PCR and Southern blotting. Purity analysis was derived 
from 6 subjects. Anti-CDI4 and anti-CD3-specific antibodies were used to 
examine adherent cells by indirect immunofluorescence. In all cases the 
adherent cells showed specific fluorescence for the CD14 marker, with less 
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Figure 3.6. Detection of HCMV Sequences in Specific FACS Populations. 
Panel A shows an autoradiograph of PCR products of 6 seropositive 
subjects (81 to 86) and two seronegative subjects (87* and 88*) after slot blot 
analysis. A positive control of 100 pg pE8 (Boom et al. , 1986) blotted directly 
without PCR amplification (+) and a non-template negative control (-) is 
also shown. Cell populations are identified as CD14+ or CD14-, and CD3+ 
or CD3- . Panel B shows DNA from subjects in (A) analyzed by histidyl-
tRNA synthetase PCR. Amplified products were separated on agarose 
gels and stained with ethidium bromide. Although some mis-primed 
smaller bands can be seen, the prominent 370 bp band was clearly seen as 
the upper-most product in lanes 2-14. Subjects are: Sl CD14+ and CD14-
(lanes 2 and 3), S2 CD3+ and CD3- (lanes 4 and 5), 86 CD3+ and CD3- (lanes 
6 and 7), 83 CD3+ and CD3- (lanes 8 and 9), 87 CD3+ and CD3- (lanes 10 
and 11), and 88 CD3+ and CD3- (lanes 12 and 13). Lane 1 is a reaction mix 
negative control and lane 14 is a DNA positive control. Lane m , is a 100 bp 
ladder (Pharmacia). 
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than 5% of cells positive for the CD3 marker, indicating a highly pure 
population of mature monocytes. After PCR amplification an HCMV-
specific band was detected in all 9 subjects. Two subjects are shown in 
Figure 3.7 and a further 7 are shown in Figure 3.10. Similar to the 
findings in the CD3+ sorts, non-adherent cells showed significantly less or 
no HCMV-specific PCR signal as compared to adherent cells. 
As cells which adhere to plastic may not consist entirely of 
monocytes (Hunt, 1987), PBMC from one individual were sorted by FACS 
into CD14+ and CD14- cells (Figure 3.6 panel A, S1). CD14 is a marker for 
mature monocytes. DNA was then amplified by asymmetric-nested PCR 
and analyzed by slot blot hybridization and probing. CD14+ cells gave a 
positive signal whereas CD14- cells were negative, and histidyl-tRNA 
synthetase PCR (Figure 3.6 panel B, lanes 2-3) amplified both these 
samples equally. 
3.4.3 HCMV DNA is Present in Some Serone~atiye Subjects 
In 6 of 9 seronegative subjects, the data for 6 of which are shown, 
HCMV IE 1 PCR results were repeatedly negative by gel electrophoresis, 
and Southern blot analysis of at least 2 DNA samples prepared separately 
(Figure 3.8). However, in three subjects, from at least two DNA samples 
prepared separately, HCMV PCR results were positive whilst comparable 
control samples were negative (Figure 3.8). All samples and controls were 
processed using the RNaselProteinase K method (2.7.1). For the 3 
seronegative but PCR positive individuals, new specimens of PBMC DNA 
were obtained and reanalyzed. On re-analysis of at least 2 separately 
prepared DNA samples from these 3 individuals, HCMV PCR remained 
positive. One of these individuals was analyzed further by cell sorting to 
yield T cell (CD3+) and non-T cell (CD3) PBMC populations (Figure 3.6 
Panel A, S7). The HCMV PCR results showed that the non-T cell 
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Figure 3.7. Detection of HCMV Sequences in Adherent PBMC. (A) 
Ethidium bromide-stained agarose gel showing the amplification products 
from adherent cells from 2 seropositive subjects (lanes 1 and 2) and PBMC 
from a seronegative subject (lane 3) after fully nested PCR. DNA was 
extracted using RNaselProteinase K method (section 2.7.1). Lane 4 
contains 104 copies of pGEM2 lEI and lane 5 represents a non-DNA-
containing reaction mix, negative control. The specific 293 bp 
amplification product is marked by an arrow. Lane m is a 1 kb marker 
ladder (Gibco, BRL). Smaller bands generated by oligonucleotide primer 
dimers or mis-priming events are not probe-positive. (B) Southern blot 
analysis of the gel in (A) probed with an HCMV-specific oligonucleotide 
probe. 
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Figure 3.8. HCMV Sequences in PBMC of Healthy Seronegative Carriers. 
(A) Panel A shows an ethidium bromide-stained agarose gel after fully 
nested IEl PCR of DNA prepared from PBMC of 6 seronegative healthy 
subjects (lanes 1 to 6), a non-template negative control (lane 7) and a 
positive control (lane 8; DNA prepared from PBMe of a seropositive 
healthy subject). Lane m is a H indIII digest of lambda phage and shows 
the 564 bp band. The arrow indicates the specific 293 bp product. Smaller 
bands are oligonucleotide primers and are not probe-positive. (B) Panel B 
shows the autoradiograph of the gel in (A) after Southern blotting and 
labeling with an HCMV-specific oligonucleotide probe. The arrow 
indicates the probe-positive 293 bp amplification product. 
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population harbored the HCMV signal, as determined by slot blot 
hybridization analysis and probing. These results were comparable to the 
findings in 5 of 6 seropositive subjects, in whom HCMV DNA was present, 
predominantly in CD3- cells. 
3.4.4 HCMV is Present in Some CD8± T Lymphocytes 
Whilst HCMV DNA was predominately found in the CD3- cells, 2 of 
the 7 HCMV carriers analyzed in Figure 3.6 (Sl & S2) showed evidence of 
weak signal or, in one case, equal signal in the CD3± population as 
compared to the CD3- population. Consequently, to further investigate 
whether HCMV could be detected in a subpopulation of CD3± T cells, 
purified populations of T cells were examined. For one individual (subject 
81 in Figure 3.6), bead-sorted CD4± and CD8± cells as well as adherent 
monocytes were analyzed for the presence ofHCMV lEI DNA (Figure 3.9). 
Purity analysis of CD8± and CD4± cells was analyzed after 
examining cytospun cells. Although in most cases there were still beads 
attached to cells (despite the use of DetachaBead), positive fluorescence 
was observed with the same antibody used to positively select the cells. In 
addition, many cells were fragmented (most likely due to residual beads) 
but a minimum of 50 intact cells per spot was able to be counted. For the 
CD8 and CD4 positive selections analyzed with CD8 and CD4 antibody, 
respectively, there were no intact cells observed without positive 
membrane fluorescence. For CD4± or CD8± selected cells analyzed with 
CD8 or CD4 antibody, respectively, there were rare cell membrane 
fragments and intact cells seen. None of the cells were positive for 
butyrate esterase. 
All DNAs were extracted using a sodium perchlorate method (2.7.2). 
Equal amounts of DNA were amplified in the HCMV early gene PCR and 
the control PCR, histidyl-tRNA synthetase. Results of the latter PCR 
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showed all DNAs to be equally amplified (Figure 3.9 B). Adherent 
monocytes were positive on both ethidium bromide gel electrophoresis and 
Southern blot, while the CD8+ cells were HCMV positive on Southern blot 
only and the CD4+ population showed no evidence of HCMV DNA even 
after blotting and probing. 
3.4.5 HCMV is Not Present in Polymorphonuclear Cells of Asymptomatic 
Subjects 
From each of 10 subjects, PMNL enriched cells and adherent 
monocytes were analyzed to determine if PMNLs were a site of HCMV 
persistence. Purity analysis of PMNL enriched cell fractions after butyrate 
esterase staining showed: differential cell counts yielded a range of 90-99% 
PMNLs (mean = 95%); all other cells were mononuclear yet none were 
positive for butyrate esterase, therefore, these latter cells were considered 
to be lymphocytes not monocytes. Purity analysis of the adherent cells, 
isolated simultaneously with the PMNL-enriched fractions, showed the 
population to be largely monocytes with 92-97% butyrate esterase positive. 
In 7 of 7 seropositive healthy subjects analyzed in at least two 
experiments, adherent PBMC DNA was HCMV PCR positive while PMNL 
DNA was negative (Figure 3.10). All DNAs were extracted using the 
sodium perchlorate method. Adherent PBMC DNA was HCMV PCR 
positive for the one seronegative subject from whom DNA was prepared 
from two separate samples obtained 2 months apart (Figure 3.10, lane 15). 
In this latter individual the results were confirmed by another HCMV 
PCR using primers in a region of the glycoprotein B gene for HCMV 
(Carolyn Tysoe, unpublished observation). Five of the 8 HCMV PCR 
positive subjects showed a discernible PCR product of the correct size on 
ethidium bromide-stained agarose gel, while the other 3 were positive by 
Southern blot only (Figure 3.10 B). The other 2 seronegative subjects were 
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Figure 3.9. HCMV PCR Analysis of Bead-Purified T Lymphocytes. 
Analysis of bead-purified T lymphocytes is seen in panel A (HCMV PCR) 
and panel B (control PCR). (A) shows the ethidium bromide-stained gel 
where lanes 2, 3 and 4 are the early gene amplifications from the test 
subject (81, Figure 3.6). Lane 2 is CD4+ T cells , lane 3 is CD8+ T cells and 
lane 4 is adherent monocytes. Lane M is a DNA marker (lkb ladder, 
Gibco) and the controls are seen in the following lanes: lane 6 is 103 copies 
of HCMV DNA, lanes 1 & 5 are 1 Ilg of adherent monocyte DNA from 2 
other healthy carriers and lane 7 is a non-DNA negative control. The 
arrow denotes the size of the amplified products for the HCMV early gene 
PCR (315 bp). The Southern blot of the HCMV early gene PCR after 
oligonucleotide probing is shown below the agarose gel. Panel B shows the 
histidyl-tRNA synthetase peR for the bead-sorted T cells and the adherent 
monocytes from the test subject shown in Panel A (lanes 2,3,4). Lane Mis 
a DNA marker (lkb ladder), lanes 1,2,3 are 100 ng of DNA from the CD4+, 
CD8+, and adherent monocytes of the test subject, respectively. Lanes 4 
and 5 are the positive (10 ng of human DNA) and negative controls (no 
DNA), respectively. The arrow denotes the 370 bp amplification product for 
the house-keeping gene/control PCR. 
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consistently negative for HCMV DNA in both cell populations, even after 
Southern blot and probing (Figure 3.10). 
For all DNA samples analyzed, equal amounts of DNA (100 ng) were 
amplified in a histidyl-tRNA synthetase gene PCR. All samples were 
amplified and all products from PMNL DNA showed an equivalent PCR 
signal or more when compared to a paired adherent PBMC PCR product, 
except the sample in track 17 where a diffuse band is seen (Figure 3.11). 
3,5 DISCUSSION 
Pure populations of cells (> than 90% in all cases) were amplified 
with highly sensitive and thoroughly optimized PCRs. The level of 
detection of these PCR systems was as little as 1-10 copies of an IEl-
containing plasmid. Targets were amplified from multiple clinical 
isolates and from adherent PBMC of all healthy seropositive individuals 
tested, and hybridized specifically to corresponding HCMV probes. In 
addition, in every case where HCMV PCR was not positive it was shown 
using a control PCR for a housekeeping gene (histidyl tRNA synthetase) 
that this was not due to a general inability to amplify DNA. Consequently, 
these PCR systems were sensitive and specific, and allowed a detailed 
analysis of the sites of low copy persistence of HCMV. 
Employing the above techniques, HCMV DNA was found primarily 
in CD3- or non-T cells of PBMC from healthy seropositive carriers. 
Further analysis of both adherent cells and CD14 positive cells 
(representing mature monocytes in both cases) suggested that the source 
of the HCMV probe-positive signal in the CD3- cells was primarily 
monocytes. In addition, 1 healthy seropositive subject, who had already 
been shown to have a weak positive HCMV signal in the FACS sorted 
CD3+ cells, showed evidence of HCMV DNA in the CD8+ T cell population 
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Figure 3.10. HCMV PCR Analysis of PMNL of Healthy Carriers. (A) 
Ethidium bromide-stained agarose gel of the HCMV PCR products are 
shown. M is a 1 kb ladder (Gibco BRL). The 315 bp amplification product 
is marked with an arrow. The (+) column represents amplification of 
HCMV AD169; while the column marked (-) is the non-DNA containing 
negative control. Tracks 1 & 2, 3 & 4, 5 & 6, 7 & 8, 9 & 10, 11 & 12 and 13 & 
14 are paired samples from 7 seropositive individuals. Tracks 1,3,5,7,9,11 
and 13 are amplification products from PBMC DNA and 2,4,6,8,10,12 and 
14 are amplification products from PMNL DNA. Tracks 15 and 16 are the 
amplification products of the PBMC and PMNL respectively for the one 
seronegativelPCR positive subject. Tracks 17, 18, 19 and 20 are paired 
samples from 2 seronegativelPCR negative individuals with tracks 17 and 
19 amplification from PBMC and 18 and 20 from PMNL. 
Panel B: The Southern blot from the gel shown in (A) after probing with 
an internal oligonucleotide to the PCR product is shown. Identical 
numbering as in (A) is used. 
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Figure 3.11. Control Gene (Histidyl-tRNA Synthetase) PCR of PMNL DNA. 
Ethidium bromide stained agarose gel of the histidyl-tRNA synthetase 
control PCR. A 1 kb ladder is used as a DNA size marker and is denoted 
M. Tracks 1 & 2, 3 & 4, 5 & 6, 7 & 8, 9 & 10, 11 & 12; 13 & 14, 15 & 16, 17 & 
18 and 19 & 20 are paired samples from the 10 subjects analyzed in Figure 
3.10. Tracks 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19 are amplification products 
from PBMC DNA and 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 are amplification 
products from PMNL DNA. The (+) column is 100 ng of human DNA and 
the (-) column is a non-DNA containing reaction mix negative control. 
Although many smaller bands due to mis-priming can be seen, the 370 bp 
predicted amplification product is clearly seen in all lanes except the 
negative control C-) and lane 17 which shows a diffuse band. 
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albeit to a lesser degree than seen in monocyte-enriched populations. The 
results presented here are in contrast to those of Schrier et al. (1985), in 
which T cells were suggested as being the major site of persistence by in 
~ hybridization. 
Another report (Toorkey & Carrigan, 1989) using an anti-HCMV lEI 
antibody and a histochemical detection method, showed a wide cell type 
and organ distribution of HCMV. Although monocytes were not reported 
as a cell type showing positive signal several tissue macrophages were 
positive including liver Kupffer cells, alveolar macrophages and splenic 
macrophages. Our results would be consistent with the macrophage sites 
identified, as monocytes differentiate into tissue macrophages (Thomas et 
al., 1976; Gale et ai., 1978; Gordon et ai., 1988; Johnston, 1988). It is, 
however, difficult to determine how closely these data reflect the healthy 
state, as samples were obtained from autopsy specimens of previously 
healthy individuals who succumbed to acute traumatic deaths. 
My examination, however, analyzed specific cell populations from 
healthy carriers and clearly showed that primarily monocytes, and to a 
lesser degree CD8+ lymphocytes in some subjects, are sites of HCMV 
persistence in PBMC of healthy carriers. It is recognized that the analysis 
of T cell sites of persistence, presented here, represents only 1 individual 
who was selected on the basis that a weak HCMV signal was seen in the 
CD3+ cell sorted population. This limited data and biased selection 
preclude drawing definitive conclusions on the extent to which T cells may 
harbor HCMV in healthy carriers. 
In addition, my study showed that approximately 30% of 
seronegative subjects analyzed had evidence of HCMV probe positive 
signals in adherent PBMC. This frequency of seronegative HCMV 
carriers is in agreement with the published literature (Stanier et ai., 1989; 
Bevan et ai., 1991; Stanier et al., 1992). In 1 of these subjects, the 
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predominant HCMV-specific signal was found in the CD3- population of 
FACS-separated cells, similar to that seen in the FACS-separated cell 
populations from seropositive subjects. It is doubtful, that these results 
represent contamination as exhaustive attempts were made to prevent this 
occurrence. These subjects most likely, represent a group of individuals 
whose anti-HCMV antibody levels are below the level of detection of the 
serologic assays used. In addition, reports of other PCR positive but 
seronegative or antigen negative viral carriers have been published for 
HIV and hepatitis B virus (Imagawa et ai., 1989; Wang et ai., 1990). 
Finally, although this implies that HCMV infection may be more 
widespread than conventional seroepidemiology suggests (Bevan et ai., 
1991) it is only rarely reported that seronegative subjects harbor 
transmissible virus (Bowden, 1991). It is much more commonly reported 
that immunocompromised adults and neonates receiving HCMV 
seronegative blood products show no evidence of HCMV transmission 
(Yeager et ai., 1981; Adler et ai., 1983; Bowden et ai., 1986; Chou, 1986; 
Paya et ai., 1989). Rare cases of HCMV transmission seen with 
seronegative blood products despite the fact that as many as 30% may come 
from seronegative HCMV carriers may be explained by these blood 
products containing less than a minimal infectious dose. This is 
supported by the fact that known HCMV seropositive blood components 
only transmit the virus to susceptible recipients in less than 113 of all 
cases. In fact, when analyzing premature neonates (one of the most 
susceptible populations) who received blood from at least one positive 
donor, only 24 % of the infants acquired HCMV infection in 2 separate 
studies (Yeager et ai., 1981; Adler, 1983). Similarly, increased HCMV 
transmission can be correlated with increased amounts of blood products 
transfused (Wilhelm et al., 1986). 
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The data presented here, suggested that monocytes are a major site 
of persistence in peripheral blood (Taylor-Wiedeman et ai., 1991; Taylor-
Wiedeman et al., in press). However, as it is difficult to infect freshly 
isolated monocytes with HCMV and PBMC appear not to replicate virus 
(Rice et al., 1984; Einhorn & Ost, 1984), the issue arises as to how these 
cells may acquire and maintain persistent HCMV. It is known that bone 
marrow progenitors can be infected in vitro (Sing & Ruscetti, 1990); 
therefore, one explanation of monocytic cell persistence may be that the 
cells acquire HCMV at an early stage of their differentiation in the bone 
marrow. However, the same myeloid precursors give rise to both 
monocytes and PMNL (Metcalf, 1971; Clark & Kamen, 1987), but PMNL do 
not appear to harbor HCMV in healthy carriers whilst monocytes do. 
Therefore, if early myeloid precursors are targets for HCMV infection it 
would appear that differentiation results in a partitioning of HCMV to the 
monocyte fraction. One explanation for this could be that HCMV infected 
PMNL precursors may be unresponsive to colony stimulating growth 
factors resulting in a loss of these cells (Sing & Ruscetti, 1990). 
Ultimately, it is well documented that HCMV can be detected in 
PMNL of immunocompromised patients and in rare instances in 
immunocompetent subjects who are symptomatic with HCMV infection 
(Fiala et al., 1975; Rinaldo et al., 1977; Saltzman et al., 1988; Dankner et ai., 
1990, Gerna et al., 1991; Revello et ai., 1992). Common to all these cases, 
however, is viremia usually with serious active disease. Nevertheless, in 
one report where 30 HCMV seropositivelHIV infected patients with no 
HIV disease and no overt HCMV disease were analyzed, no HCMV DNA 
could be detected in PMNL enriched cells (Gerna et aI., 1990). Whilst, 
these patients may be similar to the normal HCMV carrier, the PCR 
sensitivity was not adjusted to detect low copy DNA and therefore, the lack 
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of sensitivity precludes drawing definitive conclusions concerning normal 
subjects. 
Some reports have shown evidence of IE, E, or late HCMV gene 
expression in PMNL of viremic patients either by in situ hybridization 
(Dankner et at., 1990) or by immunofluorescent detection of nuclear 
localized IE proteins and in rare instances even late HCMV antigens 
(Revello et at., 1992). It is, however, not clear whether this detection of 
HCMV gene expression might result from phagocytosis of intact viral 
particles with subsequent gene expression or might be due to direct 
infection of PMNL cells (Dankner et at., 1990, Revello et at., 1992). 
Nonetheless, results presented above would suggest that HCMV is not 
normally present in PMNL of aviremic healthy HCMV carriers. 
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ENDOGENOUS HCMV GENE EXPRESSION INADUERENT 
MQNOCYTES FROM HEAI,UIY SEROPOSITIVE CARRIERS 
4.1 INTRODUCTION 
In chapter 3, investigation of sites of persistence of HCMV in the 
peripheral blood implicated monocytes as a major site of HCMV 
persistence. Consequently, experiments were designed to analyze primary 
monocytes for evidence of HCMV transcription during viral persistence. 
In particular, the spectrum of HCMV gene expression in the 
asymptomatic healthy carrier was analyzed to determine if viral 
persistence occurred by low level replication or by restricted gene 
expression as is seen with HSV, VZV and EBV (Stevens et al., 1989; 
Garcia-Blanco & Cullen, 1991). 
Previously, Schrier et al. (1985), reported finding HCMV IE 
transcripts in lymphocytes from peripheral blood of healthy carriers by in 
ilill hybridization, but were unable to co culture virus. The same group, 
however, (Gnann et al., 1988) was unable to detect IE or late transcripts in 
seropositive donor kidney biopsies obtained pre-transplant even though 
lymphocytes would have been present. Disparity in results from these two 
reports suggested that in situ hybridization may not be sensitive enough to 
detect rare copy number transcripts. 
Toorkey and Carrigan (1989), have also reported detection of IE1 
proteins in multiple tissues and cell types from post mortem 
examinations. In this report, IE 1 proteins but not late proteins were 
detected using a histochemical technique, the sensitivity of which was not 
determined. In addition, it is difficult to know what changes may have 
occurred in these tissues after death. It is well known that environmental 
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stresses induce a typical physiological reaction, the heat-shock response 
(Ashbumer et al., 1979), which has been shown to partially activate HCMV 
in semipermissive cells (Zerbini et at., 1986; Zerbini et at., 1985). It is 
possible, therefore, that the lEI expression seen in the autopsy samples 
was a reflection of this enhanced viral activity in response to post mortem 
changes and not a true reflection of gene expression seen in the healthy 
carrier. 
Thus, In an attempt to examine gene expression during HCMV 
persistence in healthy carriers, peripheral blood monocytes were obtained 
directly from seropositive healthy subjects and examined with one of the 
most sensitive techniques available, reverse transcription followed by PCR 
(Saiki et al., 1985; Yang et at., 1989; Wang et al., 1989; Chelly et al., 1990; 
Holodniy et al., 1991). The transcription units examined were lEI and IE2 
(Akrigg et al., 1985; Stenberg et al., 1985), the HQLF-l immediate early 
gene (Weston, 1988), and a true late gene (pp28) located at 0.63 to 0.65 map 
units in the UL coding region (Meyer et at., 1988). 
4.2 MATERJAIJ3 AND METIlODS 
General materials and methods are discussed In Chapter 2 
including a detailed description of the control PCR, histidyl-tRNA 
synthetase, in section 2.11.5. 
Where possible, intron-spanning PCRs were used to analyze the 
cDNA products of reverse transcription resulting in a size difference 
between DNA and cDNA amplification products. Experiments analyzing 
gene expression, examined a minimum of three healthy seropositive 
subjects and were performed at least twice to confirm reproducibility. 
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4.2.1 First Strand Reverse Transcription 
First strand reverse transcription was carried out using 10 ~g of 
total RNA (approximately equivalent to 105 cells) in a 50 III reaction in the 
presence of 10 Ilg/ml of oligo dT primer. Non-oligo dT primed RNA 
samples served as a control to determine the presence of any 
contaminating DNA or cDNA by PCR. Initially, oligo dT or H20 was 
added to 10 ~g of RNA and incubated at 68 0C for 5 minutes, cooled to 20 0C 
over 10 minutes and held for a further 5 minutes at 20 0C. Samples were 
reversed transcribed in 50 ~l containing: 50 mM KCI, 50 mM Tris-HCI (pH 
8.3 at 42 OC), 6 mM MgCI2, 5 mM spermidine, 1 mM each dNTPs, 1 U 
rRNasin (Promega), 4 mM DTT, and 4 U RT (superRT: HT Biotechnology, 
UK), by incubating for 1 hour at 42 oC, then 8 minutes at 950 C. Samples 
were then cooled to 4 oC and held at -70 0C until PCR. All incubations 
were performed in a Perkin Elmer Cetus Thermocycler using 
GeneAmpTM (Perkin Elmer Cetus) 0.5 ml tubes. 
4.2.2 Nested Intron-Spannin~ lEI PCR 
The design of the nested intron-spanning PCR for lEI as well as the 
external, internal, and probe oligonucleotide sequences and their locations 
are detailed in Figure 4.1. For this PCR, 115 of the reverse transcription 
(Le. reverse transcribed RNA from approximately 2 x 104 cells) was 
amplified in a 40 ~l reaction mix (50 mM KCI, 10 mM Tris-HCI pH 8.5 at 
room temperature, the primary PCR used 1 mM MgCl2 and the secondary 
PCR used 1.5 mM MgCI2, 0.01% gelatin, 0.5% Tween 20,0.1% Triton X-100, 
1 mM of each primer, 200 mM of each dNTP, and 1 U of Promega Taq 
polymerase). The nested PCR used 2 ~l of the primary PCR mix as 
template. For both the primary and nested PCRs, a modified hot start 
(section 3.3.1) was used and was followed by an initial denaturation of 94 
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0C for 5 minutes then 50 cycles of 94 0C for 30 seconds, 55 0C for 30 seconds 
and 72 °C for 90 seconds. 
4.2.3 Nested Intron-Spannin~ IE2 PCR 
The HCMV IE2 PCR design as well as the internal, external, probe 
oligonucleotides and their locations are shown in Figure 4.2. The 
optimized reaction mix and the cycling parameters were found to be the 
same as described above for the nested intron-spanning HCMV IE 1 PCR 
with the following exception: both the primary PCR and the secondary 
PCR required 0.25 mM spermidine (Grausz, 1991). 
4.2.4 Nested Intron-Spannin~ HQLF-1 PCR 
The design of the HQLF-1 IE gene PCR as well as the sequence of the 
primers and probe used in this analysis are shown in Figure 4.3. For this 
PCR, 1/5 of the reverse transcription (i.e. reverse transcribed RNA from 
approximately 2 x 104 cells) was amplified in a 40 f.ll reaction mix (50 mM 
KCI, 10 mM Tris-HCI pH 8.5 at room temperature, 1 mM MgCI2, 0.01% 
gelatin, 0.5% Tween 20, 0.1% Triton X-100, 1 mM of each primer, 200 mM 
of each dNTP, and 1 U of Promega Taq polymerase). The nested PCR used 
2 f.ll of the primary PCR mix as template. For both the primary and nested 
PCRs, a modified hot start (section 3.3.1) was used and was followed by 94 
oC for 5 minutes of initial denaturation then 50 cycles of 94 oC for 30 
seconds, 55 oC for 30 seconds and 72 oC for 90 seconds. 
4.2.5 Nested Late Gene PCR 
The late PCR amplified a portion of the major 28 kd structural 
phosphoprotein gene (Meyer et al., 1988), and, here after, is termed the late 
HCMV PCR. It was a nested but non-intron-spanning PCR as this is an 
unspliced gene. The optimized conditions were identical to those described 
100 
HCMV Transcripts In Monocytes of Healthy Carriers 
u.A 
IIT6 
[Kon 1 ~o: 
./\ [Kon :5 
---. 
-
1 Probe 
-
+ + 
......... + ......... 1 
!!!!!!!!! !!!!!!!!!I 
~ 
+ 
ENon 4 
~ .......... -
2 BT Primer 
1 0 eDNA 353bp 
(DNA - 1464bp) 
2 0 eDNA 117bp 
(DNA - 231 bp) 
Sense primer: 5' > GGTGCATrGGAACGCGGATT < 3' 
Anti-sense primer: 5' > ATrCTATGCCGCACCATGTCCA < 3' 
Nested sense primer: 5' > ATGGAGTCCTCTGCCAAGAG < 3' 
Nested anti-sense primer: 5' > CATAGTCTGCAGGAACGTCGT < 3' 
Probe: 5' > GACCCTGATAATCCTGACGA < 3' 
Figure 4.1. HCMV lEt Nested Intron-spanning PCR. In panel A the 
organization of the HCMV IE 1 region is shown at the top and the design of 
the nested intron-spanning PCR is shown at the bottom. The external 
primers (arrow 1 = sense primer and arrow 2 = anti-sense primer) are 
shown in exon 1 and 4, respectively. Whereas, the internal sense primer 
(arrow 3) was in exon 2 and the anti-sense primer (arrow 4) was in ex on 3. 
The external primer pair yielded a DNA product of 1464 bp and a cDNA 
product of 353 bp. The internal primers yielded a DNA product of 231 bp 
and a cDNA of 117 bp. The oligonucleotide probe was also present in exon 
2, internal to primer # 3. The reverse transcription oligo dT primer is 
labeled RT primer. Sequences of PCR primers and probe are shown in 
panel B. 
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2 e eDNA 266 bp (DNA - 1924 bp) 
Sense primer: 5' > GGTGCATI'GGAACGCGGATT < 3' 
Anti-sense primer: 5' > GCGCTGCTAACGCTGCAAGAG < 3' 
Nested sense primer: 5' > GACCCTGATAATCCTGACGA < 3' 
... 
RT Primer 
Nested anti-sense primer: 5' > ATACCGGCATGATTGACAGCCT < 3' 
Probe: 5' > GACATCCTCGCCCAGGCT < 3' 
Figure 4.2. HCMV IE2 Nested Intron-spanning PCR. Panel A shows the 
organization of the HCMV IE2 region (top) and the design of the nested 
intron-spanning IE2 PCR (bottom). Panel B shows the sequences of the 
primers and probe. The external primers yielded a DNA product of 
approximately 2900 bp and a cDNA of 406 bp, the upstream primer (arrow 
1) was in exon 1 and the downstream anti-sense primer (arrow 2) was in 
exon 5. Whereas, the internal primers yielded a DNA product of 
approximately 1924 bp and a eDNA of 266 bp. These sense (arrow 3) and 
anti-sense (arrow 4) primers were located in exon 2 and 5, respectively. 
The probe is specific for exon 5. 
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PCR DETECTRBLE HQLF 1 GENE TRRNSCR I PTS 1!~8 I! [II d IU; I Slul 
,Dt!!l BlDt!!l B' 
• 595/595 ~ • 439/595 
~ 
• 
427/595 
~ ~ 
• 
271/595 
----------- • 
112*/595 483 bp 
PCR primer 1 -
Probe PCR primer 2 
sense primer: 5' > ATCCTGGCCGTCTI'GTTCCT < 3' 
Anti-sense primer: 5' > GTTAGAGTCCGTACCTTGCA < 3' 
Probe: 5' > TGAGCAGTACCACCATGATG < 3' 
Figure 4.3. Design of HQLF-l peR. Five predicted products from 
transcription of the HQLF-1 gene are shown (Weston, 1988). The location 
of the single primer pair used to detect cDNA and DNA from the HQLF-1 
open reading frame and the size of the predicted products are detailed in 
4.3 A. The sequences of the primers and probe, the latter of which would 
recognize all but the smallest cDNA product (*) are shown in 4.3 B. 
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for the intron-spanning lEI PCR above. The external pnmer pair 
amplified a 548 bp product and the internal primers amplified a 389 bp 
product. The primers amplified an area of the HCMV genome which has 
no complementarity to that of other herpesviruses or human DNA. These 
primers were used successfully to amplify HCMV DNA from 5 unrelated 
clinical HCMV isolates and 10 healthy subjects. The sequence of the 
primers and probe are as follows: 
Sense primer: 5' > GAGGATGACGATAACGAGGA < 3' 
Anti-sense primer: 5' > TCAAACAGCACATTAGACACACGG < 3' 
Nested sense primer: 5' > GACAGTAGTAGCGGCAGCCA < 3' 
Nested anti-sense primer: 5' > GACTCGCGAATCGTACGCGA < 3' 
Probe: 5' > GACCTAGACGAAGAGGACACCTCAAT < 3' 
4.3 RESULTS; TRANSCRIPTIONAL ANALYSIS OF PRIMARY 
MQNOCXTES IN TIlE HEALTHY ASYMPTOMATIC CARRIER 
4.3.1 Sensitivity of the Reyerse Transcription 
The sensitivity of the reverse transcription allowed for detectable 
message from the equivalent of 1 infected cell when the lEI PCR was used 
for amplification and is detailed in Figure 4.4. The level of detection, 
however, was ultimately dependent on the sensitivity of the individual 
PCRs and is detailed in the results section 4.3.3. 
4.3.2 Sensitivity of the PCRs 
The sensitivity of the lEI nested PCR (Figure 4.5) was estimated to be 
equivalent to 1 copy of linearized eDNA. By comparison to known plasmid 
copy number, 1 femtogram of a standard HCMV infected cell DNA stock 
was considered to be approximately equivalent to 1 copy (compare intensity 
of lanes 4 and 7 in Figure 4.5) 
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The IE2 nested PCR, the HQLF -1 gene PCR and the late HCMV gene 
PCR were able to detect 10, 10, and 100 femtograms, respectively, of the 
stock infected cell DNA which was the same stock used above and for all 
PCRs described in this study (Figures 4.6 and 4.7). Therefore, by 
extrapolation from estimations made with the IE 1 PCR DNA and known 
copy number plasmid amplifications (Figure 4.5), the estimated 
sensitivities of the IE2, HQLF-1 and late PCR were 10, 10, and 100 copies of 
HCMV, respectively, 
All primers amplified an area of the HCMV genome which has no 
complementarity to human DNA or other herpes viruses (Shaw et ai., 
1985; Chee et al., 1990). 
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Figure 4.4. Sensitivity of the Reverse Transcription. Panel A shows the 
ethidium bromide gel of the intron-spanning lEI nested PCR (detailed in 
Figure 4.1) which amplified cDNA templates after reverse transcription of 
RNA from HCMV AD169 infected fibroblasts . Specific cDNA bands are 
marked with the 117 bp arrow and DNA bands are marked with the 231 bp 
arrow. Lanes 1 through 4 are RT-PCR of 104 infected cells, 102 infected 
cells, 1 infected cell, and a H20 RT negative control, respectively. Lanes 5 
through 8 are PCR controls and detailed as follows: Lane 5 is 100 
femtograms (100 copies) of DNA only, while Lanes 6 through 8 are 10 
copies of linearized pGEM-2 lEI cDNA plasmid along with 10 femtograms 
of infected cell DNA, 1 copy of linearized pGEM-2 lEI cDNA plasmid along 
with 1 femtogram of infected cell DNA, and a H20 PCR control. The DNA 
marker (lane M) is a 1 kb ladder (Gibco) with the band sizes detailed at the 
top right. Panel B shows the Southern blot of the gel from (A). Specific 
probe positive bands are seen in lanes 1, 2, 3, 5, 6, & 7 while H20 controls 
(lanes 4 & 8) remain probe negative. For the RT-PCR samples in lanes 1, 
2, & 3, both DNA and cDNA were present in the initial template (RNA was 
not treated with DNase) therefore both bands are seen on Southern blot and 
a DNA amplification product also can be seen in lane 1 on the ethidium 
bromide gel. 
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Figure 4.5. Sensitivity of the lEI Nested Intron-Spanning PCR. Panel A 
shows the ethidium bromide stained gel of the comparison of dilutions of 
DNA from a standard stock of HCMV AD169 infected fibroblasts (lanes 1-4) 
and linearized pGEM-2 lEI cDNA plasmid (lanes 5-7). The size of 
amplification products are marked: 231 bp arrow for DNA and 117 bp 
arrow for cDNA. Lanes 1 through 4 show: 100 femtograms of infected cell 
DNA, 50 femtograms of infected cell DNA, 10 femtograms of infected cell 
DNA and 1 femtogram of infected cell DNA, respectively. Lanes 5 through 
8 are amplifications of 102 copies ofpGEM-2 IE1, 101 copies ofpGEM-2 lEI, 
I copy ofpGEM-2 lEI, and a H20 only negative control, respectively. Lanes 
M are the 1 kb marker, detailed at the right of panel A. Panel B shows the 
Southern blot of panel A. HCMV probe positive bands are seen in lanes 
1,2,3,4,5,6,7, while the H20 control remained probe negative. 
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Figure 4.6. Sensitivity of the IE2 Nested Intron-Spanning peR and the 
HQLF-l peR. Both ethidium bromide gels show the amplification of the 
standard HCMV infected cell DNA stock used as a control for all PCRs. 
The gel on the left shows the specific 1924 bp products after the IE2 PCR in 
lane 1 (10 picograms of infected cell DNA after a 50 cycle non-nested 
amplification using the internal primers only i.e. without prior 
amplification using the external primers), lane 2, 3, and 4 ( 100, 10, and 1 
femtogram of infected cell DNA after a fully nested IE2 PCR). In addition, 
as the IE2 DNA products are much larger than most used in this analysis 
the specific sizes of the larger marker bands (1018, 1636, and 2036 bp) for 
the 1 kb marker (lanes M) are noted on the left of the IE2 gel. Thus, for the 
IE2 PCR it can be seen that the limit of detection on ethidium bromide gel 
is 10 femtograms (10 copies, see Figure 4.5) of the standard stock of infected 
cell DNA. The gel on the right shows the specific 595 bp DNA product from 
the HQLF-1 gene PCR amplification. Lanes 1-4 represent: 1000, 100, 10, 
and 1 femtogram of the standard HCMV infected cell DNA stock. It can be 
seen that the limit of detection on an ethidium bromide gel is 10 
femtograms (10 copies) of infected cell DNA. 
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Figure 4.7. Sensitivity of the Late Gene peR. The late gene peR products 
after a fully nested amplification are shown. Lanes 1-4 are as follows : 
amplification of 10,000 femtograms, 1000 femtograms , 100 femtograms and 
10 femtograms of the standard stock of HCMV infected cell DNA. Thus, 
the limit of detection for this PCR was only 100 copies of HCMV (lane 3). In 
addition, this PCR showed less distinct bands on the ethidium bromide gel 
at higher template dilutions. This was the only peR in this analysis 
where greater template quantity lead to less distinct amplification 
products after nested PCR. However, as seen below, the Southern blot 
clearly defines the presence of the late amplification products in lanes 1-3 
while the other less distinct bands running higher in the gel in lanes 1 and 
2 are not probe positive and therefore likely due to mispriming events. 
Lane M is a 1 kb marker (Gibco). 
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4.3.3 Gene Expression in Adherent Monocytes 
Comprehensive RT-PCR analysis to detect lEI (Figure 4.8), IE2 
(Figure 4.9), HQLF-1 (Figure 4.10) and late gene (Figure 4.11) transcripts 
showed no evidence of these RNA in primary monocytes. Nevertheless, 
after reverse transcription, primary monocyte RNA were successfully 
amplified in a control gene RT-PCR, histidyl-tRNA synthetase (Figure 
4.12), and HCMV DNA was shown to be present by extracting DNA 
separately from the same cells used for RNA extraction (Figure 4.13). 
In all RT-PCRs, RNA from primary monocytes were reverse 
transcribed and amplified along with matched controls which consisted of 
RNA and all other components of the RT mix except the RT-primer, oligo 
dT (denoted RT sample controls). These RT-PCR controls were necessary 
to detect the presence of DNA, which was important where non-intron-
spanning PCR was used (late gene PCR), and also controlled for any cDNA 
contamination of the individual RNA samples. The RT H20 control was a 
complete RT mix with H20 instead of RNA and controlled for cDNA 
contamination of all RT components. RT-PCR of RNA, from a standard lot 
of HCMV infected cells, was used to assess RT-PCR sensitivity. Results 
are as follows: the lEI RT-PCR was able to detect the equivalent of 1 
infected cell (Figure 4.4 and Figure 4.8) while the IE2 RT-PCR (Figure 4.9, 
lanes 8 & 9), the HQLF-l RT-PCR (Figure 4.10, lanes 4 & 5) and the late 
gene RT-PCR (Figure 4.11, lanes 17, 18 & 19) were able to detect the 
equivalent of 100 infected cells but not 1 infected cell. The standard RNA 
stock from HCMV infected cells was found to contain some HCMV DNA 
(Figure 4.8, lanes 7 & 8, Figure 4.9, lanes 7 & 8 and Figure 4.12, lane 7) 
after acid phenol RNA extraction. All RNA isolated from individual 
healthy carriers underwent RNase-free DNase treatment (section 2.8.2), 
however, it only became necessary to DNase treat the HCMV infected cell 
RNA control when non-intron-spanning PCR was used (late gene PCR 
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Figure 4.11, lanes 17, 18 & 19). Finally, it should be noted that some of the 
PCR amplifications yielded small non-specific bands (for example Figure 
4.10, lanes 7 and 8) seen on the ethidium bromide gels which were not 
probe positive and most likely due to mispriming events. Several small 
misprimed products were seen in the IE2 peR but the smallest band « 75 
bp DNA marker) seen in every lane was most likely oligonucleotide peR 
primers. It is, however, clearly seen that no probe-positive bands were 
present in any of the subjects samples while positive controls (both RT and 
PCR) amplified probe-positive products of the appropriate size and negative 
controls (both RT and peR) yielded no probe-positive products. 
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Figure 4.8. lEI RT·PCR of Primary Monocytes. The top panel (A) shows 
the ethidium bromide gel of the intron-spanning lEI nested RT-PCR on the 
left and a detailed description of the 1 kb DNA marker (lanes M) on the 
right. Specific sizes of the predicted products are marked with an arrow 
and represent DNA = 231 bp and cDNA = 117 bp. Lanes 1 & 2, 3 & 4, and 5 
& 6, are paired RT-PCR samples of primary monocytes from three healthy 
subjects. Lanes 1,3, and 5 contain complete RT-PCR mixes and lanes 2, 4, 
and 6 are RT sample controls, respectively. Other lanes are as follows : 
lanes 7 & 8 (RT-PCR of 100 and 1 HCMV infected cells, respectively), lane 9 
(a H20 RT control), lane 10 (a PCR control containing 10 copies of lEI 
cDNA and 10 copies of DNA), lanes 11 and 12 (PCR H20 controls). The 
bottom panel (B) shows the Southern blot of the ethidium bromide gel. 
Probe positive bands can be seen in lanes 7, 8, and 10 only, the RT and PCR 
positive controls. 
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Figure 4.9. IE2 RT-PCR of Primary Monocytes. The top panel (A) shows 
the ethidium bromide gel of the intron-spanning IE2 nested RT-PCR on the 
left and a detailed description of the 1 kb DNA marker (lanes M) on the 
right. Specific sizes of the predicted products are marked with an arrow 
and represent DNA = 1924 bp and cDNA = 406 bp (primary amplification) 
or 266 bp (nested amplification). Lanes 1 & 2, 3 & 4 and 5 & 6, are paired 
RT-PCR samples of primary monocytes from three healthy subjects . 
Lanes 1, 3, and 5 contain complete RT-peR mixes and lanes 2, 4, and 6 are 
RT-PCR sample controls, respectively. Other lanes are as follows: lanes 7, 
8, & 9 (RT-peR of 1000, 100 and 1 HCMV infected cells , respectively), lane 
10 (a H20 RT contro!), lanes 11 & 12 (PCR control containing 100 and 10 
copies of DNA, respectively) and lane 13 (PCR H20 control). The bottom 
panel (B) shows the Southern blot of the ethidium bromide gel using an 
exon 5 specific probe. Probe positive bands are seen in lanes 7 & 8 and 11 & 
12, the RT and peR positive controls, respectively, In lanes 7 and 8 while 
the 266 bp nested cDNA product is clearly seen, the primary cDNA 
product, 406 bp, can also be seen (lane 7 > lane 8). 
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Figure 4.10. HQLF·1 RT·PCR of Primary Monocytes. The top panel (A) 
shows the ethidiurn bromide gel of the HQLF-1 RT-PCR on the left and on 
the right is a detailed description of the 1 kb DNA marker (lanes M). 
Lanes 1 & 6, 2 & 7 and 3 & 8 represent paired RT-PCR samples of primary 
monocytes from three healthy subjects. Lanes 1, 2, and 3 contain complete 
RT-PCR mixe and lanes 6 7 and 8 are RT sample controls, respectively. 
Lane 4 shows the positive cDNA products of 439, 427, and 271 bp in size. 
Other lanes are as follows: lanes 4 & 5 (RT-PCR of 100 and 1 HCMV 
infected cells, respectively), lanes 9 & 10 (H20 RT controls), lanes 11 & 12 
(PCR control containing 10 and 1 copy of DNA, respectively) and lane 13 
(PCR H20 control). The bottom panel (B) shows the Southern blot of the 
ethidi urn bromide gel. Specific sizes of the predicted products are marked 
with an arrow on the Southern blot and represent DNA = 595 bp and cDNA 
= 439, 427, and 271 bp. The smallest detectable product, 112 bp (Figure 4.3) 
was not seen on the ethidium bromide gel and would not have been 
detectable on the Southern blot with the internal oligonucleotide probe that 
was used. Probe positive bands can be seen in lanes 4 and 11, the RT and 
peR po itive controls, respectively. 
1 1 4 
HCMV Transcripts In Monocytes of Healthy Carriers 
A 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 M 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 M 
~ 
389 
548 
389 
I···~ ... . . ,. '.:.. . ..• r """,,, ~ . . - .. ~' ,. ..... . ., - , 
-
.  ~. 
M 19 20 21 22 23 24 M 
M 19 20 21 22 23 24 M 
Figure 4.11. Late Gene RT·PCR of Primary Monocytes and Monocyte· 
Derived Macrophages (MDM). The top panel (A) shows the ethidium 
bromide gel of the late gene PCR. Specific sizes of the predicted products 
are marked with an arrow with the primary product = 548 bp and internal 
amplification product = 389 bp. Lanes 1 & 2, 3 & 4, 5 & 6, 7 & 8, 9 & 10, 11 
& 12, 13 & 14, 15 & 16 are paired RT-PCR samples from 4 healthy 
seropositive carrier s and paired RT-PCR samples of MDM from 4 healthy 
seropositive subjects, respectively. Paired MDM samples in lanes 9 & 10, 
11 & 12, 13 & 14, 15 & 16 were differentiated with PMA + HC (subject 1), 
PMA + HC (subject 2), GM-CSF + HC, and Vitamin D3 + PMA, 
respectively. Lanes 1, 3, 5, 7, 9, 11, 13, & 15 contain complete RT-PCR 
mixes and lanes 2, 4, 6, 8, 10, 12, 14 & 16 are RT sample controls, 
respectively. Lanes M are the 1 kb DNA marker. Lanes 17, 18, and 19 are 
RT controls as follows : RNA from 100 HCMV infected cells after RNase-
free DNase treatment where lane 17 is the RT sample control, 18 is the 
complete RT mix and lane 19 is the complete RT mix after reverse 
transcription of RNA from 1 HCMV infected cell after RNase-free DNase 
treatment. Lane 23 is the RT H20 control. Lanes 20, 21 and 22 are peR 
controls where lanes 20 and 21 represent amplification of 1000 and 100 
copies of the standard HCMV infected cell DNA stock and lane 22 is a 
negative H20 control. On the Southern blot (B) probe-positive bands are 
seen in lanes 18, 20 and 21 which are the RT and pCR positive controls, 
respectively. 
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Figure 4.12. Hi tidyl·tRNA Synthetase Gene RT·peR of Primary 
Monocyte . The figur how the ethidium bromide gel of the Histidyl t· 
RNA Syntheta Gene RT·P R at the top left and a detailed description of 
the 1 kb DNA marker (lane M ) at the top right. Specific sizes of the 
predicted product are marked with an arrow and represent DNA = 370 bp 
and cDNA = 12 bp. Lane 1 & 2, 3 & 4, and 5 & 6, are paired RT·PCR 
sample of primary monocyte from the three healthy subjects analyzed in 
the other four H MV RT·PCR pre ented above (Figures 4.8, 4.9,4.10, and 
4.11) where lane 1 3 and 5 contain complete RT·PCR mixes and lanes 2, 
4, and 6 are RT ample controls, re pectively. The 128 bp cDNA bands can 
be clearly een in lane 1 3, and 5 while non·primed samples are negative 
(lane 2,46). Other lane are a follow: lane 7 & 8 (RT·PCR of 100, and 1 
HCMV infected c 11 re pectively), lane 9 (a H20 RT control) and lanes 10, 
11 & 12 (P R control containing an RT·PCR of RNA from the equivalent of 
10 adherent monocyte of a healthy ubject, 10 ng of DNA from a healthy 
subject and aPR H20 control). 
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Figure 4.13. DNA PCR Control ofRT·PCR. The intron-spanning lEI PCR 
was u sed to examine DNA produced from a small aliquot of cells which 
were otherwise harvested for RNA for RT-PCR. The top panel (A) shows 
the ethidium bromide gel with the DNA product of 231 bp delineated by the 
arrow. The 1 kb marker (lanes M) is detailed at the right. Lanes 1 - 4 
represent amplification of the 4 healthy seropositive carriers whose 
primary monocyte were examined for evidence of transcription (Figures 
4.8,4.9, 4.10, 4.11 and 5.5). Lanes 4-8 are the amplifications of the 4 healthy 
seropositive carriers whose primary monocytes were differentiated in vitro 
and examined for evidence of reactivation by RT-PCR (Figures 4.11, 5.5, 
5.6, 5.7 & 5.8). In the latter instance DNA was extracted from cells after 
differentiation at the same time the remaining cells were harvested for 
RNA. Specifically, lanes 5 & 6 are PMA + HC mediated differentiation, 
lane 7 is GM-CSF + HC mediated differentiation and lane 8 is PMA and 
Vitamin D3 mediated differentiation. Lane 9 is a cDNA control (1 copy) 
and lane 10 is a H20 only negative control. The bottom panel (B) shows the 
Southern blot of the gel in A. All bands in A are seen to be probe positive 
while the PCR H20 control is probe negative 
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4.5 DISCUSSION 
As my work had shown that monocytes were a major site of HCMV 
persistence in peripheral blood of healthy carriers (chapter 3) an analysis 
of the spectrum of HCMV gene expression in these cells was undertaken. 
Primary monocytes of healthy carriers showed no evidence of HCMV lEI, 
IE2, HQLF-1 or late polyadenylated mRNA at the level of detection used 
here. Although, it should be pointed out, only 4 of five possible HQLF-1 
transcripts would have been detected with the PCR primer pair used here 
and only 3 of these would have been seen on Southern blot using a centrally 
located oligonucleotide probe. 
Consequently whilst it cannot be ruled out that IE transcripts are 
present in PBMC below the level of detection used in this study, the 
sensitivity of the RT-PCR would suggest that PBMC of healthy carriers do 
not express IE RNA and rules out low level productive infection in PBMC 
as a mechanism of persistence of HCMV. Either, HCMV persists without 
any gene expression or some as yet undefined latent HCMV transcripts 
are expressed in these cells. Similarly the detection system used here 
would not have detected any non-polyadenylated transcripts. 
Others have reported evidence of lEI HCMV gene expression in 
healthy carriers (Schrier et al., 1985) but this does not seem to be 
reproducible (Gnann et al., 1988). And one other report (Toorkey and 
Carrigan, 1990) has suggested that IE 1 proteins can be detected in tissues 
from autopsy examinations but many factors may be involved in post 
mortem changes triggering viral reactivation and make these results 
difficult to apply to persistence in healthy carriers. 
In any event, the results presented here show no evidence of 
immediate early gene transcripts or the late gene (pp28) RNA products in 
monocytes from healthy carriers and, thus, no evidence of low level 
replicative persistence in these same cells. 
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CHAPlER5 
DIFFERENTIATION OF THE MONOCrnC CEltl, IJNE THP-l AND 
APHERENTMONOCYfES FROM HEMlHY CARRIERS 
TO A pERMISSIVE PHENOTYPE FOR IN VITRO 
INFECTION AND REACTWA1]ON OF ENDOGENOUS HCMV 
5.1 INTRODUCTION 
In chapter 4, it was not possible to detect evidence of transcription 
from endogenous virus of healthy carriers after RT-PCR of primary 
monocytes and as there is no in vivo or in vitro model for HCMV 
persistence, I chose to further investigate HCMV persistence by using a 
monocytic cell line (THP-l) known to be nonpermissive for HCMV in the 
undifferentiated state and fully permissive after differentiation 
(Weinshenker et al., 1988). Although Weinshenker et al. 1988, did not 
clearly show that in the undifferentiated state THP-l cells permit viral 
penetration, it was inferred that HCMV was able to enter the cells but was 
negatively regulated by cellular factors as is seen with teratocarcinoma 
(T2) cells (Gonczol et al., 1984). Indeed, upon transient transfection, the 
HCMV MIE enhancer/promoter has been shown to be negatively regulated 
in both THP-l cells and T2 cells in vitro (Shelbourn et al., 1989a, Shelboum 
et al., 1989b, Kothari et al., 1991; Sinclair et al., 1992) and this repression is 
released upon differentiation. Moreover, there is increasing evidence that 
differentiation is necessary for infection of monocytes with HCMV, as in 
Yitm differentiated monocyte-derived macrophages have been shown to 
have increased HCMV infectability (Lathey & Spector, 1991; Ibanez et al., 
1991). Similarly, in yivo terminally differentiated alveolar macrophages 
are 100% infectable (Drew et al., 1979) compared to primary monocytes 
which are very difficult to infect (Rice et al., 1984; Einhorn & Ost, 1984). As 
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it is difficult to obtain in yivo differentiated macrophages and various in 
vitro differentiation techniques of PBMC yield large differences in 
permissiveness for HCMV infection (Lathey & Spector, 1991; Ibanez et al., 
1991), I chose to use the THP-1 model system initially to test several in vitro 
monocyte differentiation techniques. Optimum differentiation conditions 
which permitted HCMV infection of THP-1 cells would then be applied to 
primary monocytes to attempt to reactivate endogenous virus. RT-PCR 
would be used to detect any evidence of reactivation after differentiation. 
Cocultivation of differentiated monocyte-derived macrophages would also 
be carried out to detect evidence of a full productive infection. 
Molecular mechanisms involved with macrophage differentiation 
processes are not completely defined. In vitro it appears that monocyte 
differentiation is dependent on at least 2 factors, the presence of human 
serum and adherence (Dougherty & McBride, 1989). In the former case, 
1,25 dihydroxy Vitamin D3 has been proposed as the active component in 
the serum (Dougherty & McBride, 1989). GM-CSF, however, is also known 
to play an integral role in regulation of monocytopoiesis at all levels as well 
as the final development of macrophages (Auger & Ross, 1992). 
Furthermore, treatment of monocytic cell lines with phorbol esters has 
been shown to induce a differentiated state that is specifically associated 
with increased permissiveness for HCMV infection (Weinshenker et al., 
1988). Finally, increased infectability of semi-permissive MDM by HCMV 
has been shown to be associated with hydrocortisone treatment in vitro 
(Lathey & Spector, 1991) and increased incidence of HCMV disease has 
been associated with steroid therapy in renal transplant patients (Velasco 
et al., 1984). I, therefore, decided to analyze the differentiation of THP-1 
cells with PMA, 1,25 dihydroxy Vitamin D3, GM-CSF and HC in order to 
maximize their permissiveness for HCMV infection, and then apply the 
optimal combination derived from this study of the monocytic cell line to 
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prImary monocytes on the basis that similar treatment may permit 
reactivation of endogenous virus. 
5.2 MateriaJs and Methods 
General materials and methods are discussed in Chapter 2. 
Experiments presented in this chapter were repeated at least 2 times for 
each method of differentiation to confirm reproducibility. 
5.2.1 PMA and Hydrocortisone Treatment ofTHP-1 Cells 
THP-1 cells were differentiated with phorbol 12-myristate 13-acetate 
(Sigma) and treated either with or without preservative-free 
hydrocortisone sodium succinate (Organon, U.K.). In addition, 
hydrocortisone treatment alone was used. 
Hydrocortisone (HC) treatment was routinely carried out in the 
presence of 5 x 10-5 M He (Pasquale et al., 1989; Lathey et al., 1991) in 
RPMI 1640 medium with 10% FCS for 7 days. Phorbol 12-myristate 13-
acetate (PMA) was solubilized in DMSO at a concentration of 1 mg/ml then 
diluted to 10 Ilg/ml in PBS and stored at -20 °C until use. PMA 
differentiation was routinely carried out in the presence of 2 x 10-8 M PMA 
(Tsuchiya et al., 1982; Sinclair, et al., 1992) for 12 hours. Differentiation 
using a combination of both PMA + HC was carried out as follows: HC 
was added to the cell medium at time 0, then on day 6, PMA was added to 
the medium for approximately 12 hours. 
5.2.2 1.25 DihydroxY Vitamin V3 Differentiation ofTHP-1 Cells 
THP-1 cells were differentiated in the presence of 5 x 10-8 M 1,25 
Dihydroxy Vitamin D3 (Biomol Research Laboratories, Inc.) over a period 
of 4 days in RPMI 10 medium (Koeffier et al., 1989; Perkins et al., 1991). 
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5.2.3 1.25 Dihydroxy Vitamin D3 and PMA Differentiation ofTHP-1 Cells 
THP-1 cells were differentiated in the presence of 5 x 10-8 M 1,25 
Dihydroxy Vitamin D3 (Vitamin D3) over a period of 4 days in RPMI 10 
medium. On day 3,2 x 10-8 M PMA was added overnight (approximately 
12 hours). 
5.2.4 GM-CSF and HC Treatment ofTHP-1 Cells 
THP-l cells were differentiated in the presence of 5 ng/ml (Hart et 
al., 1991; and Dr. Jane Minton personal communication) of recombinant 
human granulocyte macrophage colony stimulating factor (GM-CSF) 
(Genzyme) and treated with 5 x 10-5 M HC in RPMI medium over a period 
of7 days. 
5.2.5 Infection of THP-1 Cells 
Differentiated or undifferentiated THP-1 cells were infected with 
HCMV strain AD169 (MOl of 10) or mock infected with medium overnight 
using 8-chambered tissue culture slides (Nunc), then fixed at -20 0C for 3 
minutes in acetone/methanol (1:1) and allowed to air dry. Although 
undifferentiated THP-l cells are nonadherent, the medium could be gently 
aspirated without disturbing the cells and acetone/methanol fix applied. 
5.2.6 PMA and HC Differentiation of Primary Monocytes 
After collection, isolation, and adherence, primary human 
monocytes were differentiated in the presence of 5 x 10-5 M HC over a 
period of 6 days in Iscove's Modified Dulbecco's Medium (IMDM) (Gibco, 
BRL) containing 15% donor horse serum (Sera-lab), 15% FCS (Advanced 
Protein Products, Ltd.), 2 mM L-glutamine (Flow), 100 IU/ml 
Penicillin/l00 J,lg/ml Streptomycin (Gibco, BRL) and 3 giL sodium 
bicarbonate (Flow). On day 6,2 x 10-8 M PMA was added overnight. 
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5.2.7 GM-CSF and HC Differentiation of Primary Monocytes 
Primary human monocytes were differentiated in the presence of 5 
ng/ml of GM-CSF and 5 x 10-5 M HC for a period of 7 days in IMDM 
(detailed in section 5.2.6). 
5.2.B 1. 25 Dihydroxy Vitamin D3 and PMA Differentiation of Primary 
Monocytes 
Primary human monocytes were differentiated in the presence of 5 x 
10-B M Vitamin D3 (Kreutz & Andreeson, 1990) in IMDM (detailed in 
section 5.2.6) for a period of 7 days. On day 6, 2 x 10-B M PMA was added 
overnight. 
5.2.9 Infection of Primary Monocytes and MDM 
HCMV M strain was used to infect MDM that had been isolated 
from 5 ml of blood. MDM cells were adhered to Nunc B-chambered tissue 
culture slides and differentiated as described above. On the day prior to 
infection of the MDM cells, undifferentiated adherent monocytes were 
prepared on B-chamber culture slides and incubated overnight in IMDM 
containing only horse serum, FCS, penicillin/streptomycin, L-glutamine, 
and bicarbonate. These served as undifferentiated monocyte controls. 
Differentiated or undifferentiated cells were infected or mock infected 
(with media only) overnight, then fixed at -20 0C for 3 minutes in 
acetone/methanol (1: 1) and allowed to air dry. Indirect 
immunofluorescence was performed as detailed in section 5.2.10. 
5.2.10 Indirect Immunofluorescence of THP-1 Cells and MDM 
A 1/500 dilution of an anti-lEI murine Mab, ID-66 (gift of Dr. Brian 
Rogers, Wellcome, Beckenham, UK), was applied to the fixed cells and 
incubated at room temperature for 1 hour. Following 2 washes in 
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PBS/0.1 % (v/v) Tween 20, rabbit anti-mouse fluorescein isothiocyanate-
conjugated F(ab')2 fragment (Dakopatts) was applied to the cells for a 
further 60 minutes at room temperature. Following 2 more washes, in 
PBS-Tween 20, slides were air dried and Citifluor was applied prior to UV 
microscopy and photographing. 
5.2.11 Cocultiyation ofMDM with Fibroblasts 
One T-150 flask of MDM (differentiated as described above) was 
placed on ice for 10 minutes prior to gently policing cells into the medium. 
Cells were then pelleted at low speed (200 g for 5 minutes) and medium 
was discarded. Cells were resuspended in MEM without serum and 
placed onto 1 T-75 flask of 75-80% confluent (passage 26-40) MRC5 cells. A 
control flask of MRC5 cells of equal confluency and passage number was 
set up in parallel with MEM without serum. After 24 hours, medium on 
both flasks was changed to MEM 10% FCS. Monolayers were observed 
every 5 days and fed an additional 5 ml ofMEM 10% FCSIT75. If there was 
no evidence of CPE, monolayers were passaged 1:2 after 14 days and 
observed for a second 14 day period. Cells were refed 10 ml of MEM 10% 
FCS!I'150 every 5 days. 
5.2.12 RT-PCR Analysis ofMDM 
First strand reverse transcription is detailed in section 4.2.1. IE 1 
PCR (section 4.2.2), IE2 PCR (section 4.2.3), HCMV late peR (section 4.2.5) 
and the histidyl-tRNA synthetase PCR (section 2.11.5) have been previously 
detailed. The delayed-early gene, glycoprotein B (Rasmussen et al., 1985: 
Kouzarides et al., 1987), was used to further study RNA from MDM after 
RT. The glycoprotein B (gB) peR was designed by Carolyn Tysoe and 
oligonucleotides for use in this study were kindly provided by her. The 
PCR was a non-intron spanning nested amplification of 244 bp (final 
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product) with a sensitivity of 1 copy (personal communication Carolyn 
Tysoe). An internal oligonucleotide was used for probing. The sequence of 
the primers and probe used in the gB PCR are as follows: 
Forward primary: 5'> GGAAACGTGTCCGTCTTCGA <3' 
Reverse primary: 5'> GAAACGCGCGGCAATCGG <3' 
Forward nested: 5'> GTGTTCTGGCAAGGCATCAA <3' 
Reverse nested: 5'> CGTTGATCCACACACCAGGC <3' 
Probe: 5'> TACGCCCAGCTGCAGTT <3' 
The gB PCR reaction mixture is the same as reported for the IE 
amplification in section 4.2.2 with the following exceptions: primary 
amplification used 10% glycerol in the reaction mix along with 1.5 mM 
MgCI2, while the nested PCR used 1.0 mM MgCl2 and no glycerol. 
For all RT-PCRs, RNA from MDM or primary monocytes were 
reverse transcribed and amplified along with matched controls which 
consisted of RNA and all other components of the RT mix except the RT-
primer, oligo dT (denoted RT sample controls). The RT H20 control was 
an RT-PCR negative control and consisted of the complete RT mix with 
H20 instead of RNA, while RT-PCR positive controls were amplifications 
from a standard lot of RNA from HCMV infected cells which was the same 
throughout this study. 
Finally, all RNA isolated from individual healthy carriers 
underwent RNase-free DNase treatment (see 2.8.2), however, in most 
cases for intron-spanning PCR HCMV infected cell RNA for positive RT-
PCR controls was not treated with DNase. When non-intron spanning 
amplifications were used e.g. glycoprotein B PCR or late PCR, positive 
control RNA from HCMV infected cells was treated with RNase-free 
DNase as detailed in 2.8.2. 
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5,3 RESULTS; LEVELS OF PERMISSIVENESS IN THP·! CELLS 
AFIER DWFERENTIATIQN 
5.3. I Phenotypic Chan~es 
After differentiation, the one consistent phenotypic change seen 
with all methods of differentiation was the ability to adhere to plastic 
whereas the undifferentiated cells remained in suspension. The only 
other observable change was the appearance of elongated spindle-shaped 
cells in the presence of 1,25 dihydroxy Vitamin D3 (Figure 5.1 & 5.2). 
5.3.2 Infection in Undifferentiated and Differentiated THP-I Cells 
The level of infect ability in undifferentiated and differentiated THP-I 
cells was determined by using lEI immunofluorescence (Table 5.1). The 
combination of cytokines leading to the greatest degree of lEI fluorescence 
after differentiation and infection of THP·I cells was PMA + HC. After 
differentiation, approximately 75% of the cells showed specific lEI nuclear 
fluorescence, while the undifferentiated infected cells showed only rare 
nuclear fluorescence and uninfected differentiated cells showed no 
nuclear fluorescence (Table 5.1 and Figure 5. I & 5.2). The use of HC or 
PMA alone showed specific nuclear fluorescence in about 10% and 20% of 
the cells, respectively. Second to the combination of PMA and HC, the 
next highest levels of infectability were seen with the combination of PMA 
+ Vitamin D3 and GM-CSF + HC. Both these combinations showed 
specific nuclear fluorescence after infection in approximately 30% of 
differentiated cells and no nuclear fluorescence in uninfected 
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Table 5.1: ESTIMATED LEVELS OF PERMISSIVENESS AFTER HCMV 
STRAIN AD169 INFECTION OF UNDIFFERENTIATED OR 
DIFFERENTIATED THP·I CELLS DETECTED BY lEI 
IMMUNOFLUORESCENCE 
HELF (Fully Permissive) 100%* 
THP-1 Cells (Undifferentiated) <1% 
1,25 dihydroxy Vitamin D3 5% 
Hydrocortisone (HC) 10% 
Phorbol 12-myristate 13-acetate (PMA) 20-30 % 
HC + Granulocyte Macrophage-
Colony Stimulating Factor (GM-CSF) 30-40 % 
PMA + Vitamin D3 30-40 % 
PMA + Hydrocortisone 75-90 % 
*Percentage of cells showing specific lEI nuclear immunofluorescence 
after infection overnight with HCMV strain AD169 MOl of 10. These are 
the results of at least 2 experiments per method of differentiation. 
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Figure 5.1. lEI Immunofluorescence of THP-l Cells After HCMV 
Infection. The panel how the results of IE1 immunofluorescence after 
overnight infection with HCMV strain AD169 MOl of 10. All panels are 
400-fold magnification. Nuclear fluorescence can be seen in 100% of 
permis ive HELF cell, 0% of undifferentiated THP-1 cells, approximately 
5% of Vitamin D3 differentiated THP-1 cells, and approximately 10% ofHC 
differentiated THP-l cell (labeled at the top of the panels) after infection. 
No pecific nuclear fluore cence i seen in any of the uninfected cells 
(bottom panel ). The pindle- haped phenotypic changes that occurred 
with Vitamin D3 differentiation can be seen. 
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Figure 5.2. lEI Immunofluorescence of THP-I Cells after HCMV 
Infection. In the e panel the results of lEI immunofluorescence after 
overnight infection with HCMV strain AD169, MOl of 10 can be seen. All 
panel are 400-fold magnification. Specific nuclear fluorescence can be 
een in approximately 20~ of PMA differentiated THP-l cells, 30% of HC + 
GM-C F differentiated THP-l cells, 30% of PMA + Vitamin D3 
differentiated THP-l cell and 75% ofPMA + HC differentiated THP-l cells 
after infection. Nuclear fluore cence was not een in any of the uninfected 
differentiated cell (bottom panels). 
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differentiated cells. When Vitamin D3 was used alone it yielded the lowest 
level of nuclear fluorescence after infection of only 5%. 
5.4 RESULTS: IN YITRO DIFFERENTIATED MONQCITE-DERIVED 
MACRQPHAGFS OF HEAJ,TIIY CARRIERS 
5.4. I Phenotypic Chan"es 
All MDM enlarged significantly compared to prImary adherent 
monocytes (Figure 5.3). With the combination of PMA and HC, cells 
showed the most varied phenotypes. Cells were spindle-shaped, rounded 
or irregularly shaped. Some showed large blunt pseudopods and some of 
the rounded cells showed multiple needle-like projects. Most cells had one 
nucleus but rare cells were binuclear, while no multinucleated giant cells 
were observed. With GM-CSF and HC most cells were rounded with many 
exhibiting needle-like pseudopods similar to those seen with PMA + HC 
differentiation and only single nuclei were observed. PMA + Vitamin D3 
differentiated MDM showed marked elongation similar to that seen in the 
THP-I cells (Figure 5.2) and mainly single but also some binuclear cells 
were observed. In addition, in the first two instances (PMA + HC or GM-
CSF + HC), the cells were actively phagocytic, engulfing most platelets that 
had attached to the plastic flask after the initial adherence, while the PMA 
and Vitamin D differentiated MDM appeared to phagocytize very few of the 
adherent platelets (Figure 5.3). 
5.4.2 Infection of Differentiated and Undifferentiated Monocyte-Derived 
Macropha"es 
A similar pattern to that seen in the THP-1 cells (Table 5.1) was 
observed after infection of MDM (Table 5.2), except the overall levels of lEI 
immunofluorescence were lower than that observed in THP-1 cells. The 
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Figure 5.3. Phenotypic Changes Seen in MDM. The 4 panels show, from 
left to right, undifferentiated primary monocytes, phorbol 12-myristate 13-
acetate (PMA) + hydrocortisone (HC) mediated differentiation , 
granulocyte-macrophage-colony stimulating factor (GM-CSF) + He 
mediated differentiation and PMA + 1, 25 dihydroxy Vitamin D3 (Vitamin 
D3 ) mediated differentiation. All photographs represent 400 x 
magnification. 
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combination leading to the highest level of IE1 immunofluorescence after 
infection with HCMV M strain was PMA + HC, with an average of about 
30% of the cells positive after overnight infection. Both GM-CSF + HC and 
PMA + Vitamin D3 showed 5-10% IE1 nuclear immunofluorescence after 
overnight infection. Fibroblasts appeared to be permissive in 
approximately 90% of cells after HCMV M strain infection, slightly less 
than the AD 169 strain, and the nuclear fluorescence was not as intense as 
that seen with AD 169 infection of fibroblasts (compare figures 5.4 and 5.1). 
Only rare positive cells were seen when primary monocytes were infected 
with HCMV M strain and none of the uninfected cell controls showed 
nuclear fluorescence. 
5,5 RESULTS; TRANSCRIPTIONAL ANALYSIS OF ENDOGENOUS 
HCm EXPRESSION IN MONOCYTE-DERIVED MACROPIIAGES 
5.5.1 Endo~enous IE 1 Transcripts are Present after PMA and 
HC Differentiation 
Primary monocytes from two healthy seropositive individuals were 
examined for evidence of HCMV gene transcription after differentiation 
with PMA + HC. In both healthy seropositive carriers' MDM, lEI 
transcripts were observed (Figure 5.5) while the respective RT-PCR sample 
controls were negative. From one of these subjects, 200 ml of blood was 
obtained at a single time point and divided in half for analysis of both 
primary monocytes and MDM (Figure 5.5): primary monocytes lane 9 and 
the RT sample control in lane 10 while RT-PCR of MDM from the same 
subject is shown in lane 1 and the RT sample control in lane 2. Whereas, 
RT-PCR from primary monocytes, lanes 11 & 12, represents a sample 
acquired at the same time but from a different subject than MDM RT-PCR 
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Table 5.2: ESTIMATED LEVELS OF PERMISSIVENESS AFTER HCMV 
M STRAIN INFECTION OF UNDIFFERENTIATED OR 
DIFFERENTIATED MONOCYTE-DERIVED MACROPHAGES 
DETECTED BY lEI IMMUNOFLUORESCENCE 
HELF (Fully Permissive) 
Primary Monocytes 
Hydrocortisone + Granulocyte Macrophage-
Colony Stimulating Factor 
Phorbol 12-myristate 13-acetate + 
1,25 dihydroxy Vitamin D3 
Phorbol 12-myristate 13-acetate + 
Hydrocortisone 
90%* 
<1% 
10-15 % 
10-15% 
30-40% 
*Percentage of cells showing specific lEI nuclear immunofluorescence 
after infection overnight with HCMV strain M, MOl of 10. These are the 
results of at least 2 experiments. 
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Figure 5.4. lEt Immunofluorescence Mter HCMV M Strain Infection of 
MDM. The 5 paired panels show the results of lEI immunofluorescence 
after overnight infection with HCMV strain M, MOl of 10. All panels are 
400-fold magnification. The specific cells seen in each pair of panels is 
labeled across the top. The top row of panels are infected cells and the 
bottom row are the uninfected controls, respectively. 
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shown in lanes 3 & 4. There was no evidence of IE2 (Figure 5.7, lanes 9-
12), glycoprotein B (Figure 5.8, lanes 8-11) or late transcripts (Figure 4.11, 
lanes 9-12) in the MDM differentiated by PMA + HC of either subject. 
In both subjects' MDM, cDNA from a constitutively expressed gene, 
histidyl-tRNA synthetase, was detected by RT-PCR (Figure 5.9, lanes 5 & 7) 
while non-primed RT-PCR sample controls (Figure 5.9, lanes 6 & 8) were 
negative. In addition, analysis of DNA, from a small aliquot of the same 
differentiated MDM that was otherwise used for RNA extraction, showed 
that HCMV genome was present (Figure 4.13). 
5.5.2 Endo~enous IE. Delayed Early. But Not Late Gene Transcripts are 
Present Mer GM -CSF & HC Differentiation 
Both lEI and IE2 transcripts (Figure 5.6, lanes 1 & 2 and Figure 5.7, 
lanes 1 & 2, respectively), as well as, glycoprotein B transcripts (Figure 5.8, 
lanes 1 & 2) were detectable after primary monocytes from one healthy 
individual were differentiated with GM-CSF and HC. Late transcripts, 
however, were not detectable (Figure 4.11, lanes 13 and 14). 
In Figure 5.6, where the lEI amplification is detailed, the RT-PCR of 
GM-CSF + HC differentiated MDM, lane 1, shows a probe-specific 117 bp 
amplification product while the RT-PCR sample control, lane 2, is 
negative. The HCMV infected RNA control was not treated with DNase 
and, therefore, in Figure 5.6, lane 5, where RT-PCR of RNA from 100 cells 
is shown both a DNA (231 bp) and cDNA band (117 bp) are seen. However, 
when the RNA is diluted another 100-fold, lane 6, then reverse transcribed, 
the cDNA component becomes the only visible band. 
In Figure 5.7, where the 1E2 amplification is detailed, the RT-PCR of 
GM-CSF + HC differentiated MDM, lane 1 shows probe positive 266 and 406 
bp cDNA amplification products while the RT-PCR sample control, lane 2, 
is negative. In the IE2 nested intron spanning PCR, it was not unusual to 
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see the primary cDNA amplification product (406 bp) carried over in the 
nested amplification (266 bp). This can also be seen in the RT-PCR of RNA 
from 100 HCMV infected cells seen in lane 3, while the RT-PCR of 1 
infected cell (lane 4) and the RT H20 control are negative (lane 5). The 1924 
bp DNA bands can be seen in lanes 6 and 7 (103 and 102 copies of standard 
HCMV infected cell DNA stock) while lane 8, the PCR H20 control, is 
negative. 
In Figure 5.8, the RT-PCR of the glycoprotein B gene can be seen. 
Lane 1 shows the probe positive amplification product from the GM-CSF + 
HC differentiated MDM, while lane 2 shows the RT-PCR sample control 
which is negative. The RT-PCR sensitivity is able to detect RNA from 100 
but not 1 infected cell as seen in lanes 3,4,5. Probe positive amplification 
products from the RT-PCR positive control of DNase-treated RNA from 100 
infected cells (lane 3) but not 1 infected (lane 5) can be seen, while the RT-
PCR sample control for 100 infected cells (lane 4) is negative. The PCR 
sensitivity is 1 copy of the standard HCMV infected cell DNA stock (lane 6). 
Figure 4.11, lanes 13 & 14, shown that for MDM differentiated by 
GM-CSF + HC , no late gene products were detected. 
In the subjects' MDM, cDNA from a constitutively expressed gene, 
histidyl-tRNA synthetase, was detected by RT-PCR (Figure 5.9, lane 3) 
while the non-primed RT-PCR sample control (Figure 5.9, lane 4) was 
negative. In addition, analysis of DNA, from a small aliquot of the same 
differentiated MDM that was otherwise used for RNA extraction, showed 
that HCMV genome was present (Figure 4.13). 
5.5.3 No Endo~enous HCMV Transcripts are Present After Vitamin D3 
and PMA Differentiation 
After MDM differentiation from 1 healthy subject using the 
combination of Vitamin D3 and PMA there was no evidence of lEI (Figure 
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5.6, lanes 3 and 4), IE2 (Figure 5.7, lanes 13 and 14), delayed early (Figure 
5.8, lanes 12 and 13), or late gene expression (Figure 4.11, lanes 15 and 16). 
In addition, it did not appear as if DNA was lost during the differentiation 
process as DNA was detectable in the cells after differentiation (Figure 
4.13). 
In addition, the RT-PCR of the RNA extractions from these cells 
showed expression of a constitutively expressed gene (Figure 5.9, lanes 9 
and 10), therefore, it appeared as if this method of differentiation was not 
able to reactivate any level of HCMV gene expression from endogenous 
virus. 
5.5.4 Cocultiyation Experiments with Differentiated Monocyte-Deriyed 
Macropha~es and Fully Permissive HELF Cells 
All MDM were co cultured with permissive fibroblasts as detailed in 
section 5.2.11. However, even after 4 weeks of culture, there were no 
plaques observed for any of the MDMlfibroblast cocultivations. 
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Figure 5.5. IE! Expression of Endogenous HCMV Mter PMA and HC 
Mediated Differentiation. An ethidium-bromide agarose gel (top), the 
Southern blot of that gel (bottom), and a 1 kb marker (lanes M) are shown. 
Sizes of ne ted products are indicated: DNA = 231 bp and cDNA = 117 bp. 
Lanes 1 & 2 and 3 & 4 are paired RT-PCRs from PMA + HC differentiated 
MDM and lanes 9 & 10 and 11 & 12 are paired RT-PCRs from primary 
monocytes without in vitro differentiation. Lanes 1, 3, 9 & 10 are complete 
RT-PCRs and their respective RT-PCR sample controls are 2, 4, 10 and 12. 
Lanes 5, 6, 7 & 8 are RT-PCR controls as follows: RNA from 100 and 1 
HCMV infected cell after RNase-free DNase treatment, and 2 RT H20 
control , re pectively. Lanes 13, 14, 15 and 16 are PCR controls as follows: 
10 femtogram of the standard HCMV infected cell DNA stock, 10 and 1 
copy of pGEM-2 lEI plasmid, and a H20 negative control. 
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Figure 5.6. lEI Expression of Endogenous HCMV Mter GM·CSF and HC 
Mediated Differentiation. Panel A shows the ethidium bromide gel and 
panel B shows the Southern blot of the gel. A 1 kb marker (Gibco) was used 
to estimate PCR product size (lanes M) and is detailed at the top right. 
Products were DNA = 231 bp and cDNA = 117 bp after nested PCR. Lanes 1 
& 2 and 3 & 4 are paired RT-PCRs of MDM from healthy seropositive 
carriers differentiated by GM-CSF + HC and PMA + Vitamin D3, 
respectively. Lanes 1 and 3 are complete RT-PCRs and 2 and 4 are their 
respective RT-PCR sample controls. Lanes 5, 6 and 8 are RT-PCR controls 
as follow: RNA from 100 and 1 HCMV infected cells and an RT-PCR H20 
control. Lane 7 shows an amplification of 103 copies of HCMV DNA. 
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Figure 5.7. IE2 Expression of Endogenous HCMV Mter GM-CSF and HC 
Mediated Differentiation. Panel A shows the ethidium bromide gel of the 
IE2 amplification and panel B shows the Southern blot of A. A 1 kb 
marker (Gibco) wa u ed to estimate PCR product size (lanes M) and is 
detailed at the top right. Products were nested DNA = 1924 bp, primary 
eDNA = 406 bp and nested eDNA = 266. Lanes 1 & 2, 9 & 10,11 & 12 and 13 
& 14 are paired RT-PCRs of MDM from healthy seropositive carriers 
differentiated by GM-CSF + HC, PMA + HC (subject 1), PMA + HC (subject 
2) and PMA + Vitamin D3, respectively. Lanes 1, 9, 11 and 13 are complete 
RT-PCRs and 2, 10, 12 and 14 are their respective RT-PCR sample controls. 
Lanes 3, 4 and 5 are RT-PCR controls as follows: RNA from 100 and 1 
HCMV infected cells and an RT-PCR H20 control. Lanes 6, 7 and 8 are 
PCR controls as follows: 103, 102 and no DNA (H20) from the standard 
HCMV infected cell stock. 
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Figure 5.8. Glycoprotein B Expression of Endogenous HCMV Mter GM-
CSF and HC Mediated Differentiation. Panel A shows the ethidium 
bromide gel and panel B shows the Southern blot of that gel. A 1 kb 
marker (Gibco) was used to estimate PCR product size (lanes M) and is 
detailed at the top right. Products were DNA/cDNA = 244 bp after nested 
PCR. Lane 1 & 2, 8 & 9, 10 & 11 and 12 & 13 are paired RT-PCRs ofMDM 
from healthy seropo itive carriers differentiated by GM-CSF + HC, PMA + 
HC (subject 1), PMA + HC (subject 2) and PMA + Vitamin D3, respectively. 
Lanes 1, 8 10 and 12 are complete RT-PCRs and 2, 9, 11 and 13 are their 
respective RT-PCR sample controls. Lanes 3, 4 and 5 are RT-PCR controls 
as follows: RT-PCR of DNase-treated RNA from 100 HCMV infected cells, 
the respective RT-PCR sample control and RT-PCR of DNase-treated RNA 
from 1 HCMV infected cell, respectively. Lane 6 shows an amplification of 
1 copy of the standard HCMV infected cell DNA stock and lane 7 is a PCR 
H20 negative control. 
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Figure 5.9. RT·PCR of Primary Monocytes and MDM using a Histidyl· 
tRNA Syntheta e Control PCR. Panel A shows the ethidium bromide gel 
after hi tidyl- RNA yntheta e RT-PCR and panel B shows the Southern 
blot of the gel. A 1 kb marker (Gibeo) was used to estimate PCR product 
ize (lane M) and i detailed at the top right . Products were DNA = 370 bp 
and cDNA = 12 bp. Lane 1 & 2, 3 & 4, 5 & 6, 7 & 8 and 9 & 10 are the 
fo llowing: paired RT-PCR of primary monocytes from the subject shown 
in lane 11 and 12 in Figure 5.5, MDM from a healthy seropositive carrier 
differentiated by GM-CSF + HC, MDM from a healthy seropositive carrier 
differentiated by PMA + HC (subject 1), MDM from a healthy seropositive 
carrier differentiated by PMA + HC (subject 2) and MDM from a healthy 
seropo itive carrier differentiated by PMA + Vitamin D3, respectively. 
Lane 1, 3, 5, 7 and 9 are complete RT-PCRs and 2, 4, 6, 8 and 10 are their 
respective RT-PCR ample controls . Lanes 11 and 12 are RT-PCR of 100 
and 1 HCMV infected cells respectively. Lanes 13, 14, and 15 are PCR 
control a follow: cDNA con trol (some DNA contamination of the non-
DNa e treated RNA preparation can be seen), DNA (10 ng) control and a 
H20 negativ control. 
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5,6 DISCUSSION 
It is known that monocytes are difficult to infect in vitro with HCMV 
(Rice et ai., 1984; Einhorn & Ost, 1984) while in vivo differentiated alveolar 
macrophages are fully permissive when infected in vitro (Drew et ai., 
1979). Furthermore, in the THP-1 monocytic cell line, permissiveness of 
HCMV has been correlated with differentiation (Weinshenker et ai., 1988). 
Moreover, others have reported that in vitro differentiation of primary 
human monocytes to monocyte-derived macrophages is necessary for of 
HCMV in vitro (Lathey & Spector, 1991, Ibanez et ai., 1991). Therefore, 
because analysis of primary monocytes of healthy carriers showed no 
evidence of endogenous HCMV transcription, as detailed in chapter 4, and 
because monocytes themselves are not terminally differentiated, I chose to 
examine methods of differentiating monocytic cells and their resulting 
levels of permissiveness for HCMV infection to determine the optimum 
method to differentiate primary monocytes in order to attempt to reactivate 
endogenous HCMV. 
THP-l cells were used as a representative monocytic cell line, and 
were differentiated using several different methods. There was little 
phenotypic change after differentiation other than the cells became 
adherent. After differentiation and infection, THP-l cells clearly showed 
three combinations of chemicals associated with the highest level of 
infection. These were PMA + HC (75% lEI nuclear fluorescence), GM-
CSF + HC (30% lEI nuclear fluorescence), and PMA + Vitamin D3 (30% 
lEI nuclear fluorescence). All other methods of differentiation of THP-l 
cells were inferior to these combinations in their ability to produce cells 
which were permISSIve for HCMV as determined by IE 1 
immunofluorescence. 
Therefore, the 3 differentiation methods which led to the greatest 
percentage of THP-l cells becoming permissive for HCMV infection were 
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applied to the differentiation of primary monocytes. Phenotypic changes 
after differentiation of primary monocytes were much more distinct than 
with the THP-I cells. In general, cells took on the phenotype of 
macrophages: they greatly enlarged, became adherent, developed 
pseudopods and became phagocytic. The levels of permissiveness after 
infection with a recent clinical isolate (HCMV M Strain) showed similar 
trends to that seen with infection of the THP-1 cells but the percentage of 
cells showing specific IE I nuclear fluorescence was much less. The 
optimum differentiation conditions resulting in the highest 
permissiveness of cells for HCMV infection, as determined by IE 1 
expression, was PMA and HC (which resulted in lEI fluorescence in 75% 
of THP-I cells and 30% of MDM). Whereas, GM-CSF + HC or Vitamin D3 
+ PMA resulted in similar but lower levels of IE I expression in THP-I cells 
(30% lEI expression) and in MDM (10% lEI expression), respectively. 
When these three methods of differentiation were applied to primary 
monocytes of healthy seropositive carriers and RNA was analyzed by RT-
PCR for HCMV gene expression, differences in the spectrum of HCMV 
transcripts were seen. The combination leading to the most extensive 
levels of HCMV expression was GM-CSF + HC. After GM-CSF + HC 
differentiation, the one healthy carrier who was examined showed 
immediate early (lEI and IE2) and delayed early (glycoprotein B) gene 
expression but no late (pp28) gene expression. Cocultivation of GM-CSF + 
HC differentiated MDM did not show evidence of full productive infection 
as no plaques were detected even after 28 days of culture. It should be 
mentioned that these experiments were carried out on a single individual 
and will require further analysis of other healthy seropositive carriers. In 
addition, it appeared that conditions which optimized differentiation of 
THP-I cells for HCMV IE expression did not correlate with the ability to 
reactivate endogenous virus. However, it must be remembered that the 
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THP-l infection studies were optimized for lEI expression and not virus 
production. In hindsight, it is possible that if conditions which maximized 
virus production and not lEI expression in THP-1 cells had been studied, 
this would have determined conditions more optimal for endogenous virus 
reactivation. 
In addition to GM-CSF + HC, PMA + HC differentiation of MDM 
was also able to reactivate HCMV gene expression in healthy carriers but 
to a more restricted level. Only immediate early 1, mRNA was detectable 
in two separate subjects after PMA + HC differentiation. While, for the 
combination of PMA and Vitamin D3, there was no evidence of 
endogenous HCMV gene expression after differentiation despite the fact 
that DNA was present in the cells and another constitutively expressed 
gene was able to be detect after RT-PCR. 
It is interesting to note that in both combinations leading to 
endogenous gene expression after differentiation, hydrocortisone was 
present. Some in vitro data suggest that HC may act directly on the virus 
in tissue culture of already fully permissive fibroblasts (Tanaka et al., 1984; 
Forbes et al., 1991). This has been shown by production of increased levels 
of infectious HCMV in steroid treated fibroblasts over that of untreated 
cells. While, HC treatment of MDM prior to HCMV infection in vitro has 
been shown to increase HCMV permissiveness and productive virus 
release after infection in a dose-dependent manner (Lathey & Spector, 
1991). This suggests that HC is influencing cellular factors allowing 
increased virus propagation in semi-permissive cells. Therefore, HC may 
have a dual effect, in potentiating HCMV gene expression from 
endogenous virus. 
As no one has been able to reactivate HCMV from healthy carriers, 
this is the first report of gene expression from endogenous virus after in 
v.i1I:2 differentiation. However, full productive infection was not able to be 
145 
Endogenous HCMV Reactivation from Healthy Carriers 
shown by late gene RT-PCR or coculture techniques. It may be that 
specific cellular interactions are necessary for endogenous HCMV 
reactivation in vivo. Or, it may be that other cytokines are important in 
ri.Y.2. for endogenous HCMV reactivation, and the right combination of 
these chemicals were not used to produce a full productive infection. 
Finally, as the kinetics of HCMV infection in MDM are not known it may 
also be conceivable that cells were harvested too soon after GM-CSF + HC 
differentiation (7 days) to see full reactivation and late gene expression. 
The same might be concluded for the use of PMA + HC, particularly since 
the cells were harvested only 12 hours after the addition of PMA. 
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CONCLUDING DISCUSSION 
In this analysis, HCMV persistence in the healthy carrier was 
investigated. First, specific cell types which harbored HCMV in the 
healthy carrier were analyzed. As extensive circumstantial evidence 
suggested that HCMV exists in white cells of the peripheral blood, this 
tissue was examined in asymptomatic adult volunteers. In addition, as 
persistent HCMV would most likely be present in low copy number a 
highly sensitive technique, nested PCR, was applied. Using purified cell 
populations, the predominant site of HCMV persistence in the peripheral 
blood of seropositive and some seronegative healthy carriers was found to 
be the monocyte. This data is in contrast to the previously reported T cell 
site of persistence in PBMC of healthy subjects (Schrier et al., 1985). 
However, from my analysis of one seropositive individual with weak 
positive signal in the CD3+ cells, there was evidence that a minor site of 
persistence might be the CD8+ T cells of the peripheral blood while CD4+ T 
cells showed no evidence of HCMV persistence in this subject. This is also 
in contrast to Schrier et al. 1985, who reported that the predominant 
HCMV signal was found in the OKT4 cells. On the other hand, the results 
of my analysis would be consistent with Toorkey & Carrigan's, (1989) data 
that HCMV is present in tissue macrophages. Approximately 30% of 
HCMV seronegative healthy subjects examined in my analysis showed 
consistent evidence of PCR detectable sequences in adherent monocytes 
over a period of 2 or more months, while the individuals' serostatus 
remained negative. In one of these individuals an identical pattern to that 
seen in seropositive/PCR + subjects (e.g. after FACS and PCR 
amplification, the HCMV probe-positive signal was much greater in the 
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CD3- population as opposed to the CD3+ population) was detected. 
Seronegative but HCMV PCR positive subjects have been reported by others 
and the incidence reported in this study (30%) is consistent with other 
reported studies where 16 to 34% of healthy adults were found to be 
consistently seronegative and PCR positive (Stanier et ai., 1989; Bevan et ai, 
1991; Stanier et ai., 1992). Finally, granulocytes have not been specifically 
studied in healthy carriers using a highly sensitive detection technique 
before this analysis. Yet, it is well documented that HCMV can be detected 
in high numbers of PMNL of viremic immunocompromised patients with 
active disease and in rare instances in immunocompetent subject who are 
symptomatic with HCMV infection. Such immunofluorescent data 
suggesting that PMNL were actively infected with HCMV have, however, 
recently become unreliable due to the fact that many monoclonal 
antibodies which were believed to detect IE antigen are actually specific for 
a viral structural protein (Revello et ai., 1992; Grefte et ai., 1992). 
Although, some evidence does suggest that a small number of PMNL in 
viremic patients may express HCMV IE, E, or late transcripts as detected 
by in situ hybridization as well as IE, and very rarely, late antigens as 
detected by immunofluorescence (Revello et at., 1992), it appears that most 
PMNL in viremic patients are not actively infected with HCMV and 
intracellular viral particles are primarily phagocytized (Revello et ai., 
1992; Grefte et at., 1992). In agreement with this, was the observation in 
this study that polymorphonuclear cells in healthy carriers who harbor 
persistent virus showed no evidence of HCMV genome despite that fact 
that adherent monocytes from the same subjects consistently showed 
HCMV probe-positive signals. As it is difficult to infect freshly isolated 
monocytes with HCMV and in the few cells that can be infected virus does 
not appear to replicate, the issue arises as to how these cells may acquire 
and maintain persistent HCMV. It is known that bone marrow 
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progenitors can be infected in vitro, therefore, one explanation of 
monocytic cell persistence may be that the cells acquire HCMV at an early 
stage of their differentiation in the bone marrow. However, the same 
myeloid precursors give rise to both monocytes and PMNL, but PMNL do 
not appear to harbor HCMV in healthy carriers whilst monocytes do. 
Therefore, if early myeloid precursors are targets for HCMV infection it 
would appear that differentiation results in a partitioning of HCMV to the 
monocyte fraction. One explanation for this could be that HCMV infected 
PMNL precursors may be unresponsive to colony stimulating growth 
factors resulting in a loss of these cells (Sing & Ruscetti, 1990). 
Following analysis of the sites of persistence in the peripheral blood 
of healthy carriers, I then analyzed these cells for evidence of 
transcriptional activity. As previous data addressing this same question 
has been inconclusive (Schrier et ai, 1985; Gnann et ai., 1988) or had 
analyzed tissues that were not directly reflective of the healthy state 
(Toorkey & Carrigan, 1989), I chose to analyze primary monocytes obtained 
directly from healthy carriers. In addition, I studied both immediate early 
and late transcripts in these cells by using the highly sensitive system of 
reverse transcription coupled with nested PCR. However, in no case did I 
find evidence of polyadenylated mRNA in primary monocytes from either 
the HCMV lEI or IE2 transcription units, the HCMV HQLF-l IE gene or 
the HCMV pp28 late gene in 3 healthy seropositive carriers. Despite this, 
all RT-PCR samples demonstrated a cDNA product from the constitutively 
expressed histidyl-tRNA synthetase gene. Moreover, all DNA samples 
obtained from the same cells which were extracted for RNA were positive 
for HCMV genome. Thus, in the healthy asymptomatic carrier it does not 
appear that HCMV low level replicative persistence occurs. However, I 
was not able to rule out whether non-polyadenylated mRNA or other, as 
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yet, undetermined latent transcripts not specifically examined existed in 
primary monocytes from healthy carriers. 
It is known that monocytes circulate in the peripheral blood for an 
average of 70 hours before diapedesing across endothelial borders and 
migrating to peripheral organs where terminal differentiation to 
macrophages occurs (Whitelaw, 1966). In addition, it has been reported 
that in several in vitro cell systems, differentiation is needed for fully 
permissive infection with HCMV. In particular, the embryonal 
teratocarinoma (T2 cells) cell line, that differentiates upon retinoic acid 
stimulation into several somatic cell types, has been shown to repress viral 
transcription at the IE level (Nelson & Groudine, 1985; LaFemina & 
Hayward, 1986) but with retinoic acid differentiation can produce fully 
productive infection and release of progeny virus (Gonczol et al., 1984). In 
addition, this is not due to a block in viral penetration (Gonczol et aI., 1984; 
LaFemina & Hayward, 1986). Moreover, Kothari et al. (1991), have shown 
that two upstream regions of the MIE responsible, at least in part, for this 
block and which act through binding of a potential negative regulatory 
factor(s) are the imperfect dyad (approximately -962) and the 21 bp repeat 
elements present in the enhancer. A similar analysis (Sinclair et aI, 1991) 
was performed in a monocytic cell line, THP-1, where the phorbol ester 
(PMA) was used to differentiate the cells to macrophages. This report 
showed the same results as those seen in the T2 cells, in that a potential 
candidate negative regulatory factor(s) existed in these human monocytic 
cells and that deletion of the binding sites for this factor allowed expression 
of the MIE promoter in undifferentiated THP-l cells. It is possible that 
such negative regulatory factors also exist in primary monocytes and 
could be the reason for the lack of expression of the MIE promoter in 
primary monocytes seen in my analysis 
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Because no HCMV gene expression could be seen in primary 
monocytes from healthy seropositive carriers, precluding an analysis of 
the mechanism of HCMV regulation during persistence in primary 
monocytes, I decided to analyze methods of differentiation in a monocytic 
cell line as well as primary monocytes in an attempt to reactivate 
persistent virus. Whilst, it is difficult to infect primary monocytes (Rice et 
al., 1984; Einhorn & Ost, 1984), it is known that differentiation leads to 
increased permissiveness to HCMV infection in monocytic cell lines 
(Weinshenker et al., 1988 ) as well as for in vitro and in vivo differentiated 
macrophages (Drew et al., 1979; Lathey & Spector, 1991; Ibanez et al., 
1991). Specifically, HCMV permissiveness in undifferentiated and 
differentiated adherent peripheral blood mononuclear cells (Lathey & 
Spector, 1991; Ibanez et al., 1991) have shown that hydrocortisone and T 
cell stimulation, using PHA in the first case, and T cell stimulation using 
Concanavalin A, in the second case, prior to infection can significantly 
increase the number of cells expressing IE antigens and the number of 
cells productively infected. When Concanavalin A stimulated T cells were 
used as a method of monocyte differentiation, it is not unreasonable to 
speculate that at least one cytokine mediating differentiation was GM-CSF, 
as this is a major by-product of T cell stimulation by Concanavalin A 
(Clark & Kamen, 1987). Moreover, both Lathey & Spector, (1991) and 
Ibanez et al. (1991) used human serum in the culture medium to produce 
MDM and it has been speculated that 1,25 dihydroxy Vitamin D3 is one 
factor present in human sera necessary to mediate differentiation of 
monocytes (Dougherty & McBride, 1989). I, therefore, decided to try 
combinations of the following differentiating agents in my analysis of 
endogenous HCMV reactivation: phorbol 12-myristate 13 acetate, 
granulocyte-macrophage colony stimulating factor, hydrocortisone and 
1,25 dihydroxy vitamin D3. 
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In my analysis I chose to examine methods of in vitro differentiation 
resulting in a differentiated macrophage phenotype permissive for HCMV 
IE expression using the monocytic cell line, THP-l. In these experiments, 
it was found that 3 combinations of differentiation-mediating chemicals 
(PMA + HC, GM-CSF + HC & PMA + Vitamin D3) were able to produce the 
highest level of HCMV permissiveness as determined by lEI fluorescence. 
Extrapolating from these results, the same three combinations of 
differentiation-mediating agents were used with primary monocytes from 
healthy seropositive donors in both infection studies and in studies 
attempting to reactivate endogenous HCMV virus from differentiated 
monocyte-derived macrophages. IE 1 immunofluorescence was also used 
to assess results of infection studies in the MDM cells and similar but 
lower levels of permissiveness as that seen in the THP-1 cells were found. 
PMA + HC lead to the highest level of IE 1 immunofluorescence (75% of 
THP-I cell and 30% ofMDM), while GM-CSF + HC and Vitamin D3 + PMA 
both lead to 30% lEI expression in THP-I cells and 10% lEI expression in 
MDM. However, when RNA from MDM differentiated by these same three 
combinations of chemicals were studied by RT-PCR, it was found that GM-
CSF + HC lead to the most extensive induction of HCMV endogenous gene 
expression as determined by RT-PCR analysis. In the single healthy 
individual studied, both IE 1 and IE2 polyadenylated mRNA transcripts 
were detected as well as delayed-early HCMV gB gene transcripts. 
However, HCMV late gene (pp28) mRNA was not detectable after RT-PCR 
which was consistent with the cocultivation studies where GM-CSF + HC 
differentiated MDM passaged onto permissive fibroblasts lead to no 
evidence of plaques even after 28 days. The second most successful 
combination of differentiating agents leading to expression of endogenous 
HCMV was PMA + HC. With this combination, only lEI expression was 
seen and cocultivation studies were negative. Finally, the combination of 
152 
Concluding Discussion 
PMA and Vitamin D3 lead to no detectable mRNA transcripts in MDM 
and cocultivation studies were negative. In all cases, successful RT-PCR 
was verified by the amplification of a constitutively expressed gene, 
histidyl-tRNA synthetase. As well, in all cases a nested lEI DNA peR 
was used to verify that the cells harboring HCMV had not been lost in the 
differentiation process. 
It is not surprising that the infection analysis of THP-1 cells after 
differentiation did not parallel results of HCMV endogenous gene 
expression in MDM, because the former analysis was based on an 
optimization of IE 1 expression. Retrospectively, optimization of 
differentiation of THP-l cells for productive infection might have resulted 
in different conditions to optimize production of infectious virus in MDM. 
In any event, I report in my analysis of HCMV viral persistence in the 
healthy human carrier, the first observation of reactivation of endogenous 
HCMV, albeit to the level of delayed-early gene expression. 
Finally, although in my study I have addressed the peripheral blood 
compartment with respect to HCMV persistence, epithelial cells are also 
thought to be another site of HCMV latency. In particular, ductal 
epithelium of the salivary glands (squamous epithelium of the buccal or 
pharyngeal mucosa have not been examined), renal tubular epithelium 
and cervical epithelium are thought to be the source of recurrent HCMV 
shedding from the saliva, urine and cervix, respectively, and this 
shedding is known to occur sporadically throughout the life of many 
healthy carriers (Nankervis & Kumar, 1978; Alford & Britt, 1990). 
Although these cells have not directly been shown to be the source of 
infectious HCMV shed from healthy carriers, two pieces of evidence 
suggest the likelihood of this. Firstly, epithelial cells of the cervix from 
HCMV seropositive female carriers have been found to show evidence of 
HCMV by in situ hybridization detection in the basal cells of the squamous 
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epithelium from biopsy of the cervix taken at colposcopy (Mathijs et at., 
1991). Unlike the findings with EBV (see Allday & Crawford, 1988 for 
review), however, the more differentiated superficial cells did not show 
positive in situ signal. Second, Toorkey & Carrigan, 1989, have suggested 
that tubular, bronchial and alveolar epithelial cells harbor HCMV in 
autopsy samples from ante mortem healthy subjects. In their analysis, 
salivary glands were examined in only 1 subject and did not show evidence 
of HCMV while cervical tissue was not examined. If epithelial cells do 
harbor HCMV in the healthy carrier, it will be important to determine 
whether this represents a true site of latency and whether interaction 
between HCMV -bearing macrophages plays a role in the shedding of virus 
from asymptomatic carriers. 
6.2 FlITURE AIMS 
In the analysis of sites of persistence, it will be necessary to study 
further subjects before determining whether T cells represent a minor site 
of persistence. As the bead-sort method did not allow for an easily 
interpretable level of purification of cell populations it may be more 
productive to approach this analysis by using FACS in combination with 
PCR as was used for the analysis of the T cell and non-T cell populations. 
In addition, the analysis of persistent gene transcripts in primary 
monocytes would be more complete if random hexanucleotide RT primed 
samples were analyzed. In this case, non-polyadenylated transcripts 
would be able to be detected. 
Finally, the analysis of reactivation of endogenous HCMV using 
various methods of monocyte differentiation requires further examination. 
Firstly, more individuals' MDM should be examined using the 
combination of GM-CSF + HC and PMA + HC for differentiation to both 
repeat previous work and extend the time in culture to allow for any slower 
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kinetics of infection in MDM after reactivation of endogenous virus. By 
using blood from seropositive healthy donors received from the transfusion 
service, enough cells could be obtained to analyze the same blood sample 
for evidence of gene transcription in primary monocytes as well as MDM 
and verify that the subject is not constitutively expressing HCMV genes. 
Ultimately, further investigation of the possibility of producing an in vitro 
fully productive viral reactivation of endogenous persistent HCMV will be 
required. This may need both specific cellular interactions as well as the 
use of other cytokines. Certainly, IL3 has been shown to stimulate 
formation of macrophages and with the exception of the WEHI-3 
myelomonocytic cell line and perhaps epidermal cells, IL3 is exclusively 
produced by activated T cells (Luger et at., 1985). In the system presented 
in this report, T cells would not have been present in any large number 
and would not have been specifically activated. Also, they would have been 
rendered non-functional by the use of hydrocortisone. Consequently, IL3, 
along with GM-CSF + HC or PMA + HC may be necessary to produce a 
differentiated MDM more reflective of in yiyo macrophages and thus able 
to fully reactivate endogenous virus. Finally, by using Concanavalin A-
stimulated-T-cell-conditioned medium, all cytokines produced by activated 
T cells should be present and may, ultimately, be the simplest approach to 
attempt to differentiate monocytes and reactivate endogenous HCMV. 
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